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Chronic or progressive diseases can significantly affect the lives, well-being and functional 
abilities of patients. This is exemplified in the interview of a patient with chronic obstructive 
pulmonary disease (COPD) attending pulmonary rehabilitation (PR) in Germany (Box 1). In this 
case, the chronic disease led to challenges with many daily activities and to multiple hospital 
admissions, both of which had severe and adverse effects. The impact of an illness on one’s 
life must be measured, quantified, and interpreted, especially after an intervention. Although 
traditional physiologic parameters, such as spirometry, chest x-rays, oxygen saturations, and 
blood serum results provide important information to clinicians, these outcomes are often 
of less interest and importance to the patient. In addition, such parameters tend to have 
only a weak correlation with the patient’s functional capabilities, experienced symptoms, 
and general well-being [1]. Indeed, patients with similar physiological outcomes can have 
major differences in their experienced quality of life (QoL), which has led to the integration 
of patient-reported outcomes (PROs) or questionnaires. Measuring QoL has become an 
obligatory outcome for the approval of new drug therapies during pharmaceutical trials 
[2-5], and is now used as a valid endpoint in randomised clinical trials evaluating PR and 
similar interventions. QoL measurement is also integrated in routine clinical practice (RCP) 
to validate new treatment regimens or to evaluate established guidelines [4]. However, an 
important challenge exists when interpreting observed changes in QoL among chronically 
ill patients enrolled in clinical practice, trials and interventions like PR (Box 1). The current 
thesis addresses the pivotal topic of measuring and interpreting changes in QoL during 
interventional research and routine medical care. 
1.2 Measuring quality of life
1.2.1 Quality of life
QoL is a concept that is difficult to define and for which many definitions therefore exist, 
not least because it holds different meanings for different people [6-9]. As a general 
definition, one can state that “QoL is the degree of satisfaction or dissatisfaction with 
various aspects of life that may be important to the individual” [8]. However, it may also be 
considered “the gap between what is desired by [an] individual and what is achievable [by an] 
individual” [9]. QoL also includes the following broad range of considerations: functional 
capabilities and limitations in self-care, mobility, and physical activity; experienced 
(physical) symptoms and signs; the execution of role activities in one’s work, personal 
life, and household management; the level of social functioning in personal interactions, 
intimacy, and communication; one’s emotional status, including aspects of anxiety, stress, 
depression, control experienced and spiritual well-being; cognition status; the level of 
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General introduction
1Interview 24th of July 2015: “In the Klinik Bad 
Reichenhall (Germany) I met a 63-year old female, 
who was admitted for an extended 3-week 
pulmonary rehabilitation programme. She was 
diagnosed with chronic obstructive pulmonary 
disease (COPD) in 2007. Her first symptoms were 
progressive coughing and dyspnoea that initially 
required a 3-week admission to the intensive care 
of the regional hospital. Her diagnosis was very 
severe COPD (grade IV) according to the global 
initiative for obstructive lung disease (GOLD). She 
also had severe osteoporosis and was using anti-
depressive medication.
She reported smoking approximately two packs 
of cigarettes each day for 45 years and was 
aware that this had caused her COPD. She had 
quit smoking shortly after being diagnosed with 
the disease. Initially, her symptoms were stable 
and the disease was well managed, but since 2013 
she had required frequent hospital admissions for 
exacerbations with extreme coughing, dyspnoea, 
and increased sputum production. Despite using 
multiple inhaled bronchodilators, she has since 
required daily oxygen 2 L/min by nasal cannulae. 
Initially treated with antibiotics and steroids, her 
frequent exacerbations were taken as justification 
for her referral to the pulmonary rehabilitation 
programme. 
Before being diagnosed with COPD, she and her 
husband had owned a small bed and breakfast 
in the mountains near Oberstdorf in southern 
Germany. The pulmonary physician, who had 
diagnosed COPD, recommended that she sell 
her business and take care of herself, which she 
did. However, her life had changed dramatically 
since then. Her husband had died of cancer 
and she was currently living with her daughter, 
son-in-law, and two grandchildren. In her daily 
life, she experiences many COPD symptoms 
and functional limitations, such as household 
chores, self-care (e.g., washing, showering, 
getting dressed, and cooking), and driving a 
car. Her children help with many of these tasks. 
Mentally and physically she enjoys and benefits 
from short strolls around the local lake with the 
aid of her walker and oxygen, but needs to make 
frequent stops. She benefits significantly from the 
compassion and help of her family, friends, and 
neighbors, which gives her strength, especially 
during depressive episodes. 
She is aware that COPD is progressive, and this 
contributes to her feeling down. Despite having 
tears in her eyes while talking about coping with 
COPD, I noticed an active will to fight for good 
quality of life and disease stability. She therefore 
enrolled in a randomised controlled clinical trial 
(RCT) investigating inspiratory muscle training 
(IMT) added to pulmonary rehabilitation. She 
explained that spirometry and a 6-minute 
walking test were performed at the start of 
her rehabilitation and that she had to fill out 
various questionnaires, but that she did not 
really understand why these were needed. 
Her assumption was that they were used for 
administrative purposes only. 
The rehabilitation programme consisted of 
breathing exercises, physiotherapy, aerobics, 
walking training, GALILEO vibration board 
training, massage, IMT, and an educational 
programme (e.g., smoking cessation). An 
element that she enjoyed most were the daily 
walks around the local Gradierwerk in Bad 
Reichenhall, which she reported as a means of 
exercise that helped her breath easier. Her main 
goals were to lessen her dyspnoea, prevent 
recurrent exacerbations, and slow down 
disease progression. The ability to drive her car 
again was another major goal.” 
Box 1: Interview with a patient with COPD during pulmonary rehabilitation in Bad Reichenhall, Germany
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sleep and rest; one’s experienced level of energy and vitality; general health perceptions; 
and one’s overall life satisfaction [6-7, 10].
1.2.2 Health-related quality of life and health status
QoL is a much more comprehensive term than the concepts of either health-related quality 
of life (HRQoL) or health status, because it includes aspects of the individual’s environment 
that may or may not be influenced by his or her health, illness or treatment [11-12]. By 
contrast, HRQoL mainly focuses on the “health concepts or aspects of human life and activities 
that are generally affected by health conditions, illnesses, or health services” [11]. It includes 
fundamental health dimensions, such as physical functioning, psychological and social 
functioning, performed role activities, overall life satisfaction, and perceptions of health [6, 
13-14]. Health status is often considered to be the standardised outcome measure for HRQoL, 
and as such is frequently used with equivalence. Specifically, health status has been defined 
as “the impact of health (or disease) on a person’s ability to perform and derive fulfilment from 
the activities of daily life” [11-13]. The concept of functional status is also frequently considered 
in the context of health status and HRQoL, and is defined as “a person’s ability to perform a 
variety of physical, emotional, and social activities” [11-13]. However, using the concepts of QoL, 
HRQoL, health status, and functional status interchangeably can lead to confusion with the 
terminology [6, 10].
1.2.3 The measurement of health status
Health status measurement is a standardised way of quantifying and scoring the impact of 
health or disease on a patient’s life, health, and well-being [2]. Various tools have emerged 
over recent decades [1, 4-5, 9-11, 13, 15]. Disease-specific measures include elements of health 
status relevant to a given population [9, 15]. These tools are more likely to be shorter, and the 
measures are sensitive for the specific health problems of the disease. Alternatively, general 
health status assessments can be used to compare HRQoL between patient populations 
and tend to be robust thanks to long development and testing phases [15]. Health status 
measures can range from a single question to a complex combination of questions [1, 5-6], 
and can include a single score or multiple subscores for specific health status domains (e.g., 
symptoms, functional status, and emotional well-being) [1, 5-6, 10, 15]. The measures can be 
assessed in one of several ways [1].
Measures administered directly by the patient are defined as the so-called PROs [11, 16]. 
These questionnaires capture an individual’s experience of the impact of health or disease, 
without the interpretation of others [5, 16, 17-19]. These instruments are of major interest, 
because some treatment effects are known only to the patient and not to the physician 
or researcher [5]. PROs provide a unique perspective on treatment effectiveness. Formal 




interviews. PROs usually measure concepts of overall health status, functional status (including 
daily activities and exercise capabilities), disease symptoms and signs, health perceptions, 
treatment satisfaction, and treatment adherence [5, 11]. At a minimum, they should include 
components of physical, psychological and social functioning [5].
1.3 Defining the importance of change in health status 
1.3.1 Concepts of change
An important consideration of any assessment is how the physician or researcher 
should score and interpret whether important change occurred in a patient’s disease, 
QoL or experienced health status after a therapeutic intervention (e.g., pulmonary 
rehabilitation, Box 1). A given patient will tend to have specific goals that they wish to 
achieve when engaging in an intervention, and these should be captured, scored and 
evaluated in a standardised manner. Along with traditional physiological parameters, 
health status is now routinely captured as an obligatory endpoint of treatment. It is for 
this reason, not for mere administrative purposes, that patients are required to complete 
the various PROs during research and therapy. 
A health status questionnaire or instrument should have accurate psychometric 
properties to be deemed applicable for use in evaluating interventions. These important 
characteristics include its appropriateness, reliability, validity, practicality, interpretability 
and responsiveness [1, 5-6, 11, 15, 20]. Responsiveness has been defined as “the ability of an 
instrument to detect change when it occurs” [21-22]. Random changes (i.e., intervening noise) 
in scores will always occur from before to after an intervention, but do not necessarily 
indicate real or important change for the patient (i.e., a true signal) [1]. 
The concept of change can be considered in different ways, and these have been 
grouped into specific levels or categories [21, 23]. First, change can be considered as 
either occurring within the same individual, or as a difference between individuals [21, 
23]. Second, change can be considered at a group level with multiple patients, or at an 
individual level with a single patient. Third, change can be either positive (indicating 
improvement) or negative (indicating deterioration).
The definition of change also differs by health status instrument and should be considered 
in clinical practice [21]. The first level is the minimum potentially detectable change by 
an instrument, which is the amount of change that an instrument can measure at the 
minimum level without interpreting the reality and importance of the measured change 
score. The second level is the minimum change detectable given the measurement error of 
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the instrument, which includes the minimum amount of change that an instrument can 
measure beyond any random variation in scoring (i.e., measurement error or noise). The 
third level is the observed change measured by the instrument in a given population, which 
describes the real observed change (i.e., true signal) measured in a group. Last, the 
fourth level is the observed change in a population deemed to have improved by either the 
patient, clinician or other. It includes the real observed change (i.e., true signal) measured 
in a group, but also incorporates a value statement of this change either by the patient, 
clinician, or someone else. 
1.3.2 The concept of minimal clinically important difference
Change in health status should be proven to be statistically significant in clinical trials, 
based on a low chance of the observed difference resulting from pure chance (usually at 
the 5% threshold). It is well known that the significance of such results is affected by the 
sample size [23-24], with larger cohorts being more likely to identify even small changes 
or differences as statistically significant. However, this does not necessarily mean that 
the results are also clinically important or relevant to the patient [21, 23-27]. This led to 
Jaeschke et al. developing the minimal clinically important difference (MCID) in 1989, 
defined as “the smallest difference in score in the domain of interest, which patients perceive 
as beneficial and which would mandate, in the absence of troublesome side effects and 
excessive cost, a change in the patient’s management” [28]. 
Many alternative wordings have emerged since this original definition for the same intended 
concept as the MCID, but these are not always synonymous. Terms include, among others, 
the minimum important difference (MID), subjectively significant difference (SSD), clinically 
important difference (CID), minimal clinical difference (MCD), minimally detectable difference 
(MDD), minimally important change (MIC), minimum detectable change (MDC), minimal 
clinically significant difference (MCSD), minimally perceptible difference (MPD) and many 
more [29-31]. It could be argued that any difference refers to change between groups while 
change itself can refer to change within a group. The persistence of interchangeable use of this 
terminology in the literature makes the matter less clear.
The MCID is a very important parameter for interpreting health status measurement in 
clinical trials and research. It is used to determine the required sample size in a scientific 
study based on health status as the primary outcome [25]. In addition, the MCID is used 
to interpret health status changes as an obligatory endpoint in many clinical trials, while 
clinicians may also use the MCID to guide care and set national guidelines. Most clinical 
trials in the European Union (EU) now require that a health status tool be included as a 




The MCID of an instrument is used to measure the threshold for clinically relevant change 
when interpreting results, and it is required that over 50% of patients in the trial group 
meet the MCID threshold for the intervention to be considered clinically important [17]. 
Alternatively, the mean change from pre- to post-intervention should be larger than the 
MCID of the tool. A schematic presentation of how to interpret treatment outcomes based 
on the MCID of an instrument is shown in Figure 1 [32]. This shows the mean group result and 
its 95% Confidence Interval (95%CI), together with the significance of the trial outcomes, as 
evaluated with respect to the MCID of a tool. The goal is to determine the clinical importance 
of the observed change in the trial.
Figure 1: Interpreting the importance of clinical trial results with the MCID as a pivotal parameter 
(Published in Man-Son Hing, 2002 [32], permission for printing requested) 
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1.3.3 Methods of determining an instrument’s MCID
There is currently no standard method to determine health status instruments’ MCIDs [5, 
30], but they tend to be calculated either as absolute or relative (percentage) estimates 
[23-24], even though there may be no real difference between these outcomes [33]. 
Overall, the methods can be divided into anchor-, distribution- and opinion-based methods 
(Table 1) [5, 13, 22-24, 26, 31, 34-45]. The recommended approach is to use several anchor-
based methods with relevant clinical or patient indicators as the anchors, and examining 
various distribution-based estimates as supportive information [5, 41-42, 46]. Irrespective 
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of the method used, the patient perspective on the importance of the change should be 
given greatest weighting. Triangulation on a single value or a range can be performed 
by systematic review and/or Delphi procedures to finalise the MCID process, which should 
involve synthesizing clinical, statistical and qualitative data [42, 46].
Table 1: Overview of generally used methodology in determining a health status instrument’s MCID
Anchor-based methods Distribution-based methods Opinion-based methods
Using a global rating of change (GRC) scale as an 
anchor (either patient or clinician rated):
-  Mean change score of the minimally changed 
population
-  Receiver operating characteristics (ROC) curves to 
determine the cutoff point for the minimally changed 
population
-  Regression analysis between health status 
instrument and GRC anchor
Using a rule of thumb (6%-10% of the 
maximum score of the instrument’s 
scale)
Delphi rounds of discussion 
by experts in the field of interest 
or estimates based on expert 
opinions
Using a correlated health status questionnaire 
or other clinical instrument with a known MCID as 
the anchor:
-  Mean change score of the minimally changed 
population
-  Receiver operating characteristics (ROC) curves to 
determine the cutoff point for the minimally changed 
population
-  Regression analysis between health status 
instrument and anchor
Determining the half standard 
deviation (0.5SD) / effect size (ES)  
as equivalent to the MCID
Selecting a clinical event or comparing disease 
severity states between patients as an estimate 
for the MCID
Determining the standardised error 
of measurement (SEM) as equivalent  
to the MCID
Using preference-based ratings between 
individual patients as equivalent of the MCID
Determining the reliability of change 
index (RCI) as equivalent to the MCID 
(≥1.96)
Abbreviations: ES, effect size; GRC, global rating of change; MCID, minimal clinically important difference; RCI, reliability of change index; 
ROC, receiver operating characteristics; SD, standard deviation; SEM, standard error of measurement.
Anchor-based methods use an external criterion (the anchor) as the reference point when 
quantifying changes or differences measured on a health status instrument [5, 13, 22-24, 26, 
29, 31, 34, 36-44]. Many different anchors could be used as such an external criterion. These 
may include a patient’s global rating of change (GRC) scale – also called transition rating 
(TR) scale, global perceived effect (GPE) scale, global impression of change (GIC) scale – to 
assess both the within-person change and the between-person change [5, 13, 22-25, 28-29, 
31, 34-37, 40-48]. In this way, the MCID can be considered the mean change score among 
patients indicating small (minimal), yet important, change on the anchor instrument [5, 13, 




in score between patients indicating no change and patients indicating a small change on 
an anchor question [20, 22, 49-51]. Other anchors that can function as an external criterion 
include correlated clinical instruments with a known MCID, such as other established health 
status questionnaires [5, 13, 24, 29, 34-35, 42]. Statistical techniques like receiver operating 
characteristics (ROC) curves and/or regression analysis may also help to further clarify the 
MCID threshold (Table 1) [23-24, 43].
Another anchor-based method is to compare groups by disease severity and their health 
status scores [13], which represent the analysis of between-patient differences. An external 
criterion (e.g., numbers of doctors’ appointments, exacerbations, or hospital admissions) 
may serve as anchors for differentiating clinical relevance between groups [13, 35]. Patients 
may also compare themselves (preference ratings) to others for clinically relevant differences 
in health status [13, 22, 34-35, 44-45, 49-51], or clinicians may be asked to complete prognostic 
ratings for their patients to evaluate therapy effects [13]. Regardless of the anchor-based 
method used, it is of major importance that there is a good correlation between the health 
status tool and the selected anchor, with correlations (r) preferably exceeding 0.30 (or even 
0.50) [41-42]. Anchors should also be selected based on their relevance to the disease, clinical 
acceptance, validity, and existing evidence [42].
Distribution-based methods use different statistical parameters to assess clinical 
significance [5, 13, 23-24, 26, 31, 36-37, 40-45, 52]. These include the use of Cohen’s effect 
sizes (ES), standardised response means (SRM) and standardised mean differences (SMD), 
with 0.30–0.50 standard deviations (SD) considered equivalent to the MCID [13, 22, 24, 
40-44, 52]. Cohen’s ES used to determine MCIDs vary from 0.20 for a small change, to 
0.50 for a moderate change, and to 0.80 for a large change [13, 22-23, 29, 38, 52-53]. An 
estimate of 0.50SD turned out to reflect an instrument’s MCID consistent with the results 
of anchor-based methods [5, 13, 22-23, 26, 31, 34, 38, 41-43]. As a rule of thumb (empirical 
rule), a 6%–10% change in the total score of an instrument is considered to approximate 
the MCID (Table 1) [5, 24].
The standard error of measurement (SEM) is an alternative distribution-based method that 
is used to determine the MCID. The SEM describes the error (i.e., noise) associated with an 
instrument [13, 25], representing the variation in the scores caused by the unreliability of the 
scale or measure [13, 22-23, 34, 40, 43-44, 54-55]. It is estimated as the SD of the instrument 
multiplied by the square root of one minus its reliability coefficient [54-55]. Although a SEM 
of one to two should be equivalent to an anchor-based MCID [13, 22-23, 44-45, 54-55], the 
one-SEM criterion has been shown to equate to a 0.50-point change on a 7-point scale 
[22, 38]. Next, the reliability of change index (RCI) can be calculated as the individual’s 
change score divided by the square root of the SEM [13, 23, 56). If the RCI is larger than 1.96, 
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the change can be considered a true change within the 95% confidence level. Other statistical 
parameters include the smallest detectable difference (SDD) (i.e., the minimum detectable 
difference / change (MDD/MDC)), which is the smallest difference that an instrument can 
detect beyond the random error of measurement [23, 43, 57]. It may not necessarily reflect the 
MCID of an instrument, as it carries no impact of importance [43], but the MCID should at least 
exceed this level if the result is to make sense.
Opinion-based approaches are the third and final category of methods for determining the 
MCID [25, 36-37, 58]. In such an approach, experts are asked to evaluate and determine 
what would constitute clinically relevant changes based on their experience and case 
studies, using the Delphi method over several rounds of discussion [25, 31, 45, 58]. This is 
most often the stage used to finalise MCID determinations.
1.3.4 Advantages and disadvantages of the different methods
Anchor-based methods have a clear link with clinical practice and often involve the patient’s 
own judgement of the importance and relevance of the experienced change after intervention 
[58]. The specific use of GRCs as anchors has strengths and weaknesses [48]. On the one 
hand, they are simple, easy to administer and interpret, demonstrate good validity, and 
involve the patient’s perspective. On the other hand, the approach is heavily reliant on patient 
recall of their current and previous health (i.e., retrospective or interpersonal ratings) [51]. GRCs 
may thus be influenced by this so-called recall bias and, as such, may correlate more with the 
current health state than the former state. Furthermore, GRCs may not be reproducible and 
might be too global in nature [48]. 
Another important issue when using general anchor-based methods is that there may not be 
a linear relationship between the health status instrument at stake and the selected anchor [13, 
34]. Using different anchors may also lead to different MCID estimates [13], possibly creating a 
range of values rather than a single convenient estimate for use in clinical practice [23, 36-37]. 
Moreover, MCIDs should always exceed the measurement error of the instrument, and this is 
not considered with anchor-based approaches only [23, 25].
An advantage of the distribution-based methods is that they provide a quick and easy way 
to establish change beyond a defined level of random variation [13]. However, a notable 
disadvantage is that there are few agreed-upon benchmarks for establishing clinically 
significant improvement [13]. Statistical measures of variation may also be larger in a 
more heterogeneous sample and may produce therefore a higher MCID [34]. Finally, these 
methods do not provide a sense of the clinical relevance of either the change or of patient 




1.4 Problems in determining the MCID
Assessing the MCID requires that one identifies the smallest changes that are important to 
patients, their families and their clinicians [11]. Repeated use of health status instruments 
and their MCIDs should lead to evolution over time. Given that health status is central to 
the assessment and management of chronic diseases like COPD, it is therefore crucial that 
their MCIDs are investigated thoroughly. Currently, however, the evidence for the MCIDs of 
most health status tools is limited, despite their continued use in scientific research and 
clinical practice. Several issues regarding the MCIDs of health status questionnaires have 
not been extensively investigated, which risks over- or underestimation of therapeutic 
effects. As such, interpretation of treatment outcomes in scientific trials and clinical 
practice based on these thresholds should be made with caution.
1.4.1 Lack of a standard approach for determining the MCID
Many definitions and methods are available that rely on patients, physicians 
and/or statistical analysis to evaluate clinically relevant changes in health status 
scores. However, the extent to which the various methods, anchors and statistical 
manipulations affect the MCID estimate for a health status instrument are yet to be 
clarified [13]. Researchers are currently free to (mis)use the diverse range of anchors 
and techniques to define an instrument’s MCID. One would require comparisons of the 
available methods [22-23, 25-26, 30, 34], most likely resulting in the identification of a 
range of MCIDs for use in clinical practice [23, 36-37, 42]. 
1.4.2 Impact of follow-up period in measuring change and the MCID
The follow-up (recall) period, during which change is measured, may also affect an 
instrument’s MCID [13, 24, 30, 34, 42, 48, 59-60]. GRCs assessed by patients or clinicians 
may be more closely related to current follow-up scores than to the original baseline 
health states. The longer the follow-up period, the harder it may be for patients and 
clinicians to recall a previous health state, causing possible recall bias. Patients 
correlating their rating of the importance of a perceived change with their current health 
state may be considered a response shift [49].
1.4.3 Direction of change and the MCID
Another issue is that MCIDs are mostly determined in settings where the patient has received 
a specific intervention (e.g., PR or pharmacotherapy) to improve his or her health status. It 
remains unclear whether MCIDs differ between cases of improvement and deterioration [13, 
25-26, 34]. Chronically ill patients deteriorate over time, especially in cases of COPD [4, 61-
62], so it may be that halting further disease progression is an important clinical outcome 
too. Thus, MCIDs for deterioration may be of clinical importance, but are yet to be studied.
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1.4.4 Impact of disease severity state and context on the MCID
The MCID may depend on various factors that underly both disease severity and the 
health status dimension being measured [13, 23-25, 30, 34, 63-64]. General and disease-
specific instruments have shown worse health statuses among patients with more 
severe disease stages [65], and it is unknown if one requires multiple MCIDs based on 
disease severity [17]. Worse health status scores may trigger exacerbations and hospital 
admissions, and as such, possibly require smaller changes to be clinically relevant; 
however, there will also be more room for improvement among these patients. This 
could potentially influence the relevant MCID of an instrument. A related area of concern 
is that an instrument’s MCID may also be affected by the baseline health status score 
[13, 17, 23-25, 30, 34, 63-64]. This has also not been investigated in (COPD) MCID health 
status research.
Another unexplored concern is that MCIDs may be context-specific, differing by the 
study population and setting [5, 24-25, 27, 29, 41-42, 66]. MCIDs for interventions like PR or 
pharmacotherapy might differ when compared to routine medical care, or to patients 
during and/or following an exacerbation. Moreover, certain patient characteristics could 
influence the MCID. For example, age is known to affect health status [67], with younger 
patients being more impaired by chronic diseases like COPD [62] and tending to report 
worse health status scores, not least because symptoms have a greater impact on their 
function [68]. Female sex has also been associated with more exacerbations [69-70], 
possibly resulting in greater impairment of health status, and thus, potentially require 
different MCIDs.
1.4.5 Group MCIDs and interpretation of individual change
A challenging issue remains that MCIDs are mostly determined at the group level 
where significant variation exists between individual patients. Regression to the mean 
occurs, because MCIDs represent a group estimate in which extreme change scores are 
balanced by a greater number of average change observations [13, 30]. Consequently, 
it may be difficult to make a judgement about an individual’s change in health status, 




1.5 Research objectives and thesis outline
The problems that exist in measuring and applying MCIDs for health status instruments 
(Paragraph 1.4) form the foundation of the research questions posed in this thesis. There 
is a focus on health status tools for COPD, because this chronic disease is a leading 
cause of morbidity and mortality worldwide, and the concept of health status is well 
integrated in its assessment. 
1.5.1 Research objectives 
The main research goals of this thesis are to analyse the general dynamics of determining 
the MCID for health status tools in a COPD context, and to develop an integrated system for 
use of these estimates in clinical practice and scientific research by making use of multiple 
methods over various time periods and settings, while considering factors of importance in 
doing so. Based upon these aims and the defined problems with MCIDs, the following 
objectives have been set for this thesis:
-  To examine and judge, in a systematic manner, the current evidence for the MCIDs of 
health status tools used for COPD (Chapter 3);
-  To investigate the impact of selecting different methods, statistics, and anchors on 
the resulting MCIDs of health status tools for COPD (Chapter 4);
-  To explore the impact of the recall period and measurement period on the MCID for 
health status tools for COPD (Chapter 5);
-  To compare the MCIDs of health status tools for COPD when assessing improvement 
versus deterioration scores (Chapter 6);
-  To establish an idea of the importance of patient-related factors in setting the MCID 
for health status tools for COPD (Chapter 7);
-  To quantify the effect of baseline health status and disease severity on the MCID for 
health status tools for COPD (Chapter 7); and
-  To provide an integrated framework for determining a health status instrument’s 
MCID and its application in scientific research and clinical practice (Chapter 8).
Data for this thesis derive from two main studies. Study one comprises data from a 
randomised controlled clinical trial (RCT) on inspiratory muscle training (IMT) added to 
a 3-week PR programme for patients with COPD at the Klinik Bad Reichenhall, Germany 
[71] (see Box 1 for a representative case). Study two comprises data from routine clinical 
practice (RCP) for patients with COPD managed in primary and secondary care in the 
Netherlands. In this second study, patients received no specific intervention beyond 
standard care, per the Dutch COPD treatment guidelines. The primary goal was to 




This thesis has the following outline. Chapter 2 presents additional background 
information on COPD and the integration of health status assessment in its management. 
Chapter 3 summarises the procedures and results of a systematic review on health 
status instruments used in patients with COPD and the existing evidence for their MCIDs, 
providing quantitative and qualitative analyses with a final data synthesis. Chapter 4 
focuses on determining the MCID for the recommended health status tools for COPD 
using a variety of techniques, statistics and anchors. In Chapter 5, the results of the 
investigation into the extent to which the MCIDs of health status tools for COPD change 
when measured over different periods and with different anchor transition rating scales 
(e.g., GRCs) are presented. Chapter 6 then details the results of whether MCIDs differ 
for improvement and deterioration based on data from PR and RCP. In Chapter 7, there 
is a discussion of the effects of various external factors on the measurement of MCIDs 
for health status tools for COPD. This includes the effects of the baseline health status 
score, disease severity, study context and patient-related characteristics on the MCID 
estimate for both improvement and deterioration. Chapter 8 then presents a summary 
of the main results of this thesis and continues with a discussion of the overall findings. 
The goal is to synthesise the findings to produce guidelines for creating future MCIDs 
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2.1 Introduction and rationale
The previous chapter outlined the rationale for this thesis and highlighted the need to 
investigate the dynamics of the minimal clinically important difference (MCID) of health 
status instruments as well as the known problems with this parameter. Specifically, this 
thesis will focus on the various health status instruments and MCIDs used for patients 
with chronic obstructive pulmonary disease (COPD), a leading cause of morbidity and 
mortality worldwide. In Chapter 1 (Box 1), a representative case of COPD during pulmonary 
rehabilitation (PR) was presented, detailing the impact of the disease on that patient’s 
life and well-being. This case emphasises the major discrepancy between the attainment 
of objective physical outcomes (e.g., spirometry) and the experienced burden of disease 
symptoms and daily functional or mental limitations specific to COPD. In this chapter, 
more detail will be provided about the background of this chronic disease and the 
measurement of health status in this population.
2.2 Chronic obstructive pulmonary disease
2.2.1 Definition
COPD has been defined as “a chronic respiratory disorder that is characterised by persistent 
respiratory symptoms and obstructive airflow limitation” [1-2]. Moreover, the respiratory 
symptoms and airflow obstruction are not fully reversible and are mostly progressive in 
nature. It is an under-diagnosed, life-threatening lung disease.
2.2.2 Pathophysiology
COPD results from a complex interaction between an individual’s genes and his 
or her environment [1]. In the lungs of affected patients, there is a chronic abnormal 
inflammatory response to noxious particles and gases that results in typical pathological 
changes [2-3]. The most important environmental cause of COPD is tobacco smoke, 
but other situational and personal factors are known to be important, including 
atmospheric pollution, biomass fuels, occupational exposure, age, gender and a lower 
socio-economic status [1-3]. Alpha-1-antitrypsin deficiency may be a cause of COPD too. 
The abnormal classification of the immune response in COPD concerns the fact that the 
observed inflammation does not occur to a comparable extent in healthy individuals. The 
presence of an extensive, chronic, innate, and adaptive inflammatory response interferes 
with normal repair and defence mechanisms in the lungs. This promotes and causes 
small airway fibrosis and obstruction [1-3], inducing parenchymal tissue destruction that 
can result in emphysema. In the process of airway fibrosis and obstruction, the abnormal 
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inflammatory response disrupts the epithelial barrier and interferes with the mucociliary 
clearance apparatus. This leads to an accumulation of inflammatory mucous exudates 
in the small airway lumen, because of mucus hypersecretion and ciliary dysfunction [3]. 
Inflammatory cells then infiltrate the airway walls and cause damage, whereupon the 
deposition of connective tissue leads to remodelling and wall thickening. Consequently, 
the lumen is reduced and restricts the normal increase in diameter during lung inflation. 
In addition, an imbalanced proteinase/anti-proteinase relationship and the presence 
of oxidative stress each contribute to the pathophysiology [1-3]. Overall, the abnormal 
processes in COPD are progressive and result in increased resistance and narrowing 
of the small airways, with emphysematous destruction leading to increased lung 
compliance due to diminished elastic recoil [3]. This creates a prolonged time for lung 
emptying that is defined clinically as obstructive airflow limitation.
2.2.3 Epidemiology
Despite being preventable and treatable, COPD is the leading cause of morbidity and 
mortality worldwide after ischaemic heart disease and stroke [2, 4-7]. As such it creates 
substantial economic and social burdens that are increasing [1, 8]. Current prevalence 
estimates range widely from less than 6% to over 19% [1]. The worldwide prevalence in 
adults older than 40 years is 10%–11%, equivalent to 384 million cases of COPD in 2010 [1, 
4, 9-10]. Worldwide, 2.9 million deaths were recorded due to COPD in 2010 [6-7], with most 
of these occurring in low-income regions such as Asia and central Africa [11]. However, its 
morbidity statistics are arguably most notable, it has been reported to cause a staggering 
76 million disability adjusted life years (DALYs) [12] and over 29 million years lived with 
disability (YLD) [13], ranking ninth and fifth, respectively.
The burden of COPD increases gradually from primary to secondary and tertiary care [14]. 
It has been estimated to account for approximately 6% of the total health care budget 
in the European Union (EU), equivalent to ≥50% of the costs for all respiratory diseases 
[1]. Exacerbations and limited work productivity account for most of this burden [1]. 
Here, an exacerbation is defined as “a worsening of respiratory symptoms beyond normal 
day to day variation that requires additional medication or a change in therapy” [1]. The 
burden of disease is often worse, because COPD frequently exists with cardiovascular, 
respiratory, metabolic, osteo-skeletal, and gastro-intestinal comorbidities (Table 1) [1, 15-
18]. Depression and/or anxiety are also common in COPD, with a mean prevalence of 27% 




Fibrosis and obstruction of the small airways, coupled with emphysematous destruction 
of the airway walls, leads to obstructive airflow limitation, hyperinflation, air trapping, 
abnormal gas exchange, mucus hypersecretion, ciliary dysfunction and/or pulmonary 
hypertension [1-3]. The primary symptoms of COPD that result from this pathology are 
progressive dyspnoea, breathlessness, chronic cough and/or chronic sputum production 
[1, 18, 20], with wheezing and chest tightness sometimes present [1]. Symptoms that exist 
secondary to these include anxiety, panic, fear, frustration, and fatigue [20]. Fatigue may 
also result from the significant reduction in physical activity associated with COPD [21]. 
Furthermore, extra-pulmonary or systemic effects are not uncommon, including general 
signs of systemic inflammation, oxidative stress, and activated inflammatory cells; skeletal 
muscle dysfunction including cachexia and exercise limitations; nutritional abnormalities 
and weight loss due to malnutrition and cachexia; and cardiovascular, nervous and osteo-
skeletal system effects [1-2, 22]





Peripheral artery disease 
Pulmonary hypertension
Metabolic Cachexia 







Gastro-intestinal Gastric / Duodenal ulcus 
Helicobacter Pylori infections 
Reflux
Respiratory Asthma / Asthma-COPD overlap syndrome (ACOS)
Bronchiectasis
Lung cancer 
Obstructive sleep apnoea syndrome (OSAS)
Pulmonary fibrosis
Abbreviations: ACOS, asthma-COPD overlap syndrome; COPD, chronic obstructive pulmonary disease; OSAS, obstructive sleep apnoea 
syndrome.
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2.2.5 Diagnostic considerations
To confirm the diagnosis COPD, spirometry is traditionally required with a post-
bronchodilator forced expiratory volume in one second (FEV
1
) / forced vital capacity 
(FVC) ratio of ≤0.70 or ≤70% [1-2, 23]. The predicted FEV
1
 percentage determines the degree 
of airway obstruction and the severity of the COPD, giving traditional classification 
categories I–IV of the global initiative for obstructive lung disease (GOLD) (Table 2). 
Nevertheless, identifying patients with COPD is difficult, with asthma being a particularly 
common misdiagnosis. Although demonstrating reversible airway obstruction during 
post-bronchodilation spirometry should confirm asthma [1], this does not account for 
those patients with a diagnostic overlap of asthma and COPD (ACOS). Moreover, most 
patients with COPD remain undiagnosed, because they are frequently asymptomatic 
[25], especially if they have only mild to moderate disease. Therefore, in many cases, 
an exacerbation is frequently the first presentation of symptomatic COPD [26]. Given 
that there is a more rapid decline in FEV
1
 when COPD is less severe, early diagnosis and 
treatment is of major importance [25].
Table 2:  Traditional spirometry-based classification of COPD according to GOLD grade I-IV 
(Adapted from NHG Standaard COPD 2015 [24] and GOLD 2017 [1]) 








 II Moderate ≤50 to <80
 III Severe ≤30 to <50
 IV Very severe < 30
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; 
GOLD, global initiative for obstructive lung disease; NHG, Nederlands Huisartsen Genootschap.
2.2.6 Therapy
There is no cure for COPD. However, behavioural modifications and early treatment 
may improve symptoms and slow disease progression [25]. International guidelines 
recommend smoking cessation aids, exercise and physiotherapy, self-management 
and education, pharmacotherapy (e.g., short- and long-acting bronchodilators, 
glucocorticoids, theophylline, and/or antibiotics for exacerbations), long-term oxygen 
therapy or ventilatory support, PR, nutritional support and/or surgical interventions (e.g., 
lung volume reduction, bronchoscopic coiling, bullectomy, or lung transplantation) 
[1-2, 23, 25-26]. It is therefore essential that practitioners focus on planned COPD care to 
prevent exacerbations, slow disease progression, and reduce the need for rescue therapy 
of augmented symptoms [26]. One should also remember that patient’s expectations 
and needs affect treatment adherence and outcomes, with patients often reasonably 
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wanting to have fewer exacerbations and fewer symptoms of dyspnoea, cough, and 
sputum production [27].
PR is an evidence-based, multidisciplinary, and comprehensive intervention for COPD, 
especially beneficial for symptomatic patients with decreased lung function [1, 28]. 
Programmes are individualised and include detailed patient assessment, exercise 
training, education and psychosocial support [28-30]. They are designed to reduce 
symptoms, optimise functional status, increase participation, and minimise health care 
costs by stabilising the disease [28-29]. PR can significantly improve dyspnoea, quality 
of life (QoL), and psychosocial well-being, and can decrease health care utilisation in 
a cost-effective manner [28, 30-36]. Of note, increasing physical activity – defined as 
bodily movement produced by skeletal muscles that results in energy expenditure – may 
have favourable effects on lung function decline, FEV
1
 levels, COPD symptoms, QoL, 
exacerbations, and all-cause mortality [37].
The patient interview in Chapter 1 (Box 1) highlighted a case of PR in which add-on 
inspiratory muscle training (IMT) was used as part of a randomised controlled clinical 
trial (RCT). Although the available evidence is contentious, IMT could be an additional 
component of PR [38-42]. COPD results in patients having significant inspiratory 
muscle weakness that may contribute to dyspnoea and exercise intolerance [39]. 
By implementing resistance training during inspiration, IMT may improve a patient’s 
capacity for higher ventilation levels, thereby reducing the sensation of dyspnoea [38]. 
IMT is, however, not officially recommended at present [28]. 
2.3 Health status in patients with COPD
2.3.1 Rationale for measuring health status
Airflow limitation, as measured by the FEV
1
, is important in diagnosing and measuring 
COPD. However, the clinical features of this disease are much more heterogeneous and 
cannot be captured by the FEV
1
 alone [43]. Indeed, there is only a weak to moderate 
correlation between spirometry results, symptoms, and experienced QoL impairment 
[1, 20, 44-50]. COPD results in worse health-related quality of life (HRQoL), greater 
impairment of work productivity, and greater health care utilisation [51]. Health status, 
as the standardised measure of HRQoL, seems to deteriorate over time in these patients, 
though analysis in a 5-year study indicated that accurate therapy could produce 
improvements [52-53]. Several factors are known to predict the worsening health status in 
COPD, including increased dyspnoea symptoms, depression and anxiety, functional status 
deficits, exacerbations and hospital admissions [52, 54]. A more severe health status has 
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also been associated with increased age, sleep disturbances, depression, worse COPD 
symptoms, and frequent exacerbations (>2 in the previous year) [55]. The resulting worse 
HRQoL then presents with higher morbidity and mortality [56]. COPD exacerbations are 
among the most important factors associated with decreased QoL [57-58], with higher 
GOLD I–IV grades and female sex associated with a higher prevalence of exacerbations 
[57-58]. In the US, the risk of in-hospital death due to an acute exacerbation of COPD is 
11% [59].
2.3.2 Integration of health status in COPD assessment
The optimal care for patients with COPD requires an individualised approach that 
recognises all aspects of the disease and commitment from all stakeholders [60]. In 
2017, the GOLD strategic update proposed an ABCD framework to help deliver more 
comprehensive COPD assessment [1]. In addition to the spirometry-derived GOLD 
classification (Table 2), this framework assessed the exacerbation history (≥2 or <2 
exacerbations in the past year) and the symptoms measured by specific health status 
instruments (Figure 1) [61]. The instruments used to evaluate symptoms in this revised 
framework are the COPD Assessment Test (CAT) and the modified Medical Research 
Council dyspnoea scale (mMRC). Cutoff values have been defined for both the CAT 
(10 points) and the mMRC (2 points) to distinguish symptomatic from asymptomatic 
or less symptomatic patients [1]. However, there remains debate as to what extent the 
established cutoff values may lead to misclassification and discrepancies [1, 62-70]. 
Corresponding values for symptomatic patients have been defined for other frequently 
used health status tools for COPD too, including the Clinical COPD Questionnaire (CCQ, 
1.5-2.0 points) and the St. George’s Respiratory Questionnaire (SGRQ, 20-25 points) [64, 
68]. Based on the GOLD ABCD framework, a risk classification and pharmacological 
treatment algorithms have been developed.
2.3.3 Recommended health status tools
Health status patient-reported outcomes (PROs) can quantify the extent to which the 
physiological effects and symptoms of COPD affect a patient’s health and function 
[49]. They include the major concerns for patients with COPD, such as breathlessness, 
dyspnoea, fatigue, cough, sputum production, physical function and exercise tolerance, 
social function, depression and/or anxiety and exacerbations [45, 49, 71].
Many health status instruments and functional status tools have been developed for 
use by patients with COPD (Table 3). Certain tools have been used more frequently 
than others, and at present, the CAT and CCQ are recommended in clinical practice [1, 
72]. The CAT is an 8-item unidimensional questionnaire that includes questions about 
cough, phlegm, chest tightness, breathlessness, walking up stairs/hills, activity limitation 
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at home, sleep, confidence leaving home, and energy (Supplementary material 2.4.1) [73]. 
Each item is scored on a scale from 0 to 5 points, totalling a maximum of 40 points. The 
CAT has been shown to be a reliable, valid, reproducible, and responsive tool with strong 
discriminative properties [66, 73-84]. The CCQ is a 10-item multi-dimensional health 
status tool comprising three domains including symptoms (4 items), functional status (4 
items), and mental state (2 items) (Supplementary material 2.4.2) [85]. Items are scored 
on a scale from 0 to 6 points. The total and domain scores are determined by adding 
the relevant item scores and dividing this by the number of items. The CCQ also has 
strong psychometric and discriminative properties [85-89]. Higher scores indicate worse 
HRQoL on both the CAT and CCQ, and both tools are considered equally reliable, valid, 
and reproducible [90]. Moreover, the correlation is high between the CAT and CCQ, and 
it has been suggested that they could be used interchangeably [91].
Figure 1:  GOLD ABCD Framework  
(Published in Pocket Guide to COPD Diagnosis, Management, and Prevention: a Guide for Health Care 
Professionals 2017 [61], printed with permission granted by the GOLD committee) 
Abbreviations: CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; FEV
1
, forced expiratory volume in one second; 
FVC, forced vital capacity; GOLD, global initiative for obstructive lung disease; mMRC, modified Medical Research Council dyspnoea scale; 
RCP, routine clinical practice.
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Table 3: Overview of the variety of COPD health status, functional status and dyspnoea instruments
COPD-specific health status instruments Generic health status instruments
Dyspnoea/breathlessness/cough instruments
Baseline/Transitional Dyspnoea Index (BDI/TDI) [100-102]
Borg Scale [56]
Breathing Problems Questionnaire (BPQ) [48]
Breathlessness Cough and Sputum Scale (BCSS) [103]
Cough Severity Diary (CSD) [49, 104]
Dyspnoea-12 Tool [49]
Dyspnoea Questionnaire Computer Adaptive Test (DMQ-CAT) [49] 
Global Chest Symptoms Questionnaire (GCSQ) [49]
Leicester Cough Questionnaire (LCQ) [49, 104]
Modified Medical Research Council Dyspnoea Scale (mMRC) [56, 99]
Maugeri Respiratory Failure (MRF-28) [105]
Severe Respiratory Insufficiency Questionnaire (SRI) [105]
Shortness of Breath with Daily Activities Questionnaire (SOBDA) [49]
Dartmouth Northern New England Primary Care Cooperative 
Information Project chart system (DartmCoop) [105]
EuroQol-5D (EQ-5D) [56, 104, 110]
Hyland Scale [105]
Linear Analogue Scale/Visual Analogue Scale (LAS/VAS-8) [105]
Measure Yourself Medical Outcome Profile (MYMOP) [105]
Nottingham Health Profile (NHP) [105]
Quality of Well Being Self-Administered (QWBSA) [105]
Short-Form-12 (SF-12) [56, 104]
Short-Form 36 (SF-36) [56, 104]
Sickness Impact Profile (SIP) [105]
World Health Organisation Quality of Life short version list 
(WHOQOLBREF) [105]
University of California San Diego Shortness of Breath Questionnaire 
(UCSD-SOBQ) [49]
Functional status physical tools
Multi-domain instruments 6 Minute Walking Distance (6MWD) [48-49, 56, 111-112, 104]
Airways Questionnaire (AQ) [104] Activity monitors (e.g. step counters) [48-49, 56, 111-112, 104]
Chronic Respiratory Questionnaire (CRQ) [106] PROActive tools [49]
COPD Assessment Test (CAT) [73] Shuttle Walking Test (SWT) [48-49, 56, 111-112, 104]
Clinical COPD Questionnaire (CCQ) [85]
COPD Specific Item Bank (COPD-SIB) [107]
Health States COPD (HS-COPD) [104]
Living with COPD Questionnaire (LCOPD) [49]
Mc Gill COPD Quality of Life Questionnaire [103]
Quality of Life for Respiratory Illness Questionnaire (QOLRIQ) [48, 108]
Respiratory Quality of Life Questionnaire (RQLQ) [105]
St. George’s Respiratory Questionnaire (SGRQ) [93-94]
Visual Simplified Respiratory Questionnaire (VSRQ) [105, 109]
Functional status questionnaires
Capacity of Daily Living during the Morning Questionnaire 
(CDLM) [49]
London Chest Activity of Daily Living Questionnaire (LCADL) 
[49, 113]
Pulmonary Functional Status and Dyspnoea Questionnaire 
(PFSDQ) [48-49, 56, 111-112, 104]
Pulmonary Functional Status Scale (PFSS) [48-49, 56, 111-112, 104]
Fatigue/energy instruments
Manchester COPD Fatigue Scale [49, 104]
Work-related instruments
Work Productivity and Activity Impairment Questionnaire (WPAI-
COPD) [49, 103]
Note: The provided lists are not intended to be comprehensive. The (multi-domain) COPD-specific health status instruments highlighted 
in bold italics will  form the basis of analysis in this thesis. 
Although other questionnaires are well established, such as the SGRQ and the Chronic 
Respiratory Questionnaire (CRQ), they are too long for use in daily practice. Indeed, the 
CAT, CCQ and SGRQ correlated well, but the CAT and CCQ benefit from being faster 
and easier to administer [72, 90, 92]. The SGRQ is a self-completed standardised multi-
36
Chapter 2
dimensional HRQoL instrument that contains 50 items (Supplementary material 2.4.3) 
[93-94]. It includes domains for symptoms, activity, and impact, with each item having 
an empirically derived weight in the scoring algorithm. Domain and total scores range 
from 0 (best health status) to 100 (worst health status), and the results are considered 
valid, reliable, repeatable, responsive and correlated with reference measures [93-96]. 
Both the SGRQ and CRQ had similar reliability, validity, and responsiveness in patients 
with COPD, with no clear evidence in preference of one instrument over the other [97-
98]. In addition to these health status questionnaires, the (m)MRC dyspnoea scale is 
recommended by GOLD to measure activity limitations due to dyspnoea [1, 99].
In the current thesis, the focus will be on the MCIDs of the (multi-domain) COPD-specific 
CAT, CCQ, and SGRQ health status instruments (Table 3).
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2.4 Supplementary material
2.4.1 The COPD Assessment Test (CAT) (printed with permission)
0 1 2 3 4 5X
Your name: Today’s date:
How is your COPD?Take the COPDAssessmentTest™ (CAT)
This questionnaire will help you and your healthcare professional measure the impact COPD (Chronic Obstructive
Pulmonary Disease) is having on your wellbeing and daily life.Your answers, and test score, can be used by you and
your healthcare professional to help improve the management of your COPD and get the greatest benefit from treatment.
For each item below, place a mark (X) in the box that best describes you currently. Be sure to only select one response
for each question.




COPDAssessmentTest and CAT logo is a trademark of the GlaxoSmithKline group of companies.
© 2009 GlaxoSmithKline. All rights reserved.
I never cough 0 1 2 3 4 5
0 1 2 3 4 5
0 1 2 3 4 5
0 1 2 3 4 5
0 1 2 3 4 5
0 1 2 3 4 5
0 1 2 3 4 5
0 1 2 3 4 5
I cough all the time
I have no phlegm (mucus)
inmychest at all
My chest is completely
full of phlegm (mucus)
My chest does not
feel tight at all
My chest feels
very tight
When I walk up a hill or
one flight of stairs I am
not breathless
When I walk up a hill or
one flight of stairs I am
very breathless
I am not limited doing
any activities at home
I am very limited doing
activities at home
I am confident leaving






I don’t sleep soundly
because ofmy lung
condition
I have lots of energy I have no energy at all
COPD As essment Test and the CAT logo is  trade mark f the GlaxoSmithKline group of companies.
© 2 09 GlaxoSmithKline group of companies. All rights reserved.
Last Updated: February 24, 2012
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2.4.2 The Clinical COPD Questionnaire (CCQ) (printed with permission)
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2.4.3  The St. George’s Respiratory Questionnaire (SGRQ) (printed with permission)




ST. GEORGE’S RESPIRATORY QUESTIONNAIRE
ORIGINAL ENGLISH VERSION
ST. GEORGE’S RESPIRATORY QUESTIONNAIRE (SGRQ)
This questionnaire is designed to help us learn much more about how your
breathing is troubling you and how it affects your life. We are using it to find out
which aspects of your illness cause you most problems, rather than what the
doctors and nurses think your problems are.
Please read the instructions carefully and ask if you do not understand anything. Do
not spend too long deciding about your answers.
Before completing the rest of the questionnaire:













P.W. Jones, PhD FRCP
Professor of Respiratory Medicine,
St. George’s University of London,
Jenner Wing,
Cranmer Terrace, Tel. +44 (0) 20 8725 5371
London SW17 ORE, UK. Fax +44 (0) 20 8725 5955
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St. George’s Respiratory Questionnaire
PART 1
Questions about how much chest trouble you have had over the past 3 months.
















1. Over the past 3 months, I have coughed:     
2. Over the past 3 months, I have brought up
phlegm (sputum):     
3. Over the past 3 months, I have had shortness
of breath:     
4. Over the past 3 months, I have had attacks
of wheezing:     
5. During the past 3 months how many severe or very
unpleasant attacks of chest trouble have you had?
Please tick () one:





6. How long did the worst attack of chest trouble last?
(Go to question 7 if you had no severe attacks)
Please tick () one:
a week or more 
3 or more days 
1 or 2 days 
less than a day 
7. Over the past 3 months, in an average week, how many good days
(with little chest trouble) have you had?
Please tick () one:
No good days 
1 or 2 good days 
3 or 4 good days 
nearly every day is good 
every day is good 
8. If you have a wheeze, is it worse in the morning?
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St. George’s Respiratory Questionnaire
PART 2
Section 1
How would you describe your chest condition?
Please tick () one:
The most important problem I have 
Causes me quite a lot of problems 
Causes me a few problems 
Causes no problem 
If you have ever had paid employment.
Please tick () one:
My chest trouble made me stop work altogether 
My chest trouble interferes with my work or made me change my work 
My chest trouble does not affect my work 
Section 2
Questions about what activities usually make you feel breathless these days.
Please tick () in each box that
applies to you these days:
True False
Sitting or lying still  
Getting washed or dressed  
Walking around the home  
Walking outside on the level  
Walking up a flight of stairs  
Walking up hills  
Playing sports or games  




St. George’s Respiratory Questionnaire
PART 2
Section 1
How would you describe your chest condition?
Please tick () one:
The most important problem I have 
Causes me quite a lot of problems 
Causes me a few problems 
Causes no problem 
If you have ever had paid employment.
Please tick () one:
My chest trouble made me stop work altogether 
My chest trouble interferes with my work or made me ch nge my work 
My chest trouble does not affect my work 
Section 2
Questions about what activities usually make you feel breathless these days.
Pl ase tick () in each box that
applies to you these days:
True False
Sitting or lying still  
Getting washed or dressed  
Walking around the home  
Walking outside on the level  
Walking up a flight of stairs  
Walking up hills  
Playing sports or games  
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St. George’s Respiratory Questionnaire
PART 2
Section 3
Some more questions about your cough and breathlessness these days.
Please tick () in each box that
applies to you these days:
True False
My cough hurts  
My cough makes me tired  
I am breathless when I talk  
I am breathless when I bend over  
My cough or breathing disturbs my sleep  
I get exhausted easily  
Section 4
Questions about other effects that your chest trouble may have on you these days.
Please tick () in each box that
applies to you these days:
True False
My cough or breathing is embarrassing in public  
My chest trouble is a nuisance to my family, friends or neighbours  
I get afraid or panic when I cannot get my breath  
I feel that I am not in control of my chest problem  
I do not expect my chest to get any better  
I have become frail or an invalid because of my chest  
Exercise is not safe for me  
Everything seems too much of an effort  
Section 5
Questions about your medication, if you are receiving no medication go straight to section 6.
Please tick () in each box that
applies to you these days:
True False
My medication does not help me very much  
I get embarrassed using my medication in public  
I have unpleasant side effects from my medication  
My medication interferes with my life a lot  
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St. George’s Respiratory Questionnaire
PART 2
Section 6
These are questions about how your activities might be affected by your breathing.
Please tick () in each box that applies to
you because of your breathing:
True False
I take a long time to get washed or dressed  
I cannot take a bath or shower, or I take a long time  
I walk slower than other people, or I stop for rests  
Jobs such as housework take a long time, or I have to stop for rests  
If I walk up one flight of stairs, I have to go slowly or stop  
If I hurry or walk fast, I have to stop or slow down  
My breathing makes it difficult to do things such as walk up hills, carrying things
up stairs, light gardening such as weeding, dance, play bowls or play golf
My breathing makes it difficult to do things such as carry heavy loads, dig the
garden or shovel snow, jog or walk at 5 miles per hour, play tennis or swim
My breathing makes it difficult to do things such as very heavy manual work,
run, cycle, swim fast or play competitive sports
Section 7
We would like to know how your chest usually affects your daily life.
Please tick () in each box that applies to
you because of your chest trouble:
True False
I cannot play sports or games  
I cannot go out for entertainment or recreation  
I cannot go out of the house to do the shopping  
I cannot do housework  
I cannot move far from my bed or chair  
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St. George’s Respiratory Questionnaire
Here is a list of other activities that your chest trouble may prevent you doing. (You do not have
to tick these, they are just to remind you of ways in which your breathlessness may affect you):
Going for walks or walking the dog
Doing things at home or in the garden
Sexual intercourse
Going out to church, pub, club or place of entertainment
Going out in bad weather or into smoky rooms
Visiting family or friends or playing with children
Please write in any other important activities that your chest trouble may stop you doing:
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Now would you tick in the box (one only) which you think best describes how your chest affects you:
It does not stop me doing anything I would like to do 
It stops me doing one or two things I would like to do 
It stops me doing most of the things I would like to do 
It stops me doing everything I would like to do 
Thank you for filling in this questionnaire. Before you finish would you please check to see that you have
answered all the questions.
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The minimal clinically important difference (MCID) quantifies when measured differences 
can be considered clinically relevant. This study aims to review and triangulate MCIDs 
of health status tools for patients with chronic obstructive pulmonary disease (COPD).
3.1.2 Methods 
A systematic search in PubMed, EMBASE and the Cochrane Library was conducted 
(PROSPERO #CRD42015023221). Study details, patient characteristics, MCID methodology 
and estimates were assessed and extracted by two authors. A triangulated mean was 
obtained for each tool’s MCID, with two-thirds weighting for anchor-based and one-third 
for distribution-based results. This was then multiplied by a weighted factor based upon 
the study size and quality rating.
3.1.3 Results
Overall, 785 records were reviewed of which 21 studies were included for analysis. MCIDs 
of 12 tools were presented. General quality and risk of bias were average to good. 
Triangulated MCIDs for the COPD Assessment Test (CAT), Clinical COPD Questionnaire 
(CCQ) and St. George’s Respiratory Questionnaire (SGRQ) were respectively -2.54, -0.43 
and -7.43 for improvement. Too few and/or too diverse studies were present to triangulate 
MCIDs of the other tools. 
3.1.4 Discussion and conclusions
Evidence for the MCID of the CAT and CCQ was strong and triangulation was valid. 
Currently used MCIDs in clinical practice for the SGRQ (4 points) and the Chronic 
Respiratory Questionnaire (0.5 point) did not match the reviewed content, for which the 
MCIDs were much higher. Using too low MCIDs may lead to an overestimation of the 
interpretation of treatment effects. MCIDs for deterioration were scarce, which highlights 
the need for more research.




Health status measurements and thresholds for clinically important change are 
frequently used as obligatory endpoints in medical trials, scientific research and 
clinical practice to evaluate the effects of an intervention [1-6]. The minimal clinically 
important difference (MCID) is a pivotal parameter that quantifies this threshold for 
clinically relevant change. It has been defined by Jaeschke et al. [7] as “the smallest 
difference in score in the domain of interest, which patients perceive as beneficial and which 
would mandate, in the absence of troublesome side-effects and excessive costs, a change 
in the patient’s management”. The MCID is often used as a cutoff value to compare the 
percentage of patients achieving the level of clinically relevant change after intervention 
or pharmacotherapy in comparison to a control group [5-6, 8]. It is also used to define 
sample size and to evaluate change in clinical practice. Setting an MCID too high could 
lead to underestimation of the interpretation of treatment effects; defining a MCID too 
low may result in overestimation of this interpretation. 
The measurement of health status and its MCIDs is of particular interest in chronic 
obstructive pulmonary disease (COPD). Physiologic measures like spirometry are often of 
interest to the physician, but of limited importance to patients, because these outcomes 
do not correlate well with their quality of life (QoL) [3, 9-16]. Patients can have similar 
spirometry or blood tests, but may experience very different levels of QoL and health 
status. QoL is “the degree of satisfaction or dissatisfaction with various aspects of life that 
may be important to the individual” [17]. Health status is considered “the impact of health 
on a person’s ability to perform and derive fulfillment from the activities of daily life” [10, 18]. It 
is a standardised way of measuring the concepts health-related quality of life (HRQoL), 
functional status and mental well-being [2, 10]. HRQoL and health status questionnaires 
– often patient-reported outcomes (PROs) – have received much attention in the last few 
years, resulting in their inclusion in the global initiative for chronic obstructive lung disease 
(GOLD) guidelines for the classification of patient risk groups to guide treatment [12].
Many general and disease-specific HRQoL and health status tools exist, with varying 
designs ranging from single items to complex multi-domain questionnaires [1-2, 9-11, 19-
22]. It is important that an instrument has strong measurement properties, including 
responsiveness, interpretability and good signal-to-noise ratio [1, 9-10, 22-23]. The MCID 
is an important parameter within these categories. Many authors have discussed the 
theory and methods to determine an instrument’s MCID [2, 4, 24-45]. These are generally 
divided into anchor-, distribution-, and opinion-based approaches. Each method has its 
pros and cons. To date, there is no gold standard in defining an instrument’s MCID [2, 
44]. Hence, many different practices occur, some better than others. It is recommended 
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that both anchor- and distribution-based methods are used, combined with evidence 
from clinical trial data and qualitative approaches, with a systematic review or expert 
panel to aim for triangulation [33, 45].
Given the importance of MCIDs for research and clinical practice, there has been an 
increase in studies investigating the MCID of HRQoL and health status tools for COPD. 
Various authors have provided overviews of frequently used instruments for COPD, 
incidentally reporting the value or a short description of its MCID [3, 8, 10, 16, 28-29, 38, 
46-52]. In addition, some publications have presented a description of the evidence 
for the MCID of specific COPD-related outcomes, including the St. George’s Respiratory 
Questionnaire (SGRQ) [53], exacerbations [39], Transition Dyspnoea Index (TDI) [54], 
forced expiratory volume in one second (FEV
1
) [55], Clinical COPD Questionnaire (CCQ) 
[56], and COPD Assessment Test (CAT) [57]. Most studies have not recently been updated, 
and none of these studies attempted to evaluate the quality of the MCID methodology 
or aim for triangulation. Outside the field of COPD, systematic reviews have emerged 
that summarise, quantify and make a quality assessment of the MCIDs of PROs and 
functional status tests [31, 58-64]. Our study here is the first to do so within the field of 
COPD. We aimed to systematically review the available evidence for the MCID of various 
HRQoL and health status tools used in COPD practice; to assess the quality of their 
methodology; and to attempt to triangulate the results as a kind of meta-analysis.
3.3 Methods
3.3.1 Search strategy
The preferred reporting items for systematic reviews and meta-analyses (PRISMA) 
statement served as a guideline for this systematic review [65]. The study protocol was 
prepared and published via PROSPERO (#CRD42015023221) [66]. PubMed, EMBASE and 
the Cochrane Library were searched to identify relevant original full-text articles on 
the measurement of MCIDs of HRQoL and health status tools for patients with COPD. 
The search strategy included various terms for the MCID determination of HRQoL 
questionnaires and/or health status measurement tools and/or PROs in adults with 
COPD (Supplementary material 3.7.1). The search was conducted on the 9th of June 2015 
and updated regularly with the final update on the 16th of June 2017. It included all studies 
and research designs prior to this.




Studies were considered eligible if they included approaches and original measurement 
data for the MCID of a generic or disease-specific HRQoL questionnaire and/or health 
status instrument and/or PRO used in adults with COPD. HRQoL and health status 
instruments were considered eligible when they captured more than one domain of the 
concepts physical, psychological and social functioning [1-2]. For patients with COPD, 
this would include concepts such as breathlessness, fatigue, cough, sputum production, 
physical functioning, social functioning, mental well-being and exacerbations [16]. The 
term health status will be used for future reference in this review. Only full-text studies 
containing original data were included. Conference abstracts, editorials and opinion 
articles were excluded. Reviews were initially included to explore the references. Non-
English publications were translated if considered eligible.
3.3.3 Study selection
Titles and abstracts of the identified articles were screened by two authors (HA and 
CdJ) independently. The screening process included: (1) the study design and type was 
identified; (2) the measurement tool was identified; (3) a judgement was made whether 
the tool was a questionnaire or PRO, which measured health status according to the 
predefined inclusion definition; (4) the population was identified and screened for 
adults with COPD; (5) the aim of the study was identified, which needed to determine 
the instrument’s MCID; (6) a description of the MCID methodology and final quantitative 
estimates should be available; (7) final judgement for eligibility was made. Independent 
results from both authors were compared. Where disagreement occurred, this was 
discussed and consensus was reached; or a third author (IT, TvdM or RS) was consulted. 
Full-text articles were retrieved for the selected studies and again checked according to 
the above stated seven steps. The reference lists of the selected articles were screened 
for additional titles. The abstracts of the additional titles were screened accordingly for 
meeting the pre-defined inclusion criteria.   
3.3.4 Quality assessment and risk of bias
Eligible full text articles were assessed for their quality and risk of bias by two authors (HA 
and CdJ) independently. Disagreement between the authors was solved by consensus 
or involvement of a third author (IT, TvdM or RS). The authors composed a quality 
assessment and risk of bias tool by selecting 31 relevant items from various sources, 
because there was no specific tool available for evaluating studies that measure an 
instrument’s MCID (Supplementary material 3.7.2). Furthermore, various research designs 
were included, which made it difficult to use one specific checklist. 
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Items on study methodology and questionnaire design were selected from the 
Cochrane Risk of Bias tool [67] and the COSMIN checklist [68]. These items concerned 
the attrition and missing data procedures; selective outcome reporting; risk of funding 
and ownership bias; availability of at least two health status measurements; time 
interval of measurement stated; similar test conditions for both measurements; follow-
up completed; validation and properties of the health status tool described; floor- and 
ceiling effects described; whether the MCID was calculated; and whether criterion/
anchors used were considered golden standard. Additional items were retrieved from 
the systematic reviews by Bohannon et al. [58-59]: clear inclusion/exclusion criteria; 
systematic enrollment of patients; missing data percentage less than 25%; more than one 
anchor used; and the use of receiver operating characteristics (ROC) curves with an area 
under the curve (AUC) of at least 0.70. The current authors added the following items 
based upon recommendations in the literature [2, 33, 45, 69]: adequate description of 
the anchor and its properties; anchor correlations at least 0.50; global rating of change 
(GRC) used with 11 or more scoring options; type of clinical criterion used; more than one 
distribution-based method used; MCID for more than one population measured; and 
whether the MCID was determined for improvement, deterioration or both. 
The general scoring of the quality assessment and risk of bias included the answering 
options “yes”, “no”, “unclear” and “not applicable”, as deducted from the COSMIN checklist 
[68]. “Not applicable” was selected for MCID related items that were not relevant for the 
corresponding study. Positive answers / low bias items were scored 2 points; unclear 
items were scored 1 point; and negative answers / high bias / not applicable items were 
scored 0 points. Individual items were scored and presented. An overall total score with 
a maximum of 62 could be obtained. Five categories were defined for the overall quality 
stratification, which was required for triangulation procedures. The overall risk of bias 
and quality assessment was given a star rating between one and five, calculated from 
the summed scores as follows: 0–12, one star; 13–25, two stars; 26–37, three stars; 38–49, 
four stars; and 50–62, five stars.
3.3.5 Data extraction, synthesis and analysis
Data were extracted using a standardised form including the general article properties; 
study properties; patient characteristics; health status measurements; and MCID 
properties (methodology, type of change, type of MCID, MCID estimates, and missing 
data procedures). Results from the full-text analysis were categorised per identified 
health status tool. Data were presented in tables and figures. A narrative synthesis of 
the MCID results, its methodology and its quality was prepared per instrument including 
forest plots. Primary outcome measures were the quality assessment of the MCIDs for 
health status tools in COPD, an overview of its MCID methods and estimates; as well 
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as triangulation of the MCIDs where multiple studies per instrument existed. Since no 
standard for triangulation exists, the authors determined the final triangulation as 
following. Triangulation was executed by first determining an anchor-based and 
distribution-based MCID per included study. The anchor-based result received a weight 
of two-thirds, and the distribution-based method received a weight of one-third. The 
results were multiplied by a weighted factor depending on the study size (n) and the 
quality star rating (one to five stars). An overall triangulated mean MCID was calculated 
per health status tool.
3.4 Results
The initial search in PubMed, EMBASE and the Cochrane Library resulted in 668 unique 
studies (Figure 1). Screening the references provided an additional 117 titles, resulting in 
a total of 785 unique records. After screening all titles and abstracts, 78 papers were 
assessed for eligibility. A full-text analysis lead to the removal of 57 papers (Online 
Supplementary Table 3, European Respiratory Journal), leaving 21 records for inclusion 
(Table 1) [7, 70-89]. The initial level of agreement between the authors (HA and CdJ) was 
89.2% for the study selection process. Cohens kappa for the quality and risk of bias 
assessment was 0.42. The included studies discussed in alphabetical order the tools CAT, 
CCQ, (short-form) Chronic Respiratory Questionnaire 
((SF)-CRQ), the eDiary, EuroQol five Dimensions (EQ-
5D), Feeling Thermometer (FT), SGRQ, Short-Form 6 
Dimensions (SF-6D), Short-Form 36 (SF-36), Quality of 
Life for Respiratory Illness Questionnaire (QOLRIQ) and 
Visual Simplified Respiratory Questionnaire (VSRQ). Full 
patient characteristics, inclusion- and exclusion criteria, 
and health status scores are available in the Online 
Supplementary Tables 4 and 5 (European Respiratory 
Journal). 
Most studies scored well on the overall quality of the general study methodology with 
the exception of the items on systematic enrollment, similar test conditions pre-and post-
measurement, the description of floor- and ceiling effects, and unclear/high selective 
outcome reporting bias (Table 2). Four studies scored lower on the description of general 
study methodology [7, 72, 80, 87]. Regarding the quality of the MCID methodology, various 
studies scored poorly on the use of more than one anchor and/or lacked (sufficient) 
correlations with the chosen anchor [7, 71-78, 80, 85-88]. A limited number of studies used 
ROC curves in the anchor-based method of which most failed to define sufficient AUC  [7, 
Online Supplementary Tables 
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71-75, 77-88]. A minority of studies used a GRC scale with sufficient answering categories [7, 
70, 74, 79, 88]. Two studies used criterion referencing [70, 84]. Some of the included studies 
used more than one distribution-based method [70-71, 75-76, 82, 84-86]. A limited number 
of studies measured the MCID in more than one population [7, 72-73, 75, 87]. Certain studies 
determined the MCID for both improvement and deterioration [7, 71, 75, 80, 84-86, 88].  In 
most studies, there was a risk of ownership bias. 
Figure 1: PRISMA flow-chart of the search results
Abbreviations: COPD, chronic obstructive pulmonary disease; MCID, minimal clinically important difference; N, number of items.
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3.4.1 COPD Assessment Test (CAT) 
The CAT contains eight questions with item scores ranging 0 (no limitations) up to 5 
(maximum limitations) [90]. The total score derives from summing all items (min: 0, 
max: 40). Six papers discussed the MCID for the CAT in pulmonary rehabilitation (PR) 
[70, 72, 75, 82]; in patients with acute COPD exacerbation [73, 75]; and in regular primary 
and secondary care [75, 83] with follow-up periods of 2 weeks to 12 months (Table 1). 
The included studies received overall quality assessments of respectively two [83], three 
[72-73], four [75, 82]; or five stars [70] (Table 2). Anchor-based methods resulted in an 
MCID range for improvement for the CAT of -3.50 to -1.00 including the use of various 
GRCs by patients and physicians; exacerbations as a criterion; and CCQ, CRQ and 
SGRQ as anchors in ROC curves, linear regression analysis and mean change score 
calculations (Figure 2 and Online Supplementary Table 6 European Respiratory Journal) 
[70, 72, 73, 75, 82]. The anchor-based MCID for deterioration ranged +1 (n=51) to +2 (n=3) 
[72, 75]. Distribution-based approaches including the 
half standard deviation (0.5SD), standardised error of 
measurement (SEM) and 1.96 SEM ranged 1.92-3.80 [70, 
75, 82, 83], excluding the 1.96SEM outlier of 6.43 [70]. 
The triangulated MCID for improvement was -2.54, 
excluding this 1.96SEM outlier. No structural differences 
were observed between different settings or follow-up 
periods. However, the anchor-based MCIDs by Dodd et 
al. [72] during 8 weeks of PR and by Kon et al. [75] during 
12 months of regular care were smaller (Figure 2).
3.4.2 Clinical COPD Questionnaire (CCQ)
The CCQ contains 10 questions with item scores ranging 0 (no limitations) to 6 (maximum 
limitations) [91]. Total and domain scores (symptoms, functional and mental status) result 
from summing relevant scores and dividing this by the number of items (min: 0, max: 6). 
Five papers discussed the MCID for the CCQ in PR [70, 76, 82]; in patients with acute COPD 
exacerbation [74]; and in regular primary and secondary care [83] with follow-up periods of 2 
days up to 12 months (Table 1). The overall quality of the included studies was rated as two [83], 
four [74, 76, 82], or five stars [70] (Table 2). The MCID for improvement for the CCQ total score 
ranged from -0.62 to -0.34 including various anchor-based methods with a 15-point GRC; 
criterion-referencing; and CAT, SGRQ and CRQ as anchors in linear regression, mean change 
calculations and ROC curves (Figure 3, Online Supplementary Table 6 European Respiratory 
Journal) [70, 74, 76, 82]. 
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The MCID for deterioration for the CCQ has not been determined. Results on the domain 
scores are available in the Online Supplementary Table 6 (European Respiratory Journal). 
Distribution-based methods with 0.5SD, SEM and 1.96 SEM ranged from 0.21 to 0.56 [70, 74, 
76, 82-83], excluding the outlier of the 0.80 estimate of the minimal detectable change 95% 
confidence interval (MDC95) [76]. The triangulated MCID for improvement for the CCQ was 
-0.43. Estimates from PR, patients with acute exacerbation and regular care with various 
follow-up durations were similar, except for the distribution-based estimate by Kocks et al. [74] 
in exacerbation patients (Figure 3).
3.4.3 (SF-)CRQ 
The CRQ consists of 20 items scored on a 7-point scale ranging 1 (most troubles) to 7 (no 
troubles) on the domains dyspnoea (5 items), fatigue (4 items), emotional function (7 
items), and mastery (4 items) [92]. Domain scores are determined by summing the scores 
or determining the mean of the summed items [7, 80, 88]. The SF-CRQ includes 2 selected 
items per domain [71]. 
Four papers reported the MCID for the (SF)-CRQ in PR [7, 80]; in patients with acute COPD 
exacerbation [71]; in a salbutamol trial [7]; in regular primary care [88] and by means of expert 
opinions [88] (Table 1), with follow-up periods of 2–24 weeks. Overall quality was rated two [80], 
three [7, 71] or four stars [88] (Table 2). MCID estimates for both improvement and deterioration 
were determined in all studies (Online Supplementary Table 6 European Respiratory Journal). 
The MCIDs resulted from the anchor-based method using a 5-, 7- or 15-point GRC for both 
within- and between subject change [71, 7, 88, 80]. The MCIDs for improvement for the SF-CRQ 
ranged from 0.30 to 1.60 as average domain score change (2 items per domain); and for 
deterioration from -0.60 to -0.06 [71]. The MCIDs for the CRQ for improvement per item score 
were: 0.40 to 1.00 (dyspnoea), 0.25 to 0.50 (fatigue), 0.14 (emotion), and 0 to 0.25 (mastery). 
The MCIDs for the CRQ for deterioration per item score were -0.20 (dyspnoea), -0.50 (fatigue), 
-0.14 to 0 (emotion) and -0.50 to -0.25 (mastery) [88]. A combined MCID for improvement 
and deterioration was per item 0.09 to 0.62 (dyspnoea), 0.50 to 0.68 (fatigue), 0.57 to 0.87 
(emotion), and 0.23 to 0.75 (mastery) [7, 80, 88]. Due to the limited number of studies, the 
diversity of domains and scoring approaches, and the small number of patients in certain 
studies [7], no triangulation was performed. 
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Figure 2: Overview study results and triangulation for the MCID of the CAT
Data presented as mean study MCIDs for anchor-based and distribution-based methods (squared estimates). The horizontal lines 
include the range of estimates provided in the respective study. The larger diamond represent the triangulated MCID. Results are 
categorised per setting in correspondence with the duration of follow-up period.
Abbreviations: AECOPD, acute exacerbation chronic obstructive pulmonary disease; CAT, COPD Assessment Test; COPD, chronic 
obstructive pulmonary disease; MCID, minimal clinically important difference; PR, pulmonary rehabilitation.
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Figure 3: Overview study results and triangulation for the MCID of the CCQ
Data presented as mean study MCIDs for anchor-based and distribution-based methods (squared estimates). The horizontal lines include 
the range of estimates provided in the respective study. The larger diamond represent the triangulated MCID. Results are categorised per 
setting in correspondence with the duration of follow-up period.
Abbreviations: AECOPD, acute exacerbation chronic obstructive pulmonary disease; CCQ, Clinical COPD Questionnaire; COPD, chronic 
obstructive pulmonary disease; MCID, minimal clinically important difference; PR, pulmonary rehabilitation.
3.4.4 EQ-5D Utilities Index and Visual Analogue Scale
The EQ-5D contains the 5 dimensions mobility, self-care, usual activities, pain/discomfort, 
and anxiety/depression with each three (EQ-5D-3L) or five levels (EQ-5D-5L) in scoring 
severity [93-94]. A scoring algorithm results in an utility index (UI) between -0.590 (worst 
health) and +1.000 (best health) for the 3L version; and -0.208 to +1.000 for the 5L version. 
In addition, a visual analogue scale (VAS) score must be marked from 0 (worst health) to 
100 (best health). Three papers discussed the MCID for the EQ-5D-5L UI, VAS and/or EQ-
5D-3L-VAS in PR [78, 89]; and for the EQ-5D-3L in regular secondary care [86], with follow-
up periods of 3 weeks to 12 months (Table 1). The quality assessment differed from three 
[86] to four stars [78, 89] (Table 2). The MCID for improvement for the EQ-5D-VAS ranged 
from 6.50 to 10.10 [78, 89]. The anchor-based MCID for improvement for the EQ-5D-3L 
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and EQ-5D-5L UI ranged from -0.128 to 0.063 [78, 86]. Estimates for deterioration ranged 
from -0.007 to 0.039 [86]. A combined MCID for improvement and deterioration ranged 
from -0.011 to zero [86]. Distribution-based results ranged from -0.050 to 0.150 [78, 86] 
(Online Supplementary Table 6 European Respiratory Journal). Owing to the limited number 
of included studies and the diversity of the results, no triangulation was executed.
3.4.5 SF-6D and SF-36
The SF-36 contains 36 items divided over eight domains each scoring between 0 (worst 
health) and 100 (best health) [95]. The SF-6D includes six dimensions resulting in a health 
state ranging 0.29 (worst health) to 1.00 (full health) [85]. Two papers discussed the 
MCID for the SF-6D in regular care [85-86], and one for the SF-36 in regular care and 
by means of expert opinions [88] (Table 1). Both studies on the SF-6D [85-86] were of 
average quality (three stars); the study on the SF-36 by Wyrwich et al. [88] was of good 
quality (four stars) (Table 2). The MCID for improvement for the various SF-36 domains 
ranged from 2 to 11 using a GRC scored by the patient or the physician [88]. The range 
for deterioration was -6 to +4. The expert-based panel determined that values of 8.33 
to 12.50 to represent minimal changes [88]. The MCID for improvement for the SF-6D 
using a 5-point GRC ranged from -0.004 to +0.054; for deterioration ranged from 0.012 
to 0.028; and combined ranged from 0.010 to 0.036 [85-86]. The distribution-based 
estimates for the SF-6D ranged from 0.044 to 0.410 using the standardised response 
mean (SRM), effect size (ES) and 0.5SD [85-86] (Online Supplementary Table 6 European 
Respiratory Journal). Owing to the limited number of included studies and diversity of the 
results, no triangulation was performed.
3.4.6 St. George’s Respiratory Questionnaire (SGRQ) 
The SGRQ is a 50-item questionnaire containing the domains symptoms, activities 
and impact with total and domain scores ranging 0 (best health status) to 100 (worst 
health status) [96]. Four studies analysed the MCID for the SGRQ during PR [70, 81]; 
bronchoscopic lung volume reduction (BLVR) [87]; and regular primary and secondary 
care [83] with follow-up periods of 2 weeks to 6 months (Table 1). The included studies 
scored two [83], three [81, 87], or five stars [70] (Table 2). The MCID was determined for 
improvement only. Anchor-based approaches resulted in an MCID for the SGRQ between 
-9.28 and -6.30 using a 15-point GRC, criterion-referencing; and CAT, CCQ, FEV
1
, six minute 
walking distance (6MWD) and residual volume (RV) as anchors in linear regression, mean 
change calculations and ROC curves (Figure 4, Online Supplementary Table 6 European 
Respiratory Journal)  [70, 87]. An outlying anchor-based result by Schünemann et al. [81] 
was -3.05 using the CRQ dyspnoea domain in linear regression analysis. Distribution-
based results ranged from 2.40 to 10.19 using 0.2-0.8SD, SEM and 1.96SEM [70, 81, 83, 87]. 
The triangulated MCID for improvement was -7.43. Estimates from 3 weeks of PR [70], 
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and 1 and 6 months BLVR [87] were similar (Figure 4). However, the 3 months’ PR anchor-
based estimate by Schünemann et al. [81] was much smaller using the CRQ dyspnoea 
domain as anchor. The distribution-based result by Tsiligianni et al. [83] was also much 
smaller, when measured in regular care. 
Figure 4: Overview study results and triangulation for the MCID of the SGRQ 
Data presented as mean study MCIDs for anchor-based and distribution-based methods (squared estimates). The horizontal lines include 
the range of estimates provided in the respective study. The larger diamond represent the triangulated MCID. Results are categorised per 
setting in correspondence with the duration of follow-up period.
Abbreviations: BLVR, bronchoscopic lung volume reduction; MCID, minimal clinically important difference; PR, pulmonary rehabilitation, 




The other tools discussed included the eDiary [77], VSRQ [79], FT [81] and the QOLRIQ [84] 
(Table 1). The eDiary contains 5 symptom items and 2 impact items, resulting in scores 
ranging from 0 (best possible state/no problems) to 10 (worst possible state) [77]. The 
FT is a VAS ranging from 0 (worst state) to 100 (best score) [81]. The QOLRIQ contains 55 
items regarding breathing problems, physical problems, emotions, situations triggering 
or enhancing breathing problems, general activities, daily and domestic activities, 
and social activities, relationships and sexuality [84]. Scores range on a 7-point scale 
with higher scores representing more impairment. The VSRQ contains 8 items covering 
dyspnoea, anxiety, depression, sleep, energy, daily activities, social activities, and 
sexual life [79]. Scores range from 0 to 10 with lower scores indicating higher impact 
on the patients’ HRQoL. The included studies were of average (three stars) [77, 81] to 
good quality (four stars) [79, 84] (Table 2). All studies measured the MCID using anchor-
based methods with multiple anchors using reasonable methodology. The MCID for 
improvement for the eDiary was -0.64 to -0.52 using a 7-point GRC and the TDI as anchors 
[77] (Online Supplementary Table 6 European Respiratory Journal). The MCID for improvement 
for the VSRQ was 3.20 to 3.50 using a 15-point GRC and the SGRQ as anchors in linear 
regression [79]. The MCID for the FT was 4.10 to 16.30 using the CRQ fatigue domain, and the 
SGRQ total and domain scores as anchors in linear regression; as well as the distribution-
based methods 0.2-0.8SD [79]. The MCID for improvement for the QOLRIQ was 0.51 to 0.64; 
and for deterioration 0.37 to 0.49 using a 5-point GRC [84]. The distribution-based results 
ranged from 0.18 to 0.45 [84]. No triangulation was executed owing to the low number of 
studies per instrument.
3.5 Discussion 
3.5.1 Summary of main results
The current systematic review provides a unique overview and triangulation of 21 
papers including 12 different HRQoL and health status tools for COPD, and their MCID 
methodology, quality and estimates. The tools included are the CAT, CCQ, (SF)CRQ, 
eDiary, EQ-5D, FT, QOLRIQ, SF-6D, SF-36, SGRQ, and VSRQ. The overall quality of the 
methodology and MCID calculation was average to good, with one study scoring 
excellent and two studies scoring poor. Triangulated MCIDs for CAT, CCQ and SGRQ 
were -2.54, -0.43 and -7.43 for improvement, without structural differences between 
various settings and/or follow-up duration. The other instruments had too few or too 
heterogeneous studies to attempt triangulation; however ranges have been presented. 
Studies on MCIDs for deterioration were scarce or non-existent for all tools. 
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3.5.2 Interpretation of findings
COPD assessment and management should include health status instruments combined 
with the number of exacerbations to decide on patients’ classification and therapy [12]. 
These tools are difficult to use in daily practice and scientific research without guidelines 
on what change may be considered clinically relevant [1, 3, 5, 9-10, 22-23]. The MCID 
parameter aims to quantify this threshold at the group-level [2, 6, 8]. It is an obligatory 
endpoint in clinical trials in which the percentage of patients achieving clinically relevant 
change is compared to the percentage of control patients achieving this change [2, 6, 
8]. The MCID may also indicate to what extent an individual patient experiences relevant 
change over time. It is therefore of pivotal concern that the MCID is well established, else 
this may result in over- or underestimation of the interpretation of treatment effects. This 
review has provided insight into the quality and quantity of the MCID for various HRQoL 
and health status instruments for COPD with the CAT, CCQ, CRQ and SGRQ as the most 
important tools. The short CAT and CCQ are recommended especially for use in clinical 
practice; the lengthier CRQ and SGRQ are more applicable for scientific research [12, 52, 
97]. 
The MCID for improvement for the CAT was between -4 and -1, with the majority of 
estimates between -3 and -2, resulting in a triangulated MCID of -2.54 [70, 72, 73, 75, 
82-83]. This estimate was valid from multiple studies performed at the group level, 
demonstrating consistency of results for different settings with various follow-up 
periods. Stability of MCIDs during various follow-up periods was also demonstrated by 
Alma et al. [98]. Because the CAT only allows for integer scores at the individual level 
[90], a change of -3 could be considered a clinically relevant improvement for use in 
daily clinical practice. The MCID for deterioration for the CAT was between 1 and 2; 
however this resulted from two studies with a limited number of patients [72, 75]. The 
MCID for the CCQ was valid for improvement only, ranging from -0.60 to -0.20, leading to 
a triangulated estimate of -0.43 valid from PR, patients with an acute exacerbation, and 
regular care [70, 74, 76, 82-83]. Because the quality of the included studies for CAT and 
CCQ was average to excellent, and the quality and size of the study was integrated in the 
triangulation, these estimates are valid for use in clinical practice and scientific research. 
The triangulated estimates for CAT and CCQ are close to the accepted MCIDs currently 
used in practice nowadays, respectively -2 and -0.40 [12]. MCIDs for deterioration were 
not readily available. 
The MCID for the SGRQ in the current review ranged from -11 to -2 for improvement, with 
most estimates between -10 and -6, resulting in a triangulated MCID of -7.43. However, 
the MCID for the SGRQ extensively used in clinical practice is 4 points. This estimate was 
based upon analyses of Jones and colleagues in 1991 and 2005 [53, 95]. The evidence 
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found in this review suggests the MCID to be almost double that and the studies that 
formed the basis for the currently accepted MCID for the SGRQ [53, 95] did not meet 
the study criteria for this review. It is therefore questionable how grounded the currently 
accepted MCID of 4 points is. Our evidence for the MCID for the SGRQ was of average to 
excellent quality, which validates the triangulated value of -7.43. The MCID for the SGRQ 
of 4 points for improvement has also been used as an anchor for the MCID of the CAT [70, 
73, 75, 82], CCQ [70, 76, 82], VSRQ [79], and FT [81]. It may in fact have led to lower MCIDs 
for these tools. However, these tools have used other anchors and techniques in addition 
to the SGRQ to determine the MCID, validating their currently estimated (triangulated) 
values. Still, careful selection of anchors should be advocated.
CRQ item MCIDs of 0.50 points have been regularly used for both improvement and 
deterioration based upon Jaeschke et al. [7] and Redelmeier et al. [80]. However, the range 
of item MCIDs for both CRQ and SF-CRQ were wider and more inconsistent based upon 
the current review. The assessed quality of both studies was poor to average [7, 80]. The 
MCID for the CRQ of 0.5 might therefore be too simple an interpretation of results from 
methods of questionable quality. Owing to the inconsistent results, variety of scoring 
techniques and limited size of the studies, no triangulation was executed. The item MCID 
of 0.50 points has been used as an anchor for the MCIDs of the CAT [75], CCQ [76], SGRQ 
[81] and EQ-5D [78], which may have affected their MCIDs. The use of the CRQ as anchor 
did not result in structurally different results for the MCID of the CAT and CCQ. However, 
it did result in an outlying, possibly (too) low MCID for the SRGQ using the CRQ dyspnoea 
domain as reference [81]. 
The general health status instruments EQ-5D, SF-6D and SF-36 had less evidence for their 
MCIDs in COPD. The UI estimates for the EQ-5D and SF-6D varied and inconsistently ranged 
from minus to plus scores including the zero estimate. The MCID for improvement for the 
VAS of the EQ-5D was between 6 and 10 points [89]. General instruments may be applicable 
when comparing HRQoL between patient disease groups; however it is not valid to use their 
MCIDs to evaluate therapy outcomes within a patient group. To compare within patient 
groups, disease-specific health status tools such as CAT and CCQ are more valid, with 
well-established MCIDs. The other tools in our review, including the eDiary, FT, QOLRIQ, and 
VSRQ, each had only one study available regarding its MCID. More research is required for 
these instruments for them to be used in clinical practice.  
In general, determining the MCID for an HRQoL and health status instrument requires 
a combination of anchor- and distribution-based methods, preferably measured in 
multiple settings over various follow-up periods [33, 45]. All included studies in this review, 
except for one [83], used anchor-based methods in measuring the MCID. Most studies, 
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except for five papers [7, 72-73, 80, 83], combined anchor-, distribution- and/or opinion-
based methods as recommended. Studies regarding the CRQ, SF-6D and SF-36 in general 
did not use multiple anchors to determine the MCID. Furthermore, in most studies, the 
presentation of anchor correlations or correlations being ≥0.50, the use of ROC curves 
with AUC ≥0.70, and the use of a GRC with ≥11 answering options, was poor. Most studies 
did not use multiple distribution-based methods either. These would be points of attention 
for future MCID determination processes.
3.5.3 Strength and limitations of the current study
This study is the first to systematically address the MCIDs of HRQoL and health status 
tools for COPD. Although other papers have provided an overview of instruments, none 
of them has addressed the methodology, values and triangulation of MCIDs [3, 8, 10, 16, 
28-29, 38-39, 46-57]. This study had a structurally defined protocol that was thoroughly 
executed by two independent reviewers. This review could be a starting point for further 
discussion. There are currently no fixed guidelines on how to judge studies measuring 
an instrument’s MCID nor guidelines for triangulation. Triangulation should involve a 
combination of anchor- and distribution-based methods combined with evidence from 
clinical trial data and qualitative approaches [33, 45]; however this does not provide 
clear guidelines. The current authors have selected elements from existing assessment 
tools for their own risk of bias and quality assessment to evaluate the studies, its MCID 
methodologies and quality. This combined tool has not been validated. However, 
because it contained elements of established checklists and the MCID literature, the 
authors feel that there has been a sound evaluation of the overall quality and risk of bias 
of the included studies. The triangulation process as performed in the current review has 
not been used before, but takes into account the MCID methodology, its quality and the 
study size.  
3.5.4 Implications for clinical practice and future research
This systematic review highlights gaps in the current MCID evidence and a need for 
further research. First, evidence is limited or lacking for the MCID for deterioration for all 
HRQoL and health status tools for COPD. This is relevant, because MCIDs for improvement 
are not necessarily similar to those for deterioration [2]. COPD is a progressive disease 
causing deterioration of HRQoL over time, which makes MCIDs for deterioration clinically 
important [99-100]. Second, the MCID for improvement for the CAT and CCQ were well-
established in different settings for various follow-up durations. The triangulated MCIDs 
could be used in diverse clinical practices. However, the frequently used MCIDs for SGRQ 
and CRQ lacked evidence for the currently used clinical values of, respectively, 4 and 
0.50 points. These estimates have been used as obligatory endpoints in clinical trials 
for many years. This might have resulted in an overestimation of the interpretation of 
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treatment effects. MCIDs for SGRQ and CRQ should thus be reconsidered; however this 
has major clinical consequences for the currently approved evidence-based therapies in 
COPD. It would be impossible to re-evaluate all clinical trials to date that have used the 
SGRQ and/or CRQ as outcome parameters. However, it may be worthwhile reviewing the 
existing evidence to observe which level of evidence remains valid with alternative MCIDs 
for the SGRQ and CRQ. Current knowledge and guidelines of health status measurement 
and its MCIDs have evolved over time. Older instruments such as the SGRQ and CRQ and 
their MCIDs may not have evolved with current guidelines. Last, evidence for the MCID for 
the eDiary, EQ5D, FT, QOLRIQ, SF-6D, SF-36, and VSRQ was limited in terms of consistency 
and number of studies available, highlighting the need for more research before they 
can reliably be used in clinical practice.  
3.5.5 Conclusion
This study provides a first comprehensive and systematic assessment of MCIDs for HRQoL 
and health status instruments for patients with COPD. It highlights pros and cons in the 
used methodology, as well as gaps in the evidence. Triangulated MCIDs for the CAT, 
CCQ and SGRQ were, respectively, -2.54, -0.43 and -7.43 for improvement. These values 
may be integrated in future GOLD guidelines. This is an important step for clinicians and 
patients, who could easily use MCIDs in their scientific research and clinical practice. The 
MCIDs for the CAT and CCQ are well-established; however the reviewed MCIDs poorly 
matched with currently used values for the SGRQ (4 points) and CRQ (0.50 point). It is 
recommended that CAT or CCQ are used as outcome parameters for health status in 
COPD and that MCIDs for SGRQ and CRQ are recalculated. Evidence for the MCID for 
the other tools included was inconsistent, too heterogeneous or too limited. The fact 
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3.7.2 Risk of bias and quality assessment
Table 2: Risk of bias and quality assessment form
Selected item Scoring method (points)
1. Were participant inclusion criteria clearly defined? Yes (2)      No (0)    Unclear (1) 
2. Were participant exclusion criteria clearly defined? Yes (2)      No (0)    Unclear (1) 
3. Were patients systematically enrolled? Yes (2)      No (0)    Unclear (1) 
4. Was follow-up completed? Yes (2)      No (0)    Unclear (1) 
5. Were missing data procedures reported? Yes (2)      No (0)    Unclear (1) 
6. Which % lost in follow up? <25% (2)   ≥25% (0) Unclear (1)
7. Were at least two health status measurements (pre and post) available? Yes (2)      No (0)    Unclear (1) 
8. Was the time interval for follow-up stated? Yes (2)      No (0)    Unclear (1) 
9. Were test conditions similar for both measurements? Yes (2)      No (0)    Unclear (1) 
10. Was there an adequate description given of measurement instrument? Yes (2)      No (0)    Unclear (1) 
11. Was the instrument validated in the current study, or is made reference to other 
study?
Yes (2)      No (0)    Unclear (1) 
12. Were floor effects described Yes (2)      No (0)    Unclear (1) 
13. Were ceiling effects described Yes (2)      No (0)    Unclear (1) 
14. Was the M(C)ID calculated? Yes (2)      No (0)    Unclear (1) 
15. Was an adequate description given of the anchor(s)? Yes (2)      No (0)    Unclear (1)   Not Applicable = N/A (0) 
16. Were measurement properties of the anchor(s) described? Yes (2)      No (0)    Unclear (1)   Not Applicable = N/A (0) 
17. Can the anchor(s) be considered a gold standard? Yes (2)      No (0)    Unclear (1)   Not Applicable = N/A (0) 
18. Were >1 anchor used to determine M(C)ID? Yes (2)      No (0)    Unclear (1)   Not Applicable = N/A (0) 
19. Were anchor correlations calculated? Yes (2)      No (0)    Unclear (1)   Not Applicable = N/A (0) 
20. Were anchor correlations ≥0.50? Yes (2)      No (0)    Unclear (1)   Not Applicable = N/A (0) 
21. Were receiver operating characteristics (ROC) curves produced? Yes (2)      No (0)    Unclear (1)   Not Applicable = N/A (0) 
22. Was the area under the curve (AUC) ≥0.70? Yes (2)      No (0)    Unclear (1)   Not Applicable = N/A (0) 
23. Was a global rating of change (GRC) used? Yes (2)      No (0)    Unclear (1)   Not Applicable = N/A (0) 
24. Number of GRC anchor questions? <11 (0)     ≥11 (2)        Unclear (1)   Not Applicable = N/A (0)
25. What criterion was used? Exacerbation (2) Hospital admission (1) Death (0) 
Other (1)   Not Applicable = N/A (0)
26. Was more than one distribution-based method used? Yes (2)      No (0)    Unclear (1)   Not Applicable = N/A (0) 
27. Was more than one population used in MCID? Yes (2)      No (0)    Unclear (1) 
28. MCID calculated for: Improvement (1)   Deterioration (1)    Both (2)
29. Was there selective outcome reporting? Yes (0)      No (2)     Unclear (1) 
30. Was there funding bias? Yes (0)      No (2)     Unclear (1) 
31. Was there ownership bias? Yes (0)      No (2)     Unclear (1) 
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The minimal clinically important difference (MCID) defines to what extent change on 
a health status instrument is clinically relevant, which aids scientists and physicians in 
interpreting therapy effects. This is the first study that aimed to establish the MCID of 
the COPD Assessment Test (CAT), the Clinical COPD Questionnaire (CCQ) and the St. 
George’s Respiratory Questionnaire (SGRQ) in the same pulmonary rehabilitation (PR) 
population using multiple approaches. 
4.1.2 Methods
In total, 451 patients with chronic obstructive pulmonary disease (COPD) participated 
in a 3-week PR programme (58 years, 65% male, 43 pack years, global initiative for 
obstructive lung disease (GOLD) grades II/III/IV 50/39/11%). Techniques used to assess 
the MCID were anchor-based approaches, including patient-referencing, criterion-
referencing and questionnaire-referencing; and the distribution-based methods 
standard error of measurement (SEM), 1.96SEM and half standard deviation (0.5SD). 
4.1.3 Results
Patient- and criterion-referencing led to MCID estimates of -3.12 and -2.96 (CAT); -0.62 and 
-0.56 (CCQ); and -9.28 and -8.40 (SGRQ). Negative changes represented improvement. 
Questionnaire-referencing suggested MCID ranges of -3.08 to -1.46 (CAT), -0.61 to -0.28 
(CCQ), and -9.47 to -6.86 (SGRQ). The SEM, 1.96SEM and 0.5SD were 3.28, 6.43 and 2.80 
(CAT); 0.29, 0.56 and 0.46 (CCQ); 5.20, 10.19 and 6.06 (SGRQ). Pooled estimates were 
-3.29 (CAT), -0.52 (CCQ) and -7.91 (SGRQ) for improvement. MCID estimates differed by 
the method used. 
4.1.4 Discussion and conclusions
Pooled estimates suggest clinically relevant improvements needing to be at least -3.00 
on the CAT, -0.40 on the CCQ and -7.00 on the SGRQ for patients with moderate to very 
severe COPD. The MCIDs of the CAT and SGRQ in the literature might be too low, leading to 
overestimation of the interpretation of treatment effects for patients with COPD. 




Chronic obstructive pulmonary disease (COPD) is the third leading cause of death [1]. 
Spirometry is required to make the diagnosis [2]. Its parameter forced expiratory volume 
in one second (FEV
1
) has however a weak correlation with symptoms and disease impact, 
which are factors captured by health status instruments [3]. Health status has become an 
important goal in the management of COPD [2]. Multiple instruments exist that measure 
health status with the COPD Assessment Test (CAT), Clinical COPD Questionnaire (CCQ) 
and St. George’s Respiratory Questionnaire (SGRQ) most frequently used [4-6]. These tools 
are important in assessing treatment effectiveness. Therefore, clinically relevant change 
as outcome of the questionnaires has become pivotal. The minimal clinically important 
difference (MCID) is a parameter that assesses clinically relevant change. It is defined as 
“the smallest difference in score, which patients perceive as beneficial and which would mandate 
a change in the patient’s management”[7]. 
Multiple methods for determining the MCID exist, clustered into anchor- and distribution-
based approaches [8-10]. Anchor-based approaches require change in health status 
to be compared with another measure of clinical change, such as a global rating of 
change (GRC) assessment (patient-referencing); the appearance of health events in 
the time of change (criterion-referencing); and/or a related instrument with a known 
MCID (questionnaire-referencing) [8]. Distribution-based methods require comparison 
of change with a statistical measure of variability of this change such as the standard 
error of measurement (SEM) or the half standard deviation (0.5SD) [8, 11-12]. Anchor-
based methods are preferred as they convey clinical significance, yet distribution-based 
approaches are quicker to use [9-10]. A golden standard has not been defined. Different 
methods will lead to a range of estimates [8, 10, 13]. A pledge has been made for an 
overall body of evidence to agree upon an MCID, or to use multiple MCIDs in practice [8, 
10,13-14]. This body of evidence should consist of relevant patient-reported anchors and 
clinical trial data [10, 15]. However, selecting appropriate anchors is problematic, since 
this commonly used method is highly dependent on the correlation between instruments 
(preferably ≥0.50), as well as the accuracy of the anchor instrument’s MCID [10, 15]. 
Existing evidence for the MCID of the CCQ suggests a value of 0.40, which is equivalent 
to 7% of the scale (range: 0-6) [5, 16-19]. The anchor-based methods patient-referencing, 
criterion-referencing and questionnaire-referencing with the SGRQ, CAT and Chronic 
Respiratory Questionnaire (CRQ) as anchors, were separately applied in a Dutch 
prednisolone trial following acute exacerbation, in pulmonary rehabilitation (PR) 
for both COPD and non-COPD patients, and in a Greek primary and secondary care 
population [16-18]. The SEM and 0.5SD techniques were applied too [17-19]. None of the 
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studies combined all of the approaches in the same population of patients with COPD. 
The MCID for the domain scores on the CCQ has not been established either. The MCID of 
the CAT was summarised as 2 points, equivalent to 5% of the scale (range: 0-40) [4, 19-21]. 
Both anchor- and distribution-based techniques were applied in a PR setting, for acute 
exacerbation patients with COPD and for outpatients. Criterion-referencing has not 
been specifically applied for the CAT, nor have all methods been applied simultaneously. 
The MCID for the SGRQ is set at 4 points, which is 4% of the scale (range: 0-100) [6, 22-
23]. Expert-based ratings, patient-referencing, criterion-referencing, and the use of the 6 
minute walking distance (6MWD) and the CRQ as anchors have been applied in various 
studies on patients with asthma or COPD. These studies are from many years ago; 
therefore a recent study on patients with severe COPD, who underwent bronchoscopic 
lung volume reduction (BLVR), claimed the MCID of the SGRQ to be >7 points [24]. It used 
FEV
1
, 6MWD and residual volume (RV) as anchors combined with distribution-based 
methods. Estimates on the MCID of the SGRQ seem inconsistent. None of the methods 
have been applied at once, nor has the MCID of the domain scores of the SGRQ been 
investigated.
The MCIDs of health status tools are necessary for physicians and researchers to evaluate 
therapy results and clinical trials. Expanding the body of evidence for the MCID remains 
of major importance. This study is the first to investigate the MCID of the CAT, CCQ and 
SGRQ simultaneously in PR using the largest array of methods. It examines the impact of 
using anchor- and distribution-based methods to determine an instrument’s MCID. The 




This study is a secondary analysis of a subsample from the routine inspiratory muscle 
training within COPD rehabilitation (RIMTCORE) real-life randomised controlled trial 
(#DRKS00004609) in the Klinik Bad Reichenhall, Center for Rehabilitation, Pulmonology 
and Orthopedics in Germany [25]. Patients with COPD global intiative for obstructive lung 
disease (GOLD) grades II-IV, ≥18 years, who gave informed consent, were included between 
February 2013 and July 2014. Exclusion criteria were lack of linguistic or cognitive abilities to 
fill out questionnaires; hypercapnic respiratory failure with a PaCO2 >50 mmHg at rest or 
indication for intermittent noninvasive ventilation; contra-indications for inspiratory muscle 
training (IMT) (e.g. a history of recent lung surgery, fresh pulmonary embolism, history of 
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recurrent spontaneous pneumothorax); and other severe comorbid diseases that conferred 
significantly greater morbidity than COPD (e.g. active cancer without successfully completed 
curative therapy). Patients participated in an intensive 3-week full-day inpatient rehabilitation 
programme. The therapy components were tailored to the patients’ individual needs and 
included endurance and strength training, patient education, respiratory physiotherapy, 
psychological support, tobacco cessation and dietary counselling. The RIMTCORE trial 
was approved by the Ethik-Kommission der Bayerischen Landesärztekammer (#12107) and 
registered in the German clinical trial register. 
4.3.2 Study design and data collection
For the current MCID study, completed data were analysed at pre- (T0) and post-
inpatient rehabilitation (T1) from a subset of participants without other respiratory 
comorbidities (e.g. bronchiectasis, asthma, history of bronchial carcinoma, sarcoidosis 
and tuberculosis) or alpha-1-antitrypsin deficiency. On all measurement occasions, 
parameters collected were CAT (no recall period), CCQ (weekly version) and SGRQ 
(monthly version). The CAT is an 8-item unidimensional scale with item scores ranging 
from 0 to 5 (0: no impairment, 5: maximum impairment) and a total score of 0 to 40 [4]. 
The CCQ consists of 10 items divided over 3 subdomains. Item scores range from 0 to 6 
(0: no impairment, 6: maximum impairment), with the total score derived from adding 
up item scores and dividing this by 10 [5]. The SGRQ has 50 items divided over 3 domains 
with a total score of 0 to 100 (0: no impairment, 100: maximum impairment) [6]. A GRC 
anchor question ranging from -7 to +7 was issued at T1, which required patients to assess 
their global health in relation to COPD compared with T0. Patient characteristics, post-
bronchodilator spirometry, 6MWD and exacerbations in the 12 months before PR were 
available too. 
4.3.3 Determining the MCID: Anchor-based approaches
Patient-referencing: Changes on the CAT, CCQ and SGRQ were categorised according 
to the GRC score. Scores of 0 and ±1 represented no or hardly any change; scores of ±2 
and ±3 were considered a minimal clinically relevant change; scores of ±4 and ±5 were 
considered a moderate change; and scores of ±6 and ±7 were considered a major change, 
as exemplified by Juniper et al. [26]. The MCID was established by calculating the mean 
health status change score of the patients with a minimal clinically relevant change on 
the GRC (i.e. scores of ±2 and ±3). 
Criterion-referencing: The health event exacerbation during PR was used as an anchor, 
which was defined as “worsening of COPD symptoms requiring at least treatment with 
oral corticosteroids and antibiotics”. The difference in baseline score between patients 
experiencing an exacerbation and those without represented the MCID. 
Chapter 4
92
Questionnaire-referencing: Change in one instrument was anchored against change in the 
other two instruments, as performed prior [17, 20]. Correlations between change scores were 
assessed, needing to be ≥0.30 (preferably ≥0.50) to be eligible as anchor [10]. The MCID of 
the anchor from the literature was used as reference (CAT=2.00, CCQ=0.40 and SGRQ=4.00) 
[16-17, 20, 22]. First, scatter plots and regression analysis with the anchor change score as 
the independent variable, were produced. Second, the mean was calculated for patients 
achieving or failing the anchor’s MCID. Last, receiver operating characteristics (ROC) curves 
were plotted to identify the best change in health status to discriminate between those 
achieving the anchor’s MCID and those failing to achieve it [8]. This process resulted in three 
estimates per anchor. The steps were repeated if the MCID estimates derived from patient-
referencing, criterion-referencing and the distribution-based methods were different 
compared with the literature. 
4.3.4 Determining the MCID: Distribution-based approaches
The SEM seeks correlation between single standard error units and established MCID 






 = the intraclass correlation 
coefficient (ICC) and σ
x
 = standard deviation baseline. Both the SEM and 1.96SEM were 
calculated, since there is no consensus on which represents the MCID best. The 0.5SD 
was determined as an equivalent of the MCID [8, 11]. 
4.3.5 Data analysis
Data analysis was performed using SPSS 20.0 (IBM, Chicago, USA). Descriptive data were 
evaluated at T0 for frequencies and percentage, or mean and standard deviation. Health 
status data at T0 and T1 were evaluated with mean and standard deviations, and tested 
for significance of change with paired t-tests or Wilcoxon signed-rank tests depending on 
normality of distribution. Negative change represented improvement on the health status 
instruments. Health status scores of CAT, CCQ and SGRQ were checked for floor- and 
ceiling effects defined as more than 15% of participating patients scoring in the bottom 
and top 10% of the maximum scale range.
Patient-referencing approach: Correlations between GRC and CAT, CCQ or SGRQ were 
assessed using Pearson’s or Spearman’s coefficients depending on normality. Participants 
were classified according to GRC score. Significance of change was calculated with 
paired t-tests or Wilcoxon signed-rank tests depending on normality. 
Criterion-referencing approach: The difference in baseline score between patients with 
and without an exacerbation during PR was evaluated using independent t-tests or 
Mann-Whitney U tests depending on normality. 
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Questionnaire-referencing: Correlations were assessed using Pearson’s or Spearman’s 
coefficients depending on normality. First, scatter plots and regression analysis were 
performed with the anchor variable as the independent variable. Next, mean change 
scores of the CAT, CCQ and SGRQ were calculated for those achieving or failing the 
suggested MCID of the anchors. ROC curves were plotted with the anchor’s MCID as the 
dichotomizing variable. The optimal value was selected with specificity and sensitivity 
preferably both ≥0.70, favouring sensitivity.
Distribution-based methods: The SEM, 1.96SEM and 0.5SD of the change for each 
instrument were calculated. ICC values were obtained from the literature: 0.80 (CAT), 0.94 
(CCQ) and 0.91 (SGRQ) [4-6].
Pooled MCID estimates: The mean estimates for the CAT, CCQ and SGRQ derived from 
patient-referencing, criterion-referencing, questionnaire referencing, the SEM and 0.5SD 
were multiplied with a factor 1/5 each to calculate a pooled average. Domain scores 
were averaged based on patient- and criterion-referencing results.
4.4 Results
4.4.1 Patient characteristics and health status
In total, 611 patients participated in the RIMTCORE trial among whom 50 discontinued the 
study [25]. Out of the remaining participants, 451 met the inclusion criteria for the current 
MCID analysis. Mean age was 57.87±6.56 years, 65% male and 50/39/11% GOLD grades II/
III/IV (Table 1). 
CAT, CCQ and SGRQ were normally distributed at T0 and T1; change scores were 
normally distributed for CAT, CCQ and SGRQ symptom scores. Floor- and ceiling effects 
were negligible except for the CCQ mental domain. There were no missing health status 
questionnaires at T0. There were four missing participants for the SGRQ, one for the CCQ 
and two for the CAT at T1. Pair-wise deletion was applied. Mean baseline scores were 
20.23±7.33 (CAT), 2.86±1.17 (CCQ) and 50.69±17.33 (SGRQ) with significant improvements 
after PR of respectively -3.11 (95% confidence interval (CI) -3.63 to -2.59), -0.58 (95%CI -0.67 
to -0.50), and -9.04 (95%CI -10.17 to -7.92) (Table 2). 
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Table 1: Baseline characteristics
Variable Baseline 
Age (years)a 57.87 ± 6.56
BMIa 26.82 ± 6.56
Gender (male)b 293 (65.0)
FEV
1
%preda 50.40 ± 15.11
GOLD IIb 227 (50.3)
GOLD IIIb  176 (39.0)
GOLD IVb  48 (10.6)
Smoking pack yearsa 42.61 ± 23.47
Never smokersb 6 (1.3)
Active smokersb 179 (39.7)
Ex-smokersb 266 (59.0)
Retiredb 74 (16.4)
If not retired, unable to workb 159 (35.3)
Patients with ≥1 exacerbation during 12 months prior to PRb  353 (78.4)
a  Data expressed as mean ± SD. 
b Data expressed as frequencies (% of total patients). 
N = 451
Abbreviations: BMI, body mass index; FEV
1
%pred, forced expiratory volume in one second % predicted; GOLD, global initiative for chronic 
obstructive lung disease; PR, pulmonary rehabilitation; SD, standard deviation.
4.4.2 MCID: patient-referencing
The GRC score was missing for one patient. Correlations between GRC and health status 
instruments were significant with r = 0.23 (CAT), 0.29 (CCQ), and 0.30 (SGRQ). In total, 12 
patients showed deterioration on the GRC (GRC ≤-2). No or hardly any improvement (GRC= 
0, or +1) was experienced by 21.7% (n=98). Minimal improvement (GRC= +2 and +3) was seen 
in 43.5% of patients (n=196), whereas moderate (GRC= +4 and +5) and major improvement 
(GRC= +6 and +7) represented respectively 27.3% (n=123) and 5.5% (n=25) (Table 3). At the 
threshold for minimal clinically relevant improvement (GRC= +2 or +3) mean CAT, CCQ 
and SGRQ change scores were respectively -3.12 (95%CI -3.86 to -2.37), -0.56 (95%CI -0.68 
to -0.44) and -8.40 (95% CI -10.07 to -6.73).  Mean improvements for these patients on the 
CCQ domains were -0.55 (symptoms), -0.55 (functional), and -0.58 (mental); and for the 
SGRQ domains -13.12 (symptoms), -5.98 (activity), and -8.24 (impact). 
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Table 2: Health status outcomes of pulmonary rehabilitation
Instrument Baselinea Changea 95% CIb
CAT
Total 20.23 ± 7.33 -3.11 ± 5.59 -3.63 to -2.59
CCQ
Symptoms 2.87 ± 1.24 -0.59 ± 1.16 -0.70 to -0.48 
Functional 2.86 ± 1.34 -0.56 ± 1.00 -0.65 to -0.46 
Mental 2.86 ± 1.74 -0.62 ± 1.49 -0.76 to -0.48 
Total 2.86 ± 1.17 -0.58 ± 0.92 -0.67 to -0.50
SGRQ
Symptoms 63.66 ± 21.77 -14.22 ± 21.69 -16.24 to -12.21
Activities 63.58 ± 19.82 -6.71 ± 13.44 -7.96 to -5.47
Impact 39.21 ± 18.81 -8.78 ± 13.95 -10.08 to -7.49
Total 50.69 ± 17.33 -9.04 ± 12.11 -10.17 to -7.92
6MWD (meters) 427.73 ± 110.18 80.19 ± 54.72 75.01 to 85.37
Negative change represents improvement on the CAT, CCQ and SGRQ. 
a Data expressed as mean ± SD.  
b Paired t-tests applied for normally distributed data, Wilcoxon signed rank tests for non-parametric data. 
All tests significant at level P < 0.05 comparing pre- and post-pulmonary rehabilitation scores. 
N=451
Abbreviations: 6MWD, six minute walking distance; 95%CI, 95% confidence interval; CAT, COPD Assessment Test; CCQ, Clinical COPD 
Questionnaire;  COPD, chronic obstructive pulmonary disease; SD, standard deviation; SGRQ, St. George’s Respiratory Questionnaire. 
4.4.3 MCID: criterion-referencing
During PR, 10% of patients (n=45) experienced an exacerbation. There were no missing 
data. Mean differences between both groups at baseline were -2.96 (95%CI -5.20 to -0.71) 
for CAT, -0.62 (95%CI -0.98 to -0.27) for CCQ and -9.28 (95%CI -14.56 to -3.99) for SGRQ, 
with significantly higher scores for patients with an exacerbation. Significant domain 
differences were -0.47, -0.67 and -0.86 for the respective CCQ symptoms, functional and 
mental domains; and -10.61 and -9.93 for the SGRQ activity and impact domains. 
4.4.4 MCID: questionnaire-referencing
Significant correlations between total change scores were 0.63 (SGRQ versus CCQ), 0.54 
(SGRQ versus CAT) and 0.59 (CCQ versus CAT) (Supplementary material 4.7.1). Using the 
original anchor estimates from the literature (CAT=-2.00, CCQ=-0.40 and SGRQ=-4.00) 
the various questionnaire-referencing results including 95%CI resulted in the following 
ranges: -3.00 to -2.14 (CCQ as anchor) and -3.00 to -1.46 (SGRQ as anchor) for CAT;  -0.53 
to -0.42 (CAT as anchor) and -0.50 to -0.28 (SGRQ as anchor) for CCQ; -8.30 to -6.86 (CCQ 
as anchor) and -8.48 to -6.98 (CAT as anchor) for SGRQ (Table 4, Online Supplementary 
Figures 1-6 at npj Primary Care Respiratory Medicine). 
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Table 3: MCID patient-referencing results
Instrument No/hardly any 
improvement
(GRC -1, 0 or +1)
N= 98
Minimal improvement




(GRC +4 or +5)
N= 123
Major improvement
(GRC +6 or +7)
N= 25
Δa 95%CIb Δa 95%CIb Δa 95%CIb Δa 95%CIb
CAT
Total -2.05 -3.13 to -0.98 -3.12 -3.86 to  -2.37 -3.67 -4.70 to  -2.67 -6.44 -8.99 to  -3.89
CCQ
Symptoms -0.32 -0.54 to -0.10 -0.55 -0.70 to -0.40 -0.76 -0.96 to  -0.56 -1.48 -1.97 to  -0.99
Functional -0.27 -0.47 to -0.07 -0.55 -0.68 to -0.43 -0.78 -0.98 to  -0.58 -0.97 -1.31 to  -0.63
Mental -0.53 -0.84 to -0.22 -0.58 -0.78 to  -0.38 -0.67 -0.94 to  -0.39 -1.34 -1.84 to  -0.84
Total -0.34 -0.52 to -0.15 -0.56 -0.68 to -0.44 -0.75 -0.92 to  -0.58 -1.25 -1.54 to  -0.96
SGRQ
Symptoms -7.03 -10.86 to -3.19 -13.12 -16.05 to  -10.19 -19.91 -23.92 to  -15.90 -30.62 -38.40 to  -22.84
Activities -3.03 -5.28 to -0.78 -5.98 -7.88 to -4.08 -10.33 -12.78 to  -7.87 -12.66 -18.69 to  -6.62
Impact -6.72 -9.57 to -3.86 -8.24 -10.14 to  -6.33 -10.32 -12.77 to  -7.87 -17.90 -23.64 to  -12.16
Total -5.57 -7.79 to -3.35 -8.40 -10.07 to  -6.73 -11.83 -14.00 to  -9.66 -18.50 -22.81 to  -14.18
Negative change represents improvement for all instruments. 
a Data reported as mean change scores.  
b Paired t-tests applied to normally distributed variables and Wilcoxon signed rank tests were used for not normally distributed data. 
Data reported as 95%CI. 
All change scores significant at level P < 0.05. 
Abbreviations: Δ, change score; 95%CI, 95% confidence interval; CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; COPD, 
chronic obstructive pulmonary disease; GRC, global rating of change; MCID, minimal clinically important difference; SGRQ, St. George’s 
Respiratory Questionnaire.
Using averaged estimates from the other MCID 
approaches in this study (CAT=-3.00, CCQ=-0.50 and 
SGRQ=-7.00) the results including 95%CI were: -3.08 to 
-2.54 (CCQ as anchor) and -3.00 to -2.32 (SGRQ as anchor) 
for CAT; -0.61 to -0.53 (CAT as anchor) and -0.60 to -0.44 
(SGRQ as anchor) for CCQ; -8.90 to -7.79 (CCQ as anchor) 
and -9.47 to -8.00 (CAT as anchor) for SGRQ (Table 4, Online 
Supplementary Figures 1-6 at npj Primary Care Respiratory 
Medicine). 
4.4.5 MCID: Distribution-based approach
The SEM for the CAT, CCQ and SGRQ was 3.28, 0.29 and 5.20, respectively; the 1.96SEM was 
6.43, 0.56 and 10.19, respectively; and the 0.5SD was 2.80, 0.46 and 6.06, respectively. 
Online Supplementary Figures 1-6
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CAT -2.74 -2.82 - - -2.45 -2.86
CCQ - - -0.48 -0.56 -0.46 -0.53






























































Data expressed as estimates (95%CI). 
N=451
Abbreviations: 95%CI, 95% confidence interval; AUC, area under the curve; CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; 
COPD, chronic obstructive pulmonary disease; ROC, receiver operating characteristics; Sens, sensitivity; Spec, specificity; SGRQ, St. 
George’s Respiratory Questionnaire.
4.4.6 Pooled MCID estimates
The weighted MCID estimates were -3.29 (CAT), -0.52 (CCQ), and -7.91 (SGRQ). Results for the 
domains were -0.51 (symptoms), -0.61 (functional status) and -0.72 (mental) for CCQ; and 
-13.12 (symptoms), -8.30 (activities) and -9.09 (impact) for SGRQ. Results from all approaches 




Post-hoc analysis demonstrated the power of the study to be over 90% based upon the 
number of cases (N=451), alpha 0.05 and the effect sizes for CAT (0.43), CCQ (0.50) and 
SGRQ (0.53).
Figure 1: Summary plot of the MCID estimates of the CAT 
The horizontal plots represent the MCID estimates derived in this study, classified per method. Where appropriate the estimates include the 
95% confidence interval. The red vertical line resembles the MCID estimate obtained from the literature. 
Abbreviations: CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive pulmonary disease; MCID, minimal 
clinically important difference; ROC, receiver operating characteristics; SD, standard deviation; SEM, standard error of measurement; SGRQ, 
St. George’s Respiratory Questionnaire.
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Figure 2: Summary plot of the MCID estimates of the CCQ
The horizontal plots represent the MCID estimates derived in this study, classified per method. Where appropriate the estimates include the 
95% confidence interval. The red vertical line resembles the MCID estimate obtained from the literature. 
Abbreviations: CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive pulmonary disease; MCID, minimal 
clinically important difference; ROC, receiver operating characteristics; SD, standard deviation; SEM, standard error of measurement; SGRQ, 
St. George’s Respiratory Questionnaire.
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Figure 3: Summary plot of the MCID estimates of the SGRQ
The horizontal plots represent the MCID estimates derived in this study, classified per method. Where appropriate the estimates include the 
95% confidence interval. The red vertical line resembles the MCID estimate obtained from the literature. 
Abbreviations: CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive pulmonary disease; MCID, minimal 
clinically important difference; ROC, receiver operating characteristics; SD, standard deviation; SEM, standard error of measurement; SGRQ, 
St. George’s Respiratory Questionnaire.





The use of anchor- and distribution-based methods in this study resulted in MCID ranges 
of -6.43 to -1.46 for CAT, -0.62 to -0.28 for CCQ, and -10.19 to -5.20 for SGRQ. The pooled 
MCID estimates derived from the various methods in this study (-3.29 for CAT, -0.52 for 
CCQ, and -7.91 for SGRQ) are similar or slightly higher compared with the literature. In 
general, results from the patient-referencing method were somewhat comparable to 
criterion- and questionnaire-referencing. The adjusted MCID cutpoints of the anchors 
(SGRQ=-7.00, CCQ=-0.50 and CAT=-3.00) in the questionnaire-referencing approach had 
slightly better correspondence with patient- and criterion-referencing. The distribution-
based method 0.5SD was best comparable to anchor-based results. The SEM was 
inconsistent, and the 1.96SEM was much more conservative for CAT and SGRQ, although 
not for CCQ.
4.5.2 Interpretation of findings 
Almost all MCID estimates including the pooled estimate (-3.29) for the CAT were higher 
than the suggested 2 points in the literature. Patient-referencing resulted in a much 
higher estimate compared with Dodd et al. and Kon et al., who used both a GRC with just 
5 choice options [20-21]. Preferably, more answering categories on the anchor question 
should be used to provide the full-spectrum of answers [27]. Criterion-referencing in our 
study was comparable to the other anchor-based approaches. This method has not 
been performed for the CAT before. Questionnaire-referencing resulted in ranges of 
-3.00 to -1.46 (SGRQ as anchor) and -3.08 to -2.14 (CCQ as anchor). The use of the original 
MCID of the SGRQ as anchor provided the lowest estimates for the CAT, just as for CCQ. 
Possibly the MCID of the SGRQ is not as solid as claimed. The ranges found in our study 
matched results from Kon et al. [20], but they are higher than the 2 points summarised. 
Earlier, CAT has been mapped to the SGRQ, resulting in an MCID of 1.60 [5, 21]. It seems 
that this derived from multiplication of the SGRQ MCID with a factor 40/100, which is 
rather unusual. A similar exercise for CCQ would result in an MCID of 0.24, far below 
current estimates. The distribution-based methods SEM and 0.5SD matched results from 
anchor-based approaches. The 1.96SEM is much higher and lacked correspondence.  
The pooled MCID estimate for the CCQ in our study (-0.52) is slightly higher than the literature 
estimate. Patient- and criterion-referencing in our study used comparable methodology 
[16, 18], but resulted in more conservative estimates. Differences in participants’ age, 
baseline CCQ score and period of measurement possibly influenced this. Our study 
included younger patients with more severe baseline scores. Furthermore, exacerbations 
might not be a minor event for the included patients. Questionnaire-referencing resulted 
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in ranges of -0.60 to -0.28 (SGRQ as anchor) and -0.61 to-0.42 (CAT as anchor), which 
to some extent matched results of Kon et al. for COPD [17], as well as of Canavan et al. 
for other respiratory diseases [18]. With regard to the distribution-based methods, the 
1.96SEM and 0.5SD were best comparable to results from anchor-based approaches, but 
slightly higher than the results of Kocks et al. [16]. The 0.5SD matched earlier results [17-18]. 
Domain MCID scores were approximately equivalent to MCID estimates of the total CCQ 
score, although the mental domain was higher, possibly because of floor- and ceiling 
effects in the current study. 
All MCID estimates for SGRQ were larger than the 4 points from the literature [22]. MCIDs 
of the domain scores on the SGRQ (except for symptoms) seemed comparable to the 
estimate for the total score. The suggested literature MCID of the SGRQ originates from 
patient-referencing in two studies, featuring the use of salmeterol in COPD and nedocromil 
sodium in asthma [28-29], in which a limited 5-point GRC scale was used to review therapy 
effects [23]. Osman et al. report the results of criterion-referencing comparing SGRQ 
scores between patients re-admitted within 12 months and those, who were not, resulting 
in an MCID estimate of 4.80 [30]. The results in the current study are nearly double the 
original MCID estimates, which date back to the nineties. Differences in study setting, age 
of patients, time period of measurement, and different health event criterion may have 
influenced this large difference. Poor methodologic quality of the patient-referencing 
approach might be another explanation. 
Questionnaire-referencing provided ranges of -9.47 to -6.98 (CAT as anchor) and -8.90 
to -6.86 (CCQ as anchor), which was somewhat comparable to patient- and criterion-
referencing results. MCID estimates from the adjusted questionnaire-referencing approach 
were slightly higher and better comparable with the other anchor-based approaches. 
Upon development of the SGRQ, a hypothesised multivariate model estimated a 6% mean 
difference on the 6MWD (22m) to be equivalent to 4 points on the SGRQ [6]. However, 
nowadays the MCID of the 6MWD is considered to be doubled [31]. Schünemann et al. 
found a change of (-)3.05 on the SGRQ to match the MCID of the CRQ dyspnoea domain 
[32]; however this is only a measure for dyspnoea and not the complete health status 
concept. It could have underestimated the MCID of the SGRQ severely. Recently, a study by 
Welling et al. suggested the MCID of the SGRQ to be over 7 points for patients with severe 
COPD undergoing BLVR using both anchor-based and distribution-based methods [24]. 
Our current study includes moderate to very severe patients with COPD in PR. The results 
overlap one another using different anchors.
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The SEM and the 0.5SD for the SGRQ are both lower than the anchor-based results, whereas 
the 1.96SEM was higher and lacked correspondence too. Tsiligianni et al. calculated the 
1.96SEM of the SGRQ to be 4.84, which is substantially lower than all estimates here [19]. 
Jones argued that distribution-based methods were not applicable to the SGRQ, since 
they lack agreement with anchor-based approaches, and determined a Standard Error 
of the Estimate (1.3) and 0.5SD (8.4) based upon averaging data from 11 studies [22]. This 
pooled 0.5SD matched with results in our study. 
4.5.3 Strengths and limitations of this study
This study applied for the first time multiple approaches to determine the MCID of the 
CAT, CCQ and SGRQ simultaneously in one strong dataset of patients with COPD in PR. 
It is also the first study to include estimates of the possible MCIDs for domain scores of 
the CCQ and SGRQ as well. Estimates are valid for improvement and for patients with 
moderate to very severe COPD (GOLD grades II-IV). No patients with mild COPD (GOLD 
grade I) were included in this study. During PR too few patients deteriorated (n=12) to 
analyse the MCID for deterioration. MCIDs for improvement and deterioration may differ 
though [13]. 
Our current study has applied an ambiguous anchor-based method of questionnaire-
referencing. However, this approach is widely used and accepted elsewhere to estimate 
another instrument’s MCID [17-18, 20]. The pooled thresholds for clinically relevant change 
of the CCQ, CAT and SGRQ in our study (CCQ=-0.52, CAT=-3.29 and SGRQ=-7.91) seem 
different from values reported in the literature (CCQ=-0.40, CAT=-2.00 and SGRQ=-4.00). 
This has had impact on the questionnaire-referencing results. Averaged MCID estimates 
from patient-referencing, criterion-referencing and distribution-based methods were 
included therefore in the analysis as cutoff values for the anchor’s MCID. The revised 
MCIDs of the anchor questionnaires had better correspondence with results from these 
other approaches. It highlights that careful selection of anchors should be considered. 
A limitation of the current study is that the correlations between both CAT, CCQ SGRQ, and 
the GRC were below the preferred lower limit to be appropriate as anchor (r ≥0.30 and 
preferably ≥0.50). Other studies using a GRC seldom published correlation coefficients, 
making it unclear whether this problem is widespread. Another limitation of this study is 
that the PR period was 3 weeks, whereas the SGRQ has a recall period of 1 month and the 
CCQ has a recall period of 1 week. A study by Meguro et al. compared the shorter SGRQ-C 
without recall period with the original SGRQ with a specified 4-week recall period [33]. No 
differences in scores between both questionnaires were observed. We therefore expect 
little influence of the recall period on our MCID results. Last, exacerbations during PR were 
used as criterion to estimate the MCID. The estimates from this approach are higher for 
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CCQ and SGRQ compared with other methods. This might indicate that exacerbations 
were not a minor clinically relevant event for patients.
4.5.4 Implications for future research, policy and practice
Our study demonstrated that the existing MCIDs of the SGRQ and possibly of the CAT 
are set too low in current practice. Using a low threshold could lead to overestimation of 
treatment effects. Patients currently considered to experience clinically relevant change 
as a result of treatment may in fact not experience this. On the other hand, a more 
conservative cutoff point may not approve therapy, although benefits for the patient 
do exist. Even though the current study adds to the body of evidence, the analysis is 
based on one patient group only, where many would be preferred. More studies are 
necessary to build a more complete body of evidence and understanding, preferably 
with the full scope of approaches and in different patient groups. These should also 
further investigate whether the MCID for the domain scores for the CCQ and SGRQ is 
comparable to the total score estimate. The quest in finding the gold standard for the 
MCID for health status tools for COPD must continue.
4.5.5 Conclusions
The current study suggests that improvements need to be at least 3 points on the CAT, 
0.40 points on the CCQ, and 7 points on the SGRQ to be considered clinically relevant for 
patients with moderate to very severe COPD. The MCID for domain scores on the SGRQ 
and CCQ could be equivalent to these thresholds.
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4.7 Supplementary material 
4.7.1 Health status correlations
Table 1: Relevant correlations between health status questionnaires
CAT SGRQ
CCQ Symptoms Activity Impact Total
Symptoms 0.47 0.51* 0.33 0.38 0.50*
Functional 0.45 0.39 0.43 0.47 0.55*
Mental 0.36 0.27 0.29 0.43 0.43
Total 0.59* 0.50* 0.44 0.54* 0.63*
CAT  - 0.40 0.33 0.41 0.54*   
Data expressed as correlation coefficients. 
All correlations significant at level P < 0.05. 
* Correlations were ≥0.50. 
N= 451
Abbreviations: CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive pulmonary disease; SGRQ, St. 
George’s Respiratory Questionnaire.
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4.7.2 Summary MCID results
Table 2: Summary of all MCID Results
MCID approaches CAT CCQ SGRQ


















SGRQ=4 and SGRQ=7 as anchor 
Scatter plots / regression -2.91 to -1.46 -0.53 to -0.28
Mean failing/achieving estimate -2.86 to -2.45 -0.53 to -0.46
ROC Curves -3.00 to -3.00 -0.60 to -0.50
CAT=2 and CAT=3 as anchor 
Scatter plots / regression -0.61 to -0.42 -9.47 to -6.98
Mean failing/achieving estimate -0.56 to -0.48 -8.69 to -7.78
ROC Curves -0.60 to -0.50 -8.00 to -7.50
CCQ=0.40 and CCQ=0.50 as anchor 
Scatter plots / regression -3.08 to -2.14 -8.90 to -6.86
Mean failing/achieving estimate -2.82 to -2.74 -8.36 to -8.14
ROC Curves -3.00 to -3.00 -8.63 to -8.30
Distribution-based approaches
SEM 3.28 0.29 5.20
1.96SEM 6.43 0.56 10.19
0.5SD 2.80 0.46 6.06 









Abbreviations: 0.5SD, half standard deviation; CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive 
pulmonary disease; MCID, minimal clinically important difference; ROC, receiver operating characteristics; SD, standard deviation; SEM, 
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The minimal clinically important difference (MCID) assesses what change on a 
measurement tool can be considered minimal clinically relevant. Although the recall 
period can influence questionnaire scores, it is unclear if it influences the MCID. This 
study is the first to examine longitudinally the impact of the recall period of an anchor 
question and its design on the MCID for health status tools for patients with chronic 
obstructive pulmonary disease (COPD) using the COPD Assessment Test (CAT), Clinical 
COPD Questionnaire (CCQ) and St. George’s Respiratory Questionnaire (SGRQ).
5.1.2 Methods
Patients with moderate to very severe COPD, but without respiratory comorbidities, 
were recruited during 3-week pulmonary rehabilitation (PR). CAT, CCQ and SGRQ were 
completed at baseline, discharge, 3, 6, 9 and 12 months. A 15-point global rating of 
change scale (GRC) was completed at each follow-up. A 5-point GRC was used as a 
second anchor at 12 months. Mean change scores of a subset of patients indicating 
a minimal improvement on each of the anchor questions were considered the MCID. 
The MCID estimates over different time periods were compared with one another by 
evaluating the degree of overlap of confidence intervals (CI) adjusted for dependency. 
5.1.3 Results
In total, 451 patients were included (57.9±6.6 years, 65% male, 50/39/11% global initiative 
for obstructive lung disease class II/III/IV), of whom 309 completed follow-up. Baseline 
health status scores were 20.2±7.3 (CAT), 2.9±1.2 (CCQ) and 50.7±17.3 (SGRQ). MCID 
estimates for improvement ranged -3.1 to -1.4 for CAT, -0.6 to -0.3 for CCQ, and -10.3 to 
-7.6 for SGRQ. Absolute higher - though not significant - MCIDs were observed for CAT 
and CCQ directly after PR.  Significantly absolute lower MCID estimates were observed 
for CAT (difference -1.4: CI -2.3 to -0.5) and CCQ (difference -0.2: CI -0.3 to -0.1) using a 
5-point GRC. 
5.1.4 Discussion and conclusions
The recall period of a 15-point anchor question seemed to have limited impact on the 
MCID for improvement of the CAT, CCQ and SGRQ during PR; although a 3-week MCID 
estimate directly after PR intervention might lead to absolute higher values. However, 
the design of the anchor question was likely to influence the MCID of the CAT and CCQ. 




Health status can be defined as “the impact of health on a person’s ability to perform and 
derive fulfilment from the activities of daily life” [1]. Its measurement is a standardised 
means of quantifying this impact on a patient’s daily life, health and wellbeing [1-
2]. Multiple general- and disease-specific health status tools have been developed to 
detect and quantify health status [3-4]. Physiological measures alone do not reflect the 
full impact of the disease and correlations with health-related quality of life (HRQoL) 
are often weak [4]. Determining treatment effects requires a parameter that assesses 
to what extent change on a health status tool can be considered clinically relevant. 
The minimal clinically important difference (MCID) is used to evaluate this. It has been 
defined as “the smallest difference in score, which patients perceive as beneficial and which 
would mandate a change in the patient’s management” [5]. Observed change should 
exceed the estimated MCID value in order to be clinically relevant. 
MCID estimates can be determined using both anchor- and distribution-based 
methods [6-8]. A frequently applied anchor-based technique is the use of a reference 
(anchor) question, requiring patients to retrospectively assess their current health state 
compared to a prior measurement in time or their experienced degree of change over 
time [6-8]. This anchor question usually consists of multiple ordinal reply options varying 
from much worse, a little worse, no change, a little better, up to much better [9-10]. The 
technique may also be referred to as patient-referencing [6]. In the literature, several 
descriptions are used for this kind of anchor question: global rating of change scale 
(GRC), patient global impression of change, global perceived change, transition rating 
scale and many more [9-10]. The MCID of a health status instrument can be determined 
by calculating the mean change score observed for those patients indicating a minimal 
change (i.e., little better or little worse) on the anchor question, assuming data being 
normally distributed [9].
The use of these patient rating scales has pros and cons. Its main strengths are the ease 
of administration and MCID determination, as well as the involvement of a patient-related 
clinical anchor [9]. However, it remains unclear over which period of time change on a 
GRC should be assessed and how many answering options the anchor question should 
include. When assessing change over a longer period of time, it might be more difficult 
for the patient to recall their former health state. A longer recall period could result in a 
different MCID [10]. On the other hand, shorter periods of measurement may not reflect 
real change. There is no golden standard in defining an instrument’s MCID [11].  
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In chronic obstructive pulmonary disease (COPD) much focus is nowadays on health 
status measurement [12-13], because spirometry assessment has only a weak to moderate 
correlation with the patient’s wellbeing [14-15]. The COPD Assessment Test (CAT) [16], the 
Clinical COPD Questionnaire (CCQ) [17], and the St. George’s Respiratory Questionnaire 
(SGRQ) [18] are recommended by the global initiative for chronic obstructive lung 
disease (GOLD) for the assessment of COPD in order to determine whether a patient is 
symptomatic and to what extent therapy has been successful [19]. The CAT and CCQ are 
most applicable in clinical practice, and the SGRQ in scientific research [19-20]. 
Various studies examined the MCID of the CCQ to be 0.40-0.50 points [21-26], including 
three studies using an anchor question with recall periods ranging from 2 to 3 days [21], 
up to 3 weeks [25], and 8 weeks [23]. The MCID of the CAT was estimated to be 2-3 
points [24-28], of which three studies used an anchor question with recall periods of 3 
weeks [25] and 8 weeks [27-28]. For the SGRQ, the MCID of 4 points is frequently used in 
clinical trials. However, estimates in the literature range 4-8 points [25, 29-31], of which 
two studies used patient-referencing techniques with recall periods of 3 weeks [25] and 
16 weeks [29, 31]. No studies have investigated the influence of the recall period of the 
anchor question and the number of its ordinal reply categories upon the MCID of these 
instruments. Therefore, this study aimed to investigate the impact of the length of the 
anchor’s recall period and the number of reply options on the GRC on the MCID of the 
most frequently used health status tools CAT, CCQ and SGRQ in patients with COPD 
recruited from a pulmonary rehabilitation (PR) setting.
5.3 Methods
5.3.1 Study subjects
The routine inspiratory muscle training within COPD rehabilitation (RIMTCORE) study 
was a real-life randomised controlled trial (German clinical trial #DRKS00004609) in 
the Klinik Bad Reichenhall, Center for Rehabilitation, Pulmonology and Orthopedics in 
Germany [32]. Patients were included between February 2013 and July 2014. Detailed 
inclusion- and exclusion criteria have been published elsewhere [25, 32]. This study is 
a secondary analysis of a subsample including participants with COPD GOLD grades 
II-IV, aged ≥18 years, who gave informed consent, and who were without respiratory 
comorbidities (e.g. bronchiectasis, asthma, history of bronchial carcinoma, sarcoidosis, 
tuberculosis) or alpha-1-antitrypsin deficiency. 
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5.3.2 Study design and data collection
Patients participated in an intensive 3-week full-day inpatient PR programme tailored 
to the patient’s individual needs including components of physical training, education, 
smoking cessation, physiotherapy and counselling [25, 32]. Patient characteristics and 
post-bronchodilator spirometry were collected at baseline and after 3 weeks at the end 
of PR. Primary parameters collected for this substudy were the CAT (no recall period), CCQ 
(weekly version) and SGRQ (monthly version) at baseline, discharge and during follow-up 
measurements at 3, 6, 9 and 12 months. Measurements were taken in the clinic pre- and post-
rehabilitation. Patients were blinded to their previous answers during PR. The remaining 
follow-up questionnaires were sent to the patient’s home by regular mail. 
The CAT is an 8-item unidimensional scale with item scores ranging from 0 to 5 (0: no 
impairment; 5: maximum impairment), summing up to a total of maximum 40 points 
[16]. The CCQ consists of 10 items scoring from 0 to 6 (0: no impairment; 6: maximum 
impairment) [17]. Domain scores (symptoms, functional status and mental status) and the 
total questionnaire score can be determined by summing all relevant item scores divided 
by the number of items. The SGRQ has 50 items divided over the domains symptoms, 
activities and impact [18]. Scores are calculated using the developers’ scoring file. Domain 
and total SGRQ scores can range from 0 to 100 (0: no impairment, 100: maximum 
impairment). Scores of the CAT and CCQ were multiplied and standardised into a scale 
from 0 to 100 to be comparable with SGRQ. All questionnaires were validated and reliable 
in primary and secondary care, as well as PR for patients with COPD [18, 29, 33-34]. The 
three instruments are recommended according to the GOLD strategical guidelines [19]. 
At each follow-up moment a 15-point Likert scale GRC anchor question was scored by the 
patients requiring assessment of their global health in relation to their COPD compared 
with the start of PR (Supplementary material 5.7.1). Answers were marked on a scale from 
-7 to +7, ranging from very much worse to very much better and zero representing no 
change [9]. At 12-months follow-up a 5-point GRC, analogue to the second question of 
the Short-Form 36 (SF-36), was also scored by the patient (Supplementary material 5.7.2) 
[35]. It required patients to rate their general health compared to one year prior. Patients 
could assess their status as the same, somewhat better or somewhat worse, or as much 
better or much worse. Both GRCs are frequently used in MCID research [9]. The term 
recall period in this sense, refers to the recall period of the GRCs.
5.3.3 Determining the MCID 
Scores for CAT, CCQ and SGRQ refer to their total scores. All change scores on the three 
questionnaires were calculated as the difference between baseline and each respective 
follow-up measurement. Negative change on these health status tools indicated 
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improvement and positive change represented deterioration in HRQoL. Changes on 
these instruments were categorised using the corresponding score on the GRC anchor 
question. Scores of 0 and ±1 on the 15-point GRC indicated no change; scores of ±2 and 
±3 represented a minimal change; scores of ±4 and ±5 were summarised as a moderate 
change; and scores of ±6 and ±7 indicated a large change [9]. The 5-point GRC resulted 
in a division of patients as not changed, somewhat better, somewhat worse, much 
better, or much worse [35]. MCID estimates for the CAT, CCQ and SGRQ total scores 
were calculated as the mean change scores compared with baseline including the 95% 
confidence interval (95%CI) of those patients indicating a minimal improvement (+2 
and +3) on the GRC at each follow-up measurement, after checking for normality of 
distribution of the data. In addition to the 15-point Likert GRC scale, the 5-point anchor 
question was used in a similar way to classify patients as somewhat better. Only patients 
that indicated an improvement on the GRC were included, since patients tend to get 
better after intervention and a limited number of patients were expected to deteriorate. 
5.3.4 Data analysis
Data analysis was performed using SPSS 23.0 (IBM, Chicago, USA). Descriptive data were 
evaluated at baseline for either frequencies with percentages (%), mean with standard 
deviation (SD) or median with range. This was depending on the variable characteristics 
and/or normality of distribution. CAT, CCQ and SGRQ were evaluated at baseline (T0), 
at discharge (T1), after 3 months (T2), after 6 months (T3), after 9 months (T4) and after 
12 months (T5). Normality of distribution was assessed using histograms combined with 
skewness and kurtosis results. Values between -1 and +1 were considered indicative for 
normality. Mean and SDs (or median and range) were calculated for each measurement. 
Data were checked for floor- and ceiling effects defined as more than 15% of the patients 
in the lowest and highest 10% of the maximum scale score [36]. All health status change 
scores were calculated between baseline and each follow-up measurement. These 
change scores were tested for significance using paired t-tests after verifying normality 
of distribution. All tests were assessed for significance using the level P<0.05.
The MCID determination process included several steps. First, correlations between the 
GRC anchor questions, and respectively the CAT, CCQ or SGRQ were assessed using 
Pearson or Spearman correlation coefficients depending on normality of distribution. 
Correlations (r) needed to be ≥0.30 (preferably ≥0.50) to be eligible as anchor [7]. 
Next, participants were categorised according to their GRC score at each follow-up 
measurement. The respective change versus baseline was tested for significance using 
paired t-tests after checking for normality. Each MCID estimate was calculated as the 
mean change score compared with baseline including its 95% confidence interval (CI) 
for those patients indicating a minimal improvement/somewhat better on the GRC for 
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each follow-up moment. Correspondence between the 15-point and 5-point GRC was 
analysed using cross tabulations, correlation coefficients and bar charts. 
All MCID estimates were tested for significance with one another by determining the 
degree of overlap of the adjusted CIs. Due to the dependency of the data, the intraclass 
correlation coefficient (ICC) between follow-up measurement and baseline was calculated 
and used to construct CIs. Adjusted CIs were calculated based on the ICC between follow-
up moment and baseline [37]. The degree of dependency affects the width of the CI 
required to be able to test for significant differences between the various MCID estimates. 
Results were visualised in plots. A lack of overlap between the MCID estimates and their 
respective CIs indicated significant differences between MCIDs. Finally, the MCID estimates 
and their adjusted CIs from the current study were also compared with the available 
thresholds from the literature (CAT (-)2.00, CCQ (-)0.40, and SGRQ (-)4.00 points).
5.4 Results
5.4.1 Patient characteristics 
This secondary analysis of the RIMTCORE trial included 451 patients [32]. All patients 
had completed baseline data and at discharge, with the exception for one incomplete 
CCQ questionnaire, two incomplete CAT questionnaires and four incomplete SGRQ 
questionnaires at discharge. During follow-up 355 patients had completed data after 
3 months; 319 after 6 months; 304 after 9 months; and 309 after 12 months (Figure 1). In 
total, eight patients died during follow-up according to our knowledge, 41 dropped out at 
own request and a varying number of non-responses at follow-up was present. Mean age 
was 58 years, 65% was male and had a mean forced expiratory volume in one second % 
predicted (FEV
1
%pred) of 50.4±15.1 (Table 1). There were no significant baseline differences 
between patients completing the 12-months follow-up and those who did not. Full patient 
characteristics at baseline have been published elsewhere [25].
5.4.2 Health status scores
CAT, CCQ and SGRQ total scores were normally distributed for all measurement moments 
between T0 and T5. Completed pairs of change scores (follow-up versus baseline) were 
included only (i.e., pair-wise deletion). There were no floor- and ceiling effects observed. 
There were no significant baseline differences in health status between complete and 
incomplete follow-up patients (Table 1). Mean baseline scores were 20.2±7.3 (CAT), 2.9±1.2 
(CCQ) and 50.7±17.3 (SGRQ) (Table 1). Mean change after 12 months of follow-up was 
significant compared with baseline of -0.9 (95%CI -1.7 to -0.1) for CAT; -0.2 (95%CI -0.3 to -0.1) 
for CCQ; and -3.9 (95%CI -5.7 to -2.2) for SGRQ (Table 2).
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Figure 1: Consort flow-chart of the number (n) of patients during follow-up
Abbreviations: N, number of patients; PR, pulmonary rehabilitation
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Table 1: Baseline patient characteristics
Variable Baseline all patients
n=451
Patients with complete follow-up
n=309
Patients with incomplete 
follow-up at 12 months
n=142
Significance 
Age (years)a 57.9 ± 6.6 58.1 ± 6.5 57.5 ± 6.6 p = 0.39
Gender (male)b 293 (65.0) 197 (63.8) 96 (67.6) p = 0.43
FEV
1
%preda 50.4 ± 15.1 50.6 ± 14.9 50.0 ± 15.6 p = 0.72
GOLD IIb 227 (50.3) 158 (51.1) 69 (48.6)
p = 0.63
 
GOLD IIIb  176 (39.0) 121 (39.2) 55 (38.7)
GOLD IVb  48 (10.6) 30 (9.7) 18 (12.7)
Smoking pack yearsa 42.6 ± 23.5 41.1 ± 23.1 45.9 ± 24.0 p = 0.05
CATa 20.2 ± 7.3 20.0 ± 7.6 20.8 ± 6.8 p = 0.28
CCQ Totala 2.9 ± 1.2 2.8 ± 1.2 3.0 ± 1.1 p = 0.06
SGRQ Totala 50.7 ± 17.3 49.6 ± 17.8 53.0 ± 16.2 p = 0.05
ª Data expressed as mean ± SD. 
b Data expressed as frequencies (% of total). 
Significance tested with independent t-tests or Chi Square tests at level P < 0.05. 
Abbreviations: CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive pulmonary disease; FEV
1
%pred, 
forced expiratory volume in one second % predicted; GOLD, global initiative for chronic obstructive lung disease; N, number of patients; SD, 
standard deviation; SGRQ, St. George’s Respiratory Questionnaire. 
Table 2: Health status change scores
N CAT CAT 
Standardised 
CCQ Total CCQ Total 
Standardised 
SGRQ Total


















































Change scores were calculated in comparison to baseline. 
Negative values represent improvement for CAT, CCQ and SGRQ. 
Change scores reported as means (95%CI). 
CAT and CCQ were standardised into a scale from zero to 100 to be comparable with SGRQ. 
* Significance of change scores at level P < 0.05 at T1/T2/T3/T4/T5 compared to baseline T0.
Abbreviations: 95%CI, 95% confidence interval; CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire;  COPD, chronic obstructive 
pulmonary disease; N, number of patients; SGRQ, St. George’s Respiratory Questionnaire; T0, baseline measurement;  T1, measurement 
at discharge; T2, 3-months follow-up; T3, 6-months follow-up; T4, 9-months follow-up; T5, 12-months follow-up.
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Figure 2: Correspondence between the 5- and 15-point global rating of change anchor at 12-months
follow-up
Abbreviations: GRC, global rating of change













N of Patients 451 355 319 304 309 309
CAT change score -0.23 -0.33 -0.40 -0.43 -0.41 0.46
CCQ total change score -0.29 -0.42 -0.44 -0.48 -0.47 0.50*
SGRQ total change score -0.30 -0.48 -0.51* -0.58* -0.54* 0.57*
Data reported as Pearson or Spearman correlation coefficients between health status change scores and the respective anchor GRC. 
* Correlations were ≥0.50. 
Abbreviations: CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive pulmonary disease; GRC, 
global rating of change; SGRQ, St. George’s Respiratory Questionnaire; T1, measurement at discharge; T2, 3-months follow-up; T3, 
6-months follow-up; T4, 9-months follow-up; T5, 12-months follow-up.
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5.4.3 Minimal clinically important differences for the CAT, CCQ and SGRQ
All change scores and 15-point anchor question scores were normally distributed. The 
5-point GRC at 12 months was treated as non-parametric data. At T1, one patient had a 
missing GRC score. No other GRC scores were missing for T2-T5. Correlations between the 
5-/15-point anchor questions and the health status change scores on the CAT, CCQ and 
SGRQ were all ≥0.30, except for CCQ and CAT at T1 (Table 3). The Spearman correlation 
coefficient between the 5- and 15-point GRC at 12 months was 0.81. The overlap between 
the 5-point GRC and the 15-point GRC classification at 12-months was 55% based upon a 
cross-tabulation (Figure 2). 
A subset of the total patient population, indicated a minimal improvement according to 
their GRC score. Patients indicating a minimal improvement on the 15-point GRC (scores 
of +2 or +3) noted significant absolute mean changes between the start of PR and 12 
months of follow-up of -2.8 (95%CI -4.2 to -1.4) on the CAT; -0.5 (95%CI -0.7 to -0.3) on the 
CCQ; and -8.8 (95%CI -11.8 to -5.8) on the SGRQ (Table 4). MCID estimates ranged from 
-3.1 to -2.3 for CAT; -0.6 to -0.4 for CCQ; and from -10.3 to -7.6 for the SGRQ. Mean change 
scores of those patients feeling somewhat better on the 5-point GRC after 12 months 
were -1.4 for CAT (95%CI -2.7 to -0.1), -0.3 for CCQ (95%CI -0.5 to -0.2), and -7.7 for SGRQ 
(95%CI -10.5 to -4.8) (Table 4).  
Table 4: MCID estimates for minimally improved patients as indicated on the GRC during follow-up
Measurement period N CAT CAT 
Standardised 
CCQ Total CCQ Total 
Standardised 
SGRQ Total




























































Change was measured compared to baseline. Negative values represent improvement for CAT, CCQ and SGRQ. 
Minimal change scores were reported as mean ± SD (95%CI). 
CAT and CCQ were standardised into a scale from zero to 100 to be comparable with SGRQ.
* Significance of change scores at level P < 0.05 at  T1/T2/T3/T4/T5 compared to baseline T0. 
Abbreviations: 95%CI, 95% confidence interval; CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive 
pulmonary disease; GRC, global rating of change scale; N, number of patients; SD, standard deviation; SGRQ, St. George’s Respiratory 
Questionnaire; T0, baseline measurement; T1, measurement at discharge; T2, 3-months follow-up; T3, 6-months follow-up; T4, 9-months follow-
up; T5, 12-months follow-up. 
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5.4.4 Tests of significance between MCID estimates
ICC values ranged 0.5-0.7 for CAT and CCQ, and 0.6-0.7 for SGRQ (Table 5). 














Mean change -3.1 -2.7 -2.7 -2.3 -2.8 -1.4
SD of the change 5.3 6.4 6.7 6.1 6.7 5.9
N of patients 196 107 96 80 88 81
ICC 0.7 0.6 0.5 0.6 0.5 0.6
Z score required 0.62 0.98 0.98 0.98 0.98 0.98
Standard Error 0.4 0.6 0.7 0.7 0.7 0.7
Adjusted CI -3.4 to -2.9 -3.4 to -2.1 -3.4 to -2.1 -3.0 to -1.6 -3.5 to -2.1 -2.0 to -0.8













Mean change -0.6 -0.4 -0.4 -0.5 -0.5 -0.3
SD of the change 0.8 1.0 1.1 0.8 1.0 0.8
N of patients 196 107 96 80 88 81
ICC 0.7 0.6 0.5 0.7 0.5 0.6
Z score required 0.62 0.98 0.98 0.62 0.98 0.98
Standard Error 0.1 0.1 0.1 0.1 0.1 0.1
Adjusted CI -0.7 to -0.5 -0.5 to -0.3 -0.5 to -0.3 -0.6 to -0.4 -0.6 to -0.4 -0.4 to 0.2













Mean change -8.4 -7.6 -9.2 -10.3 -8.8 -7.7
SD of the change 11.8 13.8 14.0 12.9 14.1 12.9
N of patients 196 107 96 80 88 81
ICC 0.7 0.7 0.7 0.7 0.6 0.6
Z score required 0.62 0.62 0.62 0.62 0.98 0.98
Standard Error 0.8 1.3 1.4 1.4 1.5 1.4
Adjusted CI -8.9 to -7.9 -8.4 to -6.8 -10.1 to -8.3 -11.2 to -9.4 -10.3 to -7.4 -9.1 to -6.3
Abbreviations: CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; CI, confidence interval; COPD, chronic obstructive pulmonary 
disease; GRC, global rating of change; ICC, intraclass correlation coefficient; N, number of patients; SD, standard deviation; SGRQ, St. George’s 
Respiratory Questionnaire; T0, baseline measurement; T1, measurement at discharge; T2, 3-months follow-up; T3, 6-months follow-up; T4, 
9-months follow-up; T5, 12-months follow-up.
Figures 3 and 4 visually plot the MCID estimates for CAT, CCQ and SGRQ including their 
respective adjusted CIs for each recall period on both GRCs. Overlap was present for all 
CAT MCID estimates, except for the 12-months estimate using the 5-point anchor question 
compared with the 15-point GRC (Figure 3). A significantly absolute lower MCID estimate 
















































































































































































































































































































was observed for CAT using the 5-point GRC (difference -1.4: adjusted CI -2.3 to -0.5). The 
MCID measured with the 15-point GRC after 9 months as well as the MCID using the 5-point 
anchor question overlapped with the CAT estimate from the literature of 2 points. 
The MCID plotted for the CCQ visualised that all estimates with their corresponding CIs 
overlapped one another, except for the estimate after 12 months with the 5-point GRC in 
comparison to the 15-point GRC (Figure 3). A significantly absolute lower MCID estimate 
was observed for the CCQ using the 5-point GRC at 12 months (difference -0.2: adjusted 
CI -0.3 to -0.1). All estimates included the MCID from the literature of 0.40 points, except 
for the 15-point GRC anchor question estimate after 3 weeks. The plot for the MCID of the 
SGRQ showed all ranges overlapping one another, except for the 9-months 15-point GRC 
anchor question method, which was significantly different from the 15-point GRC estimate 
after 3 weeks and after 3 months (Figure 4). There were no significant differences between 
the 5-point and 15-point GRC at 12 months. All estimates were significantly different from the 
4 points estimate in the literature. 
5.5 Discussion
5.5.1 Summary of main findings
This study found no systematic significant differences between various recall periods 
of a 15-point anchor question on the MCID for improvement of the health status tools 
CAT, CCQ and SGRQ for patients with COPD in a PR setting. Using this 15-point GRC, 
MCID estimates for improvement ranged -3.1 to -2.3 for CAT; -0.6 to -0.4 for CCQ; and 
-10.3 to -7.6 for SGRQ. Higher absolute MCID estimates were observed for CAT and CCQ 
with a shorter recall period directly after PR, although not significant. The 9-month recall 
period on the 15-point GRC for the SGRQ was significantly higher in absolute value when 
comparing with the estimates at 3 weeks and 3 months. However, an anchor question 
with only 5 answering options did result in significantly absolute lower MCIDs for CAT 
and CCQ in comparison with the 15-point GRC at 12 months. Estimates were -1.4 for CAT 
(significant difference -1.4), -0.3 for CCQ (significant difference -0.2), and -7.7 for the SGRQ 
(nonsignificant difference -1.1). 
5.5.2 Interpretation of findings
The MCID ranges found in the current study for both CAT and CCQ were in correspondence 
with those available in the literature [21-28]. Recall periods on the anchor question of 2-3 
days, 3 weeks and 8 weeks have been used before for CAT and CCQ [21, 23, 25, 27-28]. 
Most MCID estimates for the CAT in the current study were significantly higher than the 
2 points threshold, which had been advocated using a 5-point GRC scale [27-28]. Since 





















































































































































































































































































































































CAT only allows for integer scores, a cutoff MCID of 3 points would be suggested here. 
For the CCQ, all recall periods and anchor question types included the 0.40-point MCID 
as reported in the literature, although our estimates were closer to 0.50 points [21-26]. 
Both 5- and 15-point GRCs were used generating the original 0.40 MCID estimate for the 
CCQ [21, 23]. 
The estimates for the SGRQ in the current study were significantly higher compared with 
the existing 4 points MCID, which is used extensively in scientific research [29, 31]. This MCID 
was among others based upon a 5-point question requiring patients with COPD to assess 
their treatment effects over a 16-week period. It did not require patients to assess their 
experienced change in health status, hence this may result in a different MCID. The current 
study provided additional support to the recommendation by Welling et al. [30] and Alma 
et al. [25] that the MCID of the SGRQ of 4 points should be set higher. 
There was a remarkable significant difference between the 5- and 15-point anchor 
question GRC scale in estimating the MCIDs for CAT and CCQ at 12 months, although 
the Spearman correlation between both anchor scales was strong. However, the 
classification of patients according to both GRCs was only for 55% consistent, resulting 
thus in a different categorisation of the degree of change assessed by patients 
themselves. Although the 15-point GRC was analysed as a 7-point scale, the patients 
had 15 answering options to choose from, compared with just five on the other GRC. Too 
few reply options on an anchor question might lead to a loss of relevant information, 
leading to less discriminative power and lower sensitivity [9]. It may result into lower 
MCIDs. This seems to be the case for the current study for both CAT and CCQ, and to a 
lesser extent for SGRQ as well. Earlier studies used only 5-point GRCs for CAT and SGRQ 
[27-29, 31]. These studies showed lower absolute MCIDs. A 5-point anchor scale may 
therefore not discriminate sufficiently. Kamper SJ et al. recommended to include 7-11 reply 
options for optimal discrimination [9]. Another difference between the current 5- and 
15-point GRC was that the first one was a verbal scale, while the latter one was a numeric 
scale. Possibly this has influenced the classification, as words may result in a different 
perception in comparison to numbers. 
Using an anchor question to determine an instrument’s MCID is common practice [6-
8]. Jaeschke et al. were the first to use this approach in determining the MCID of the 
Chronic Respiratory Questionnaire (CRQ) using a 15-point Likert scale GRC [5]. Since 
then many have adopted this method, but have also applied alternative versions to 
determine the MCID. The approach is easy to administer and the single best measure 
of the significance of change from the patient’s perspective [9-11]. However, anchor 
questions rely on the patient’s ability to recall their former health state [9-11]. Accurate 
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recall is determined by factors such as forgetting, more recent (impactful) health events, 
and current mood state [11]. GRC scales may therefore not provide an accurate reflection 
of the real experienced change due to these recall biases. 
It has been speculated that longer recall periods would lead to less accurate estimates 
of change and even to different MCIDs [10, 38-42]. Evaluation of change turned out to 
be more correlated with the current health state and severity of experienced symptoms, 
rather than with the former (baseline) condition [9-10, 41-48]. There are, however, also 
studies that did not find specific differences between recall periods [39, 49-51]. There is no 
single optimal recall period [39, 51]. The required window is dependent upon whether or 
not acute effects need to be measured, whether acute events occur, as well as the nature 
of the disease [39, 52]. Longer recall periods may therefore be appropriate for chronic 
conditions with slow changes. It was argued that the optimal length for measuring 
change on a patient-reported outcome (PRO) in COPD would be six to 12 months [53]. 
A recall period of more than one year could lead to problems due to the progressive 
nature of the disease. In addition to the impact of recall bias, a patient’s evaluation of a 
specific health state might change over time due to a response shift [54]. This concept 
refers to a change in the meaning of the concept HRQoL for the patient. Response shift 
was demonstrated to have an influence on the MCID for HRQoL tools in breast cancer 
research [55]. Evidence for the influence of response shift as well as recall bias on the 
MCID for health status for COPD is currently absent in the literature. 
The current study had a fixed recall moment, which was related to the start of an intense 
PR programme. The effects of PR would be expected to remain over a longer period 
of time, leading to less exacerbations and less acute changes in the health state of 
the patients with COPD [56]. Jones et al. [53] recommended measurement of PROs in 
COPD over a 6-12 month period as the optimal recall period, which our study did. The 
assessment of change compared with the start of PR, the expected stability of COPD 
symptoms over time after PR and the use of the optimal recall period might help explain 
why this study found stable MCID estimates during follow-up.
Correlations between the anchor question and the health status change scores were 
sufficient to be used as anchor, except for the 3-week measurement period. It may, 
therefore not be surprising, that those estimates were especially for CAT and CCQ higher 
than the other MCID estimates. Evaluating change directly after an impacting event, such 
as PR or exacerbations, could potentially bias the MCID measurement of an instrument. The 
estimates of the SGRQ seemed rather stable over time, perhaps because SGRQ is a more 
extensive and lengthier tool in comparison to the CAT and CCQ. 
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5.5.3 Strengths and limitations
This is the first study to investigate the impact of the recall period of the patient’s GRC 
and its design on the MCID for improvement of health status tools for COPD. It is to the 
best of our knowledge the only study, which measured the MCID of the CAT, CCQ and 
SGRQ in one study over multiple study periods, and included a unique test of significance 
for the MCID according to the methods of Afshartous et al. [37]. In the current study, 
MCIDs were tested over multiple periods of time. No correction for multiple testing was 
made, risking an increase in the probability to run a type I error. However, since this 
was a diagnostic study, we considered this to be of limited importance as there is no 
intention to make a formal statement about efficacy or safety based on hypothesis 
testing [57]. Furthermore, the confidence intervals for the MCID estimates were adjusted 
for the dependency of multiple follow-up data. 
The results found in this study are valid for a PR setting. As MCIDs may differ per setting, the 
results need not necessarily be valid in other populations [11]. However, our results were in 
line with the existing MCIDs in the literature, which were also determined outside the field 
of PR. MCIDs were determined based upon a patient’s perspective of their health status 
change. No clinician, neither the patient, was involved to make a judgement about the 
clinical relevance of the perceived change though. Correlations between the GRCs and the 
health status questionnaires were sufficient according to pre-determined criteria, however 
in fact these correlations are still only small to moderate. 
Another limitation is that the data used in this study were based on improvement 
only, as the number of patients deteriorating for each follow-up period was small to 
allow for significance testing. MCIDs for improvement may, however, differ from those 
for deterioration [11]. Furthermore, this study determined the MCID over different recall 
periods using the 15-point GRC scale. The 5-point anchor question was, however, only 
measured over a 12-month period. It would not be possible to conclude whether recall 
bias occurred for the 5-point GRC. Last, the anchor-based MCID technique can be 
considered a population-based figure, rather than a reflection of the individual’s change 
[6-8, 11]. This is a limitation of the technique in itself. Using a larger sample would lead to 
regression to the mean of the MCID estimate, which is less subject to larger changes in 
an individual’s health state. 
5.5.4 Implications for future clinical practice and theory
No other evidence exists for the impact of the recall period and the design of the anchor 
question on the determination of MCIDs in health status for COPD. Ideally, more research 
is needed to confirm or falsify the current findings in both PR and other settings. It would 
be recommended to use various patient-referencing anchors over multiple periods of 
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time to carefully estimate an instrument’s MCID. Multiple MCIDs might potentially apply to 
practice for different time periods of measurement used in clinical trials. However, this study 
was the first to suggest otherwise. It indicated a differentiation might be needed between 
measurement of change directly after an impacting event and in stable patients, as this 
may be an important factor influencing recall bias.
5.5.5 Conclusions
Various recall periods on a 15-point anchor question seemed not to be associated with 
systematic significant differences in the MCIDs for improvement of the CAT, CCQ and 
SGRQ; with the exception of the shortest 3-week measurement period directly after 
PR for CAT and CCQ, resulting in absolute higher MCID estimates. Measuring change 
with a shorter recall period directly after an impacting event might potentially bias 
measurement. Using an anchor question with less answering options over a one-year 
period of time in determining an instrument’s MCID may also coincide with (significantly) 
lower absolute MCID estimates as less discriminative options might be available for the 
patient.
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5.7.1 15-point global rating of change anchor question
Figure 1: 15-point global rating of change anchor question used during follow-up (in German)
5.7.2 5-point global rating of change anchor question











Im Vergleich zum vervangenen Jahr, wie würden 
Sie Ihren derzeitigen Gesundheitszustand 
beschreiben?
1 2 3 4 5
Globale Veränderung des Gesundheitszustandes
Bitte bewerten Sie auf Folgender Skala die Veranderung Ihres jetzigen Gesundheitszustands gegenüber 
der Zeit direkt vor Beginn der Rehabilitation. Bitten kreuzen Sie nur das Kästchen an, das am besten 
zutrifft:
Im Vergleich zu der Zeit direkt vor Beginn der Rehabilitation ist mein Gesundheitszustand jetzt...
Sehr viel schlechter ............................. .............................unverändert sehr viel besser
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Chronic obstructive pulmonary disease (COPD) is a progressive disease. Preventing 
deterioration of health status is therefore an important therapy goal. (Minimal) clinically 
important differences ((M)CIDs) are used to interpret changes observed. It remains 
unclear whether (M)CIDs are similar for both deterioration and improvement in health 
status. This study investigates and compares these clinical thresholds for three widely-
used questionnaires. 
6.1.2 Methods
Data were retrospectively analysed from an in-house 3-week pulmonary rehabilitation 
(PR) randomised controlled trial in the German Klinik Bad Reichenhall (study 1), and 
observational research in Dutch primary and secondary routine clinical practice (RCP) 
(study 2). Patients with COPD aged ≥18 years (study 1) and aged ≥40 years (study 2) 
without respiratory comorbidities were included for analysis. The COPD Assessment Test 
(CAT), Clinical COPD Questionnaire (CCQ) and St. George’s Respiratory Questionnaire 
(SGRQ) were completed at baseline, and at 3, 6, and 12 months. A global rating of 
change (GRC) scale was added at follow-up. Anchor- and distribution-based methods 
were used to determine clinically relevant thresholds.
6.1.3 Results
In total, 451 patients were included from PR and 207 from RCP. MCIDs for deterioration 
ranged from 1.30 to 4.21 (CAT), from 0.19 to 0.66 (CCQ), and from 2.75 to 7.53 (SGRQ). 
MCIDs for improvement ranged from -3.78 to -1.53 (CAT), from -0.50 to -0.19 (CCQ), and 
from -9.20 to -2.76 (SGRQ). Thresholds for moderate improvement versus deterioration 
ranged from -5.02 to -3.29 versus 3.89 to 8.14 (CAT), from -0.90 to -0.72 versus 0.42 to 1.23 
(CCQ), and from -15.85 to -13.63 versus 7.46 to 9.30 (SGRQ).
6.1.4 Discussion and conclusions
MCID ranges for improvement and deterioration on the CAT, CCQ and SGRQ were 
somewhat similar. However, estimates for moderate and large change varied and were 
inconsistent. Thresholds differed between study settings.
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6.2 Background
The use of health status questionnaires is recommended by the global initiative 
for chronic obstructive lung disease (GOLD) for the assessment, evaluation and 
management of patients with chronic obstructive pulmonary disease (COPD) [1]. The 
COPD Assessment Test (CAT) [2], the Clinical COPD Questionnaire (CCQ) [3], and the 
St. George’s Respiratory Questionnaire (SGRQ) [4] are frequently used patient-reported 
health status tools important for clinical practice and scientific research [5], especially 
since the burden of COPD is high worldwide [6-7]. 
Various studies have examined clinically relevant thresholds for change on the CAT, 
CCQ and SGRQ in order to be able to evaluate and interpret treatment effects [8-18]. 
The minimal clinically important difference (MCID) is a parameter that quantifies this 
threshold. It has been defined as “the smallest difference in score, which patients perceive 
as beneficial and which would mandate a change in the patient’s management” [19]. MCIDs 
are particularly interesting for health status questionnaires, where a change in its score 
is not intuitively meaningful. Change exceeding the level of the MCID can be considered 
clinically relevant, thus justifying therapy and help developing guidelines. It is pivotal that 
clinically relevant thresholds for change on a health status tool are rigorously studied 
and analysed carefully. 
Most clinical studies that determine the MCID of patient-reported outcomes (PROs) are 
executed in the context of an intervention such as pharmacotherapy or pulmonary 
rehabilitation (PR). This usually results in an improvement in the patients’ health-related 
quality of life (HRQoL). MCIDs for improvement have thus been investigated; however, 
there is a lack of evidence for the MCIDs for deterioration [20]. It remains unclear and 
debated upon to what extent clinically relevant thresholds for improvement should be 
similar to those for deterioration [21-24]. Certain studies outside the field of COPD have 
analysed the MCIDs of PROs and found evidence that values for improvement differed 
from deterioration [25-29]. On the other hand, there is also evidence that thresholds 
might be similar [30]. Interpreting worsening of HRQoL is of major importance, since one 
needs to differentiate between real worsening of patients’ status and random variations. 
Furthermore, the effects of therapy may also halt further deterioration especially for 
a progressive chronic disease like COPD. So, no relevant worsening or a reduction in 
clinically relevant deterioration over time might also be considered a success of therapy 
and in clinical trials [31]. 
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In health status for patients with COPD, the estimated MCID for the CAT score is 2.00 
to 3.00 units [11-15, 20], for the CCQ score 0.40 to 0.50 units [8-13, 20], and for the SGRQ 
score 4.00 to 8.00 units [12, 16-18, 20]. This is valid for improvement only, as there were 
too few patients with deterioration to investigate. There are currently no studies that 
specifically investigate clinically relevant thresholds for deterioration on these PROs. It is, 
however, worrying that up to date, multiple studies included the MCIDs for improvement 
on these health status instruments for COPD to interpret deterioration observed in clinical 
trials [32-34]. This study therefore aims to determine and compare clinically relevant 
thresholds for deterioration and improvement on the health status questionnaires CAT, 




This study was a retrospective analysis of data obtained from two prospective clinical 
trials. Study 1 was a secondary analysis of a subsample from the routine inspiratory 
muscle training within COPD rehabilitation (RIMTCORE) real-life randomised controlled 
trial in the Klinik Bad Reichenhall, Center for Rehabilitation, Pulmonology and Orthopedics 
in Germany [12, 35]. Patients were recruited on arrival in the clinic between February 2013 
and July 2014. Participants were included if they had COPD GOLD grades II-IV, were aged 
≥18 years and gave informed consent [12, 35]. Exclusion criteria were the presence of other 
respiratory comorbidities (e.g. bronchiectasis, asthma, history of bronchial carcinoma, 
sarcoidosis, tuberculosis), or alpha-1-antitrypsin deficiency. 
Study 2 (MCID study) was an observational trial of patients with COPD GOLD grades I-IV 
aged ≥40 years without other respiratory comorbidities or alpha-1-antitrypsin deficiency. 
Patients were recruited from Dutch primary and secondary RCP between September 2015 
and September 2016. Patients were approached via multiple general practices, hospitals 
and the Dutch patient lung federation. The study was evaluated by the Medical Ethical 
Committee of the University Medical Center Groningen (UMCG), the Netherlands. All 
patients provided written informed consent.
6.3.2 Patient and public involvement
In both studies, patients and the public have not actively been involved during the design 
of the study, nor in the assessment of the burden. Summary results are disseminated to 
participating patients after completion.
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6.3.3 Study design and data collection
Patients in study 1 participated in an intensive 3-week full-day inpatient PR programme 
tailored to the patient’s individual needs. Details have been presented previously [12, 
35]. Patient descriptives and post-bronchodilator spirometry were collected at baseline 
and discharge in the clinic. Patients in study 2 received routine care from their physician 
according to national treatment guidelines. Evaluation of health status over a 12-month 
period was the primary measurement outcome. Patient descriptives and spirometry 
data were obtained at baseline. Spirometry results were obtained via the including 
physician after approval of the participant. 
The primary outcomes selected from both prospective studies for this retrospective 
analysis were the CAT (no recall period), CCQ (weekly version) and SGRQ (monthly 
version). In study 1, these questionnaires were collected at baseline, at PR discharge 
and during follow-up at 3, 6, 9 and 12 months. Baseline and discharge measurements 
were taken in the clinic, where patients were blinded to their baseline scores. Follow-up 
questionnaires were sent by mail. In study 2, all questionnaires were sent by mail and 
scored at home at baseline, and at 3, 6 and 12 months. For this retrospective analysis 
baseline and follow-up scores at 3, 6 and 12 months were included, to allow for sufficient 
time for deterioration in HRQoL, to include various time periods of measurement, and to 
allow for comparison between both study settings. 
The CAT is an 8-item unidimensional scale with item scores ranging 0-5 (0: no impairment; 
5: maximum impairment) and a total score summing up to a maximum of 40 [2]. The 
CCQ consists of 10 items scoring 0-6 (0: no impairment; 6: maximum impairment) [3]. 
The items cover the domains symptoms (4 items), functional status (4 items) and mental 
status (2 items). Total and domain scores on the CCQ derive from adding up relevant 
item scores and dividing this by the number of items. The SGRQ has 50 items classified 
into the domains symptoms (8 items), activities (16 items) and impact (26 items) [4]. 
Domain and total SGRQ scores can range from 0-100 (0: no impairment; 100: maximum 
impairment). A 15-point Likert scale anchor question (global rating of change GRC) was 
scored retrospectively by the patient at each follow-up visit in both datasets. The GRC 
required patients to assess their health status for COPD compared with baseline. The 
answers were marked on a scale from -7 to +7, ranging from very much worse to very 
much better and zero equaling no change [36-37].
6.3.4 Study methods
All change scores for the total scores of the CAT, CCQ and SGRQ were calculated as 
the difference between baseline and the respective follow-up visit (3, 6 and 12 months). 
Negative change on all questionnaires represented improvement, and positive change 
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deterioration. First, in the anchor-based approach, changes on the health status 
instruments were classified using the corresponding score on the GRC. Scores of 0 and ±1 
on the GRC indicated no change; scores of ±2 and ±3 represented a minimal improvement/
deterioration; scores of ±4 and ±5 were summarised as a moderate improvement/
deterioration; and scores of ±6 and ±7 indicated a large improvement/deterioration [36-
37]. MCID estimates for both improvement and deterioration on the CAT, CCQ and SGRQ 
were calculated as the mean change scores including 95% confidence interval (95%CI) 
of those patients indicating a minimal improvement/deterioration (±2 and ±3) on the 
GRC for each follow-up visit, verifying normality of distribution. Mean estimates including 
95%CI were determined in a similar way for patients indicating no change (GRC 0 and 
±1), moderate change (GRC ±4 and ±5) and large change (GRC ±6 and ±7). Second, the 
distribution-based method half standard deviation (0.5SD) of the change score was 
calculated for improved and deteriorated health status patients at respective follow-up 
visits [38].  
6.3.5 Data analysis
Data analysis was performed using SPSS 24.0 (IBM, Chicago, USA). Descriptives were 
evaluated at baseline for either frequencies with percentages (%), mean with standard 
deviation (SD) or median with range. This was depending on the variable characteristics 
and/or normality of distribution. Health status data on the CCQ, CAT and SGRQ were 
evaluated at baseline (T0), 3 months (T2), 6 months (T3) and after 12 months (T5). 
Normality of distribution was verified using skewness and kurtosis. Values between 
-1 and +1 were considered indicative for normality. Data were checked for floor- and 
ceiling effects defined as over 15% of patients scoring in the lowest and highest 10% of 
the maximum scale range [39]. Mean and SD (or median and range) were calculated 
at each measurement moment for all patients, as well as specifically for patients 
with improved and deteriorated health status scores. Baseline scores were compared 
between improving and deteriorating patients, and tested using independent t-tests 
after verifying normality of distribution. Baseline scores were compared between 
both datasets (PR vs. RCP) using independent t-tests, Mann-Whitney U tests or χ2 tests 
depending on the variable characteristic and/or normality of distribution. Health status 
change scores were all calculated in comparison with baseline. Follow-up scores were 
compared with baseline to test for significance of change using paired t-tests verifying 
normality of distribution. 
In order to determine clinically relevant thresholds for change, first correlations between 
the GRC and the CCQ, CAT and SGRQ respectively were assessed using Pearson or 
Spearman correlation coefficients depending on normality of distribution. Correlations 
needed to be ≥0.30 (preferably ≥0.50) to be eligible as anchor [22]. Correlations were 
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assessed between GRC and questionnaire change scores, and between GRC, baseline 
and follow-up questionnaire scores to assess for a possible response shift. Next, 
participants were categorised according to their GRC score at each follow-up. Mean 
changes (95%CI) for each respective category were determined to define thresholds for 
clinically relevant change. Significance of change for each GRC class at the respective 
follow-up visit was compared with baseline and assessed with paired t-tests verifying 
normality of the data. Last, the 0.5SD of the change score was determined for patients 
with improved and deteriorating health status change scores separately at each follow-
up. Thresholds were compared between both study settings (PR versus RCP).
An absolute overall weighted mean MCID estimate for both improvement and deterioration 
was calculated at the end by multiplying the number of observations (n) at each follow-up 
visit times the MCID estimate for that period. The sum was divided by the total number of 
observations. Anchor- and distribution-based approaches had similar weights. Estimates 
for improvement and deterioration were compared visually in a plot.
6.4 Results
6.4.1 Patient characteristics 
Study 1 included 451 patients with completed baseline data (Table 1) [12, 35]. During 
follow-up 355 patients (78.7%) had completed data at T2, 319 patients (70.7%) at T3, and 
309 patients (68.5%) at T5. During the 12-months follow-up 8 patients passed away, 41 
dropped out at own request, and a varying number of non-response was present. Study 
2 included 207 patients with full baseline data (Table 1), of whom 201 (97.1%) completed 
T2, 186 (89.9%) T3 and 177 (85.6%) T5. Four patients died, 12 patients discontinued at own 
request, and a various number of non-response was present. There were no significant 
baseline differences between completers and non-completers of the 12-months follow-
up in both studies, except that significantly more women (28.4%) compared with men 
(10.0%) did not complete the follow-up during RCP. Significant differences in age, forced 
expiratory volume in one second percentage predicted (FEV
1
%pred) and health status 
were observed between both studies (Table 1).   
6.4.2 Health status scores for improvement and deterioration
In study 1 and 2, CAT, CCQ and SGRQ total were normally distributed at baseline and 
follow-up. Completed pairs of change scores (follow-up vs. baseline) were included (i.e., 
pair-wise deletion). Floor- and ceiling effects were negligible. Mean health status baseline 
scores were significantly different for PR and RCP (Table 1). Overall, 58-59% of patients 
had improved health status scores (negative change) at T5 after PR, compared with 
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44-47% during RCP (Table 2). After PR mean changes observed on the CAT questionnaire 
at T5 were -5.45±4.66 for improvers and 5.47±4.22 for patients, who deteriorated; on the 
CCQ questionnaire -0.87±0.72 for improvement and 0.83±0.62 for deterioration; and 
on the SGRQ questionnaire -13.83±10.43 for improvers and 10.19±8.94 for patients, who 
deteriorated (Table 2). In RCP, these estimates were for the CAT -4.53±3.15 for improvement 
and 3.88±2.59 for deterioration; for the CCQ -0.54±0.54 for improvement and 0.51±0.39 
for deterioration; and for the SGRQ -7.74±9.51 for improvement and 8.46±7.06 for 
deterioration (Table 2). 
Table 1: Baseline patient characteristics
Variable Study 1: PR Study 2: RCP Significance
N 451 207 -
Age (years)a 57.87 ± 6.56 66.69 ± 7.91 < 0.001*
Gender (male)b 293 (65.0) 121 (58.5) 0.507
FEV
1














Smoking pack yearsa 40 (30-50) 37.5 (22.50-51.25) 0.081
CAT Totala 20.23 ± 7.33 18.32 ± 7.22 0.002*
CCQ Totala 2.86 ± 1.17 2.12 ± 1.02 < 0.001*
CCQ Symptomsa 2.87 ± 1.24 2.48 ± 1.03 < 0.001*
CCQ Functional Statusa 2.86 ± 1.34 2.28 ± 1.40 < 0.001*
CCQ Mental Statusa 2.86 ± 1.74 1 (0-1.50) < 0.001*
SGRQ Totala 50.69 ± 17.33 42.88 ± 19.16 < 0.001*
SGRQ Symptomsa 63.66 ± 21.77 48.04 ± 24.16 < 0.001*
SGRQ Activitiesa 63.58 ± 19.82 61.48 ± 21.10 0.259
SGRQ Impacta 39.21 ± 18.81 30.52 ± 19.73 < 0.001*
mMRCa 2 (2-4) 1 (1-2) < 0.001*
a Data expressed as mean ± SD or median (IQR). 
b Data expressed as frequencies (% of total). 
* Significance testing at level P < 0.05 using independent t-tests, Mann-Whitney-U tests or χ2 tests.
Abbreviations: CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive pulmonary disease; FEV
1
%pred, 
forced expiratory volume in one second % predicted; GOLD, global initiative for chronic obstructive lung disease; mMRC, modified Medical 
Research Council Dyspnoea scale; N, number of patients; PR, pulmonary rehabilitation; RCP, routine clinical practice; SGRQ, St. George’s 
Respiratory Questionnaire.
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There were no baseline differences in terms of age, gender and GOLD classification 
between patients with improved health status and patients, who deteriorated at T5 
in both studies. Patients with a worse (read higher) CAT, CCQ or SGRQ baseline score 
prior to PR had significantly more improved health status after one year. Patients, who 
improved during RCP, had a significantly better baseline FEV
1
%pred. 
Table 2: Health status baseline and change scores for all, improved and deteriorated patients
Patients Change after 3 
months (T2)
N (%) Change after 6 
months (T3)




All patients PR -1.44* (-2.16 to -0.71) 354 -0.91* (-1.66 to -0.16) 319 -0.89* (-1.68 to -0.11) 309
Improvement PR -5.45 ± 4.57 227 (64.1) -5.49 ± 4.33 184 (57.7) -5.45 ± 4.66 180 (58.3)
Deterioration PR 5.75 ± 4.20 127 (35.9) 5.33 ± 4.10 135 (42.3) 5.47 ± 4.22 129 (41.7)
All patients RCP 0.30 (-0.42 to +1.02) 201 0.18 (-0.53 to +0.90) 186 0.14 (-0.59 to +0.87) 177
Improvement RCP -4.04 ± 3.33 102 (50.7) -4.64 ± 3.05 81 (43.5) -4.53 ± 3.15 79 (44.6)
Deterioration RCP 4.23 ± 3.66 83 (41.3) 3.76 ± 2.88 91 (48.9) 3.88 ± 2.59 86 (48.6)
No change RCP - 16 (8.0) - 14 (7.5) - 12 (6.8)
CCQ Total
All patients PR -0.26* (-0.37 to -0.15) 355 -0.11 (-0.23 to +0.01) 319 -0.16* (-0.28 to -0.04) 309
Improvement PR -0.88 ± 0.71 225 (63.4) -0.84 ± 0.68 181 (56.7) -0.87 ± 0.72 180 (58.3)
Deterioration PR 0.82 ± 0.68 130 (36.6) 0.84 ± 0.67 138 (43.3) 0.83 ± 0.62 129 (41.7)
All patients RCP 0.00 (-0.09 to +0.08) 200 0.00 (-0.10 to +0.10) 185 -0.02 (-0.12 to +0.09) 174
Improvement RCP -0.45 ± 0.37 96 (48.0) -0.52 ± 0.51 87 (47.0) -0.54 ± 0.54 77 (44.3)
Deterioration RCP 0.50 ± 0.38 89 (44.5) 0.56 ± 0.46 80 (43.2) 0.51 ± 0.39 88 (50.6)
No change RCP - 15 (7.5) - 18 (9.7) - 9 (5.2)
SGRQ Total
All patients PR -5.35* (-6.92 to -3.78) 350 -4.85* (-6.47 to -3.23) 312 -3.94* (-5.67 to -2.21) 306
Improvement PR -13.11 ± 9.65 237 (67.7) -13.51 ± 9.88 193 (61.9) -13.83 ± 10.43 180 (58.8)
Deterioration PR 10.93 ± 10.18 113 (32.3) 8.19 ± 8.92 119 (38.1) 10.19 ± 8.94 126 (41.2)
All patients RCP -0.52 (-1.77 to +0.73) 198 -1.34 (-2.76 to +0.07) 184 -0.87 (-2.60 to +0.86) 174
Improvement RCP -6.61 ± 5.58 97 (49.0) -7.91 ± 5.52 75 (40.8) -7.74 ± 9.51 81 (46.6)
Deterioration RCP 7.36 ± 5.49 101 (51.0) 7.78 ± 6.18 108 (58.7) 8.46 ± 7.06 92 (52.9)
No change RCP - - - 1 (0.5) - 1 (0.6)
Change calculated compared with baseline. Negative change representing improvement for CAT, CCQ and SGRQ.  
Change scores for all patients reported as mean (95%CI).  
Change scores for improvement and deterioration presented as mean ± SD. 
*Paired t-tests significant at level P < 0.05 testing follow-up versus baseline measurements. 
Abbreviations: 95%CI, 95% confidence interval; CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive 
pulmonary disease; N, number of patients; PR, pulmonary rehabilitation; RCP, routine clinical practice; SD, standard deviation; SGRQ, St. 
George’s Respiratory Questionnaire; T2, 3-months follow-up; T3, 6-months follow-up; T5, 12-months follow-up.
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6.4.3 Clinically important improvement versus deterioration
Significant correlations between the health status change scores and the GRC ranged 
respectively for study 1 from -0.33 to -0.41 (CAT), from -0.42 to -0.47 (CCQ), and from -0.48 
to -0.54 (SGRQ) (Table 3). These ranges were for study 2 respectively from -0.29 to -0.37, 
from -0.38 to -0.48, and from -0.35 to -0.44. GRC scores had stronger correlations with 
the respective follow-up health status score compared with baseline and change scores 
for both studies.
 
Table 3: Correlations between health status (change) scores and the GRC













CAT Change Score -0.33 -0.29 -0.40 -0.30 -0.41 -0.37
CAT T0 -0.31 -0.11 -0.25 -0.22 -0.34 -0.22
CAT T2 -0.56* -0.31 -0.50* -0.31 -0.50* -0.33
CAT T3 - - -0.55* -0.40 -0.59* -0.34
CAT T5 - - - - -0.64* -0.48
CCQ Change Score -0.40 -0.38 -0.44 -0.40 -0.47 -0.48
CCQ T0 -0.26 -0.14 -0.19 -0.22 -0.29 -0.23
CCQ T2 -0.61* -0.35 -0.52* -0.26 -0.54* -0.33
CCQ T3 - - -0.56* -0.43 -0.59* -0.39
CCQ T5 - - - - -0.66* -0.51*
SGRQ Change Score -0.48 -0.35 -0.51* -0.33 -0.54* -0.44
SGRQ T0 -0.28 -0.13 -0.24 -0.20 -0.32 -0.22
SGRQ T2 -0.62* -0.29 -0.56* -0.25 -0.58* -0.28
SGRQ T3 - - -0.61* -0.35 -0.62* -0.35
SGRQ T5 - - - - -0.69* -0.51*
Data reported as Pearson or Spearman correlation coefficients between the health status (change) scores and the GRC.  
* Correlations ≥0.50.
Abbreviations: CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive pulmonary disease; GRC, 
global rating of change; N, number of patients; PR, pulmonary rehabilitation; RCP, routine clinical practice; SGRQ, St. George’s Respiratory 
Questionnaire; T0, baseline measurement; T2, 3-months follow-up; T3, 6-months follow-up; T5, 12-months follow-up.
Tables 4-6 and figures 1-3 present the clinically relevant thresholds for minimal, 
moderate and large changes on the CAT, CCQ and SGRQ during PR and RCP. On the 
CAT anchor- and distribution-based estimates ranged from -2.80 to -2.17 (weighted 
mean -2.51) for minimal improvement and from 2.05 to 4.21 for minimal deterioration 
(weighted mean 2.76) during PR (Table 4, Figure 1). These ranges were respectively, from 
-3.78 to -1.53 (weighted mean -2.49) and from 1.30 to 1.97 (weighted mean 1.65) during 
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RCP. On the CCQ minimal clinically important improvements were determined at -0.50 to 
-0.34 (weighted mean -0.40) for PR and -0.44 to -0.19 (weighted mean -0.33) for RCP (Table 
5, Figure 2). These thresholds for deterioration were from 0.31 to 0.66 (weighted mean 
0.43) during PR and from 0.19 to 0.46 (weighted mean 0.30) during RCP. On the SGRQ 
estimates ranged from -9.20 to -4.83 (weighted mean -6.74) for minimal improvement 
and from 4.46 to 7.52 for minimal deterioration (weighted mean 5.31) during PR (Table 6, 
Figure 3). These ranges were respectively, from -4.76 to -2.76 (weighted mean -4.06) and 
from 2.75 to 7.53 (weighted mean 4.78) during RCP. 
6.5 Discussion
6.5.1 Summary of main findings
Using both anchor- and distribution-based methods, the weighted MCIDs for improvement 
and deterioration on the CAT were, respectively, -2.51 versus 2.76 during PR, and -2.49 versus 
1.65 during RCP. These thresholds for improvement and deterioration on the CCQ were, 
respectively, -0.40 versus 0.43 during PR, and -0.33 versus 0.30 during RCP. MCIDs for the 
SGRQ were, respectively, -6.74 versus 5.31 during PR, and -4.06 versus 4.78 during RCP for 
improvement and deterioration. Estimates for minimal clinically important improvement 
and deterioration were overall somewhat similar; however, absolute MCIDs differed 
between PR and RCP. Thresholds for moderate and large improvement and deterioration 
differed from each other, as well as between study settings. 
6.5.2 Interpretation of findings
Little evidence exists whether MCIDs for improvement are similar for deterioration [21, 23, 40]. 
Jaeschke et al. were the first to determine the MCID of a health status tool using a 15-point GRC 
combining both improved and deteriorated patients with COPD into one group of minimally 
changed participants [19]. Juniper et al. elaborated on this by separating minimally improved 
patients from deterioration in asthma, but only a limited number of patients indicated 
deterioration and no conclusions on the MCID for deterioration were drawn [37]. Outside 
the field of COPD, Crosby et al. and de Vet et al. stated that some studies demonstrated 
that a smaller MCID for improvement was required compared with deterioration [21, 40]. 
The current study does not confirm this, although MCIDs seemed smaller for RCP patients 
compared with PR. Patients experienced more change (hence larger absolute MCIDs) during 
intervention, possibly as a result of treatment. In RCP, smaller changes may be noted and 
regarded as relevant for the patient. Up to now it remains unclear, whether the reported 
differences between PR and RCP are a rehab-specific finding or generally as a result of 
intervention. Overall, the absolute values of the MCIDs for improvement versus deterioration 
did not seem to differ much here, with the exception of the SGRQ during PR. 
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The ranges found in this study for the MCID of the CAT (improvement -3.78 to -1.53; 
deterioration 1.30 to 4.21) matched with estimates found in other studies [11-15, 20]. Two 
studies used a patient-assessed GRC to estimate the MCID of the CAT [14-15]. However, no 
results were reported for worsened patients or the numbers of patients were too few. Other 
anchor-based methods suggested that a change of 1 point on the CAT might represent 
the MCID for deterioration [14]. The weighted thresholds for minimal clinically relevant 
improvement (-2.51 in PR and -2.49 in RCP) seemed somewhat comparable with the ones 
for deterioration (2.76 in PR and 1.65 in RCP) in the current study, except for deterioration 
during RCP. As CAT allows only integer scores [2], a change of 3 points seems a valid 
threshold for improvement and deterioration, although the MCID for deterioration in 
RCP could be closer to 2 points. Thresholds for moderate improvement (-4.23 in PR) and 
moderate deterioration (7.06 in PR and 3.89 in RCP) turned out less similar. The number of 
patients moderately deteriorating was low and differences were observed between both 
study settings. Moderate change might be experienced with a change on the CAT score 
of 4-7 points. Two previous studies suggested that a cutoff value of 4 points was identified 
for acute HRQoL deterioration in clinical practice [41-42]. This would match our estimates 
for moderate change. The number of patients with a large change was too low with wide 
CIs to enable valid conclusions. 
Regarding the CCQ, the MCID ranges found for both improvement (-0.50 to -0.19) and 
deterioration (0.19 to 0.66) overlapped each other in absolute sense, indicating that 
estimates for improvement and deterioration may be similar. However, differences 
were noted between PR (±0.40) and RCP (±0.30) for both minimal improvement and 
deterioration. These estimates for the MCID matched with earlier evidence [8-13]. One 
other study used a GRC to determine the MCID of the CCQ [8]. Unfortunately, no data 
were available on worsening patients. Thresholds for moderate change on the CCQ 
were broad (±0.62 to ±1.23). Few patients experienced large changes, but estimates for 
both types of MCID from both study settings were approximately 1 point. 
Minimal thresholds for improvement (-9.20 to -2.76) and deterioration (2.75 to 7.53) on 
the SGRQ overlapped each other, although more variation was present here. A change 
of approximately 4-7 points for both improvement and deterioration seemed to be the 
minimal clinically important threshold in the current study. The MCID for improvement 
during PR (-6.74) was larger than for deterioration (5.31); however, CIs for deterioration 
were wide. Estimates for the thresholds during RCP (4-5 points) were smaller compared 
with PR (5-7 points). Moreover, the distribution-based estimates turned out smaller 
than the anchor-based estimates, lowering the absolute weighted MCIDs. Thresholds 
for moderate improvement and deterioration in the current study were not very similar 
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ranging absolutely from 7.46 to 16.06 points. Estimates for clinically relevant large HRQoL 
improvement on the SGRQ ranged from -20 to -18 points for PR and RCP, but too few 
patients were included to draw valid conclusions.
The SGRQ MCID matched to some extent with previous results [12, 16-18, 20]. Jones et al. 
published a threshold of 4 points, which is generally accepted and applied in practice 
[16, 18]. Interestingly, most results in our current study suggest a larger MCID, although 
estimates from RCP included this 4 point estimate. The estimate by Jones et al. was based 
on a study using patient preference-based techniques in COPD by applying a 5-point 
patients’ judgement of treatment efficacy of Salmeterol. This MCID of 4 points was valid 
for the group of patients that experienced effective treatment. In addition, a clinicians’ 
5-point GRC was scored, resulting in an MCID of 4 points. Clinicians’ and patients’ ratings 
are, however, not necessarily similar [43].     
6.5.3 Strengths and limitations of the current study
This retrospective analysis of two prospective studies was the first to investigate clinically 
relevant thresholds for minimal, moderate and large changes in COPD health status 
comparing both improvement and deterioration using a combination of both anchor- 
and distribution-based methods. There were sufficient correlations between the GRC 
and respective health status questionnaires as required [22], although they were still only 
weak to moderate. It should be noted that correlations were stronger with the follow-up 
score compared with the baseline and/or change score, possibly due to a response shift. 
Another strength is that multiple follow-up visits were included to limit possible influence 
of the period of measurements on the MCID and recall bias [21, 24]. Moreover, this study 
investigated clinically relevant thresholds for both PR and RCP, improving its clinical 
application and external validity. 
Although this is the first study to investigate thresholds for clinically relevant deterioration, 
still a limited number of patients indicated deterioration in HRQoL after PR and during 
RCP. This is a major limitation lowering the statistical power of the analysis, especially 
since sample size calculations were not based on the separate GRC categories. A second 
limitation is that the found thresholds demonstrated broad ranges with wide CIs, limiting 
its accuracy and requiring a larger sample size than our current studies had. Third, it 
should be taken into account that anchor- and distribution-based approaches each 
has its own relevance, either based on clinical retrospective assessments or statistical 
parameters. It is recommended to combine both methods in measuring an instrument’s 
MCID [22]; however, estimates were rather different between these methods.  
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6.5.4 Implications for future research and clinical practice
Patients with COPD tend to have worsening HRQoL over time; hence, MCIDs for deterioration 
have an important implication for clinical practice [44-45]. Clinicians and researchers 
should be able to judge whether groups of patients were really worsening over time or 
that change observed was subject to random fluctuation. Preventing clinically relevant 
deterioration in HRQoL by means of therapy is thus an important goal too. Ideally, more 
research is needed to validate our thresholds for clinically relevant deterioration on the 
CAT, CCQ and SGRQ for instance in studies of other kinds of interventions than PR. One 
cannot directly transform the thresholds for improvement into those for deterioration. 
Evidence outside the field of COPD has found differences. However, in the current study, 
the estimates turned out rather similar with differing MCIDs between studies. Setting 
could thus potentially impact the MCID, implying that the results in the current study do 
not necessarily need to be valid in other settings too. 
6.5.5 Conclusions
Determining deterioration in HRQoL is of importance, since one needs to differentiate 
between real worsening of patients’ status and random variations. In this study, 
estimates for clinically relevant thresholds for improvement and deterioration were 
somewhat similar, but differed between PR and RCP. It could be recommended to use the 
following cutpoints for minimal important changes: CAT ≥3 (intervention), CAT ≥2 (RCP), 
CCQ ≥0.40 (intervention), CCQ ≥0.30 (RCP), SGRQ ≥6 (intervention) and SGRQ ≥5 (RCP) 
for both minimal improvement and deterioration. Thresholds for respectively moderate 
and large changes should be further explored, but could approximately be in the range 
of respectively 4-5 and 5-6 for CAT, 0.80 and 1.00 for CCQ, and 10-15 points and 15-20 
points for SGRQ.
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Minimal clinically important differences (MCIDs) are used as fixed numbers in the 
interpretation of clinical trials. Little is known about its dynamics. This study aims to 
explore the impact of baseline score, study setting and patient characteristics on health 
status MCIDs in chronic obstructive pulmonary disease (COPD). 
7.1.2 Methods
Baseline and follow-up data on the COPD Assessment Test (CAT), Clinical COPD 
Questionnaire (CCQ) and St. George’s Respiratory Questionnaire (SGRQ) were 
retrospectively analysed from pulmonary rehabilitation (PR) and routine clinical practice 
(RCP). Anchor- and distribution-based MCID estimates were calculated and tested 
between settings, gender, age, global initiative for obstructive lung disease (GOLD) 
classification, comorbidity level, and baseline health status.
7.1.3 Results
In total, 658 patients were included with 2299 change score measurements. MCID 
estimates for improvement and deterioration ranged for all subgroups 0.50-6.30 
(CAT), 0.10-0.84 (CCQ), and 0.33-12.86 (SGRQ). Larger MCID estimates for improvement 
and smaller ones for deterioration were noted in patients with worse baseline health 
status, females, elderly, patients with COPD GOLD grades I/II, and patients with fewer 
comorbidities. Estimates from PR were generally larger.
7.1.4 Discussion and conclusions
Baseline health status and setting affected MCID estimates of health status 
questionnaires for patients with COPD. Patterns were observed for gender, age, 
spirometry classification and comorbidity levels. These outcomes would advocate the 
need for tailored MCIDs.
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7.2 Background
Health status measurement has been defined as “a standardised way of quantifying 
the impact of disease on a patient’s life, health and well-being” [1]. It provides important 
information about the burden of disease - especially in patients with chronic obstructive 
pulmonary disease (COPD) - because physiologic measures like spirometry alone do not 
measure the full aspect of this chronic disorder [1-7]. Many factors may impact health 
status in patients with COPD, including the number and severity of exacerbations [8-10]; 
the disease severity defined according to the global initiative for obstructive lung disease 
(GOLD) spirometry classification [5, 9-12]; the patient’s gender and age [5, 8-10, 13-15]; and 
the amount of comorbidities [12]. Moreover, the baseline score may also be predictive of 
(worsening) health status [11, 14].
Health status is, in addition to spirometry, an obligatory endpoint in evaluating treatment 
outcomes of clinical trials [16]. An intervention or therapy should result in meaningful clinical 
changes using outcomes that are relevant for patients themselves [16-18]. A parameter to 
interpret and define important change in health status is the minimal clinically important 
difference (MCID). It has been defined as “the smallest difference in score in the domain 
of interest which patients perceive as beneficial and which would mandate, in absence of 
troublesome side effects and excessive costs, a change in patient management” [19]. Like 
health status, MCIDs may also be influenced by multiple patient- and disease-related 
factors. Previous publications speculated that MCIDs for quality of life (QoL) tools may 
be affected by patient characteristics such as age, gender and education; the number of 
comorbidities; initial baseline condition of the patient; and pathologic characteristics of 
the disorder including disease severity [16-17, 20-39]. It remains, however, unclear whether 
different MCIDs should be used in practice depending on disease severity, patient 
characteristics and baseline health state.
Various studies have discussed the MCID for health status tools for COPD [40], including 
the recommended questionnaires COPD Assessment Test (CAT), Clinical COPD 
Questionnaire (CCQ) and the St. George’s Respiratory Questionnaire (SGRQ) [2, 41-42]. 
The MCIDs were determined as a rather fixed range of 2-3 points on the CAT [40, 43-
49], 0.40-0.50 points on the CCQ [40, 43-44, 48-52] and 4-7 points on the SGRQ [40, 
43-44, 53-57]. However, little is known about the dynamics of these MCIDs and the 
impact of different (disease) characteristics of patients on it. The present study aims 
to explore patient- and disease-related influences upon the MCID estimates for these 
recommended instruments in patients with COPD from different settings, in this case 




7.3.1 Study subjects and design
Data from patients with COPD in two studies were retrospectively analysed: (1) the 
3-week full-day inpatient routine inspiratory muscle training within COPD rehabilitation 
(RIMTCORE) real-life randomised controlled trial during PR in the Klinik Bad Reichenhall 
(Center for Rehabilitation, Pulmonology and Orthopedics) in Germany [43, 58]; (2) an 
observational trial (MCID study) aimed primarily at measuring health status changes in 
Dutch primary and secondary RCP [59]. 
7.3.2 Data collection
Patient descriptive characteristics and post-bronchodilator spirometry were collected 
at baseline. CAT (no recall), CCQ (one week recall) and SGRQ (one month recall) were 
scored at baseline and during follow-up as study outcomes. In the RIMTCORE trial, 
follow-up questionnaires were scored at discharge (3 weeks) and at 3/6/9/12 months 
(Figure 1). In RCP, respective health status questionnaires were scored at baseline 
and after 3/6/12 months. The CAT contains 8 items and a total maximum score of 40 
(maximum impairment) [60]. The CCQ consists of 10 items and a total maximum score 
of 6 (maximum impairment) [61]. The SGRQ contains 50 items and a total score of 
100 (maximum impairment) [62]. A 15-point global rating of change (GRC) scale was 
scored in both studies for each follow-up moment. It required patients to assess their 
experienced change in health status for COPD compared with baseline. Answers were 
scored on a scale from -7 (very much worse) to +7 (very much better) with zero equalling 
no change [63].
7.3.3 Study methods to determine MCIDs
Health status change scores were calculated as the difference between follow-
up and baseline scores. Negative change represented improvement, and positive 
change represented deterioration. MCID estimates were calculated using anchor- and 
distribution-based methods. The anchor-based approach required patients to be 
categorised according to their GRC score. Scores of 0 and ±1 on the GRC scale indicated 
no change; scores of ±2 and ±3 represented minimal improvement/deterioration; scores 
of ±4 and ±5 were considered moderate improvement/deterioration; and scores of ±6 
and ±7 indicated large improvement/deterioration [63]. The mean health status change 
score of the minimal change group according to the GRC represented the MCID estimate, 
assuming normality of distribution. In addition, the GRC score for minimally improved 
and deteriorated was used as cutoff value for dichotomisation in the receiver operating 
characteristics (ROC) curve analysis [64]. Finally, the distribution-based approach 
included the half standard deviation (0.5SD) of the health status change score [65]. 
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Study methods were performed separately for improvement and deterioration. MCID 
estimates were evaluated and statistically tested between subgroups for study setting 
(PR and RCP); males and females; low and high age (median as cutpoint); low (GOLD 
grade I-II) versus high (GOLD grade III-IV) COPD disease severity; low and high levels of 
comorbidities on the Charlson Index (median as cutpoint); and better and worse baseline 
health status (median as cutpoint).
7.3.4 Data analysis and statistics
SPSS version 25.0 (IBM, Chicago, USA) was used for data analysis. Baseline, follow-up 
and change scores were assessed. Frequencies with percentages, mean with standard 
deviation (SD), or median with interquartile range (IQR) were determined depending 
on the variable characteristics. Normality of distribution was assessed for continuous 
variables using histograms, and skewness and kurtosis with values between -1 and 
+1 indicative for normality. Baseline scores between both datasets were tested for a 
difference using independent t-tests, Mann-Whitney U tests or Chi-Square tests depending 
on type of data and whether assumptions were met. Health status and GRC scores were 
assessed for floor- and ceiling effects, defined as over 15% of patients scoring in the lowest 
and highest 10% of the maximum scale range [66]. Baseline and follow-up health status 
scores were tested for significance of change using paired t-tests or Wilcoxon-signed 
rank tests. Pair-wise deletion was applied. The false discovery rate (FDR) due to multiple 
testing was controlled for by Benjamini–Hochberg’s stepup procedure to maintain an 
overall two sided type I error rate of 5% [67]. Adjusted P-values are reported. Intraclass 
correlation coefficients (ICCs) of the health status change scores were determined to 
asses dependency of data. The impact of regression to the mean was determined as 
100(1-r1/2) with r reflecting the ICC. 
Correlations were assessed between the GRC and health status change scores using 
Pearson coefficients assuming normality of distribution and the GRC to be a continuous 
variable. Correlations were required ≥0.30 (preferably ≥0.50) [68]. Patients were 
categorised per GRC class. Significance of change within each GRC category was tested 
using paired t-tests or Wilcoxon signed rank tests. ANOVA was performed to statistically 
test for significant differences between GRC categories and to determine the mean 
change scores including confidence interval (CI) per class. The mean change scores of 
the minimally improved and/or deteriorated group of patients represented the MCID 
estimates. Furthermore, ROC curves used a GRC of ±2 as cutoff value to dichotomise 
the dataset to differentiate between important and unimportant change [24, 34, 38]. 
The area under the curve (AUC) was calculated, and the optimal combination of 
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Independent t-tests were used to determine significance of the difference between MCID 
estimates for the various subgroups. These subgroups were determined for nominal 
values as the respective categories. For the continuous variables, the median was used 
to dichotomise patients into subgroups [24, 28, 34-35, 69]. To control for the possible 
impact of the baseline level, relative MCIDs were also calculated as a percentage of 
change from baseline [21, 29, 36]. Finally, 0.5SDs were determined for all patients as well 
as the respective subgroups. 
Multiple linear regression modeling was applied to quantify the impact of the various 
factors (baseline health status, gender, age, GOLD classification and study setting) on 
the MCID estimates, including the analysis of possible interaction terms.  
7.4 Results
7.4.1 Baseline characteristics 
This retrospective analysis included 451 patients from PR, of whom 309 patients completed 
follow-up; and 207 patients from RCP, of whom 177 completed follow-up (Table 1). 
7.4.2 Global rating of change (GRC)
Correlations between the GRC and health status change scores (n = 2299) were -0.38 
(CAT), -0.45 (CCQ) and -0.52 (SGRQ). The scores on the GRC differed significantly 
between both study settings  (P < 0.001) (Figure 2). ANOVA tests between GRC groups were 
all significant (P < 0.001). 
7.4.3 Study Setting
Mean MCID estimates were for all patients for improvement and deterioration respectively 
-2.82 vs. 2.66 (CAT), -0.48 vs. 0.43 (CCQ), and -8.30 vs. 5.95 (SGRQ) (Table 2). Estimates 
were larger during PR compared with RCP for improvement on the CCQ (-0.49 vs -0.40, 
P = 0.687) and SGRQ (-8.71 vs. -3.04, P = 0.020); and for deterioration on the CAT (3.44 vs. 
1.50, P = 0.023), CCQ (0.51 vs. 0.30, P = 0.090) and SGRQ (6.11 vs. 5.69, P = 0.825) (Table 2). 
ROC curves demonstrated a similar pattern, although estimates for deterioration were 
overall smaller than for improvement (Table 3). The 0.5SD estimates were also larger 
during PR than RCP (CAT 3 vs. 2 points; CCQ 0.5 vs. 0.3 points; and SGRQ 6-7 vs. 4-5 
points) (Table 4). ICCs of the health status change scores and percent regression to the 
mean ranged 0.59-0.68 (17.66-23.12%) for PR and 0.75-0.89 (5.50-13.69%) for RCP.
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Table 1: Patient characteristics and health status scores
Variable Pulmonary Rehabilitation Routine Clinical Practice Significance
Number of patients (N) 451 207
Age (years)a 57.87 ± 6.56 66.69 ± 7.91 < 0.001*
Gender (male)b 293 (65.0) 121 (58.5) 0.507
FEV
1














Smoking pack yearsa 40 (30-50) 37.5 (22.50-51.25) 0.108
Baseline CATa 20.23 ± 7.33 18.32 ± 7.22 0.003*
Baseline CCQ Totala 2.86 ± 1.17 2.12 ± 1.02 < 0.001*
Baseline SGRQ Totala 50.69 ± 17.33 42.88 ± 19.16 < 0.001*
Baseline mMRCa 2 (2-4) 1 (1-2) < 0.001*
Δ CAT 12 monthsa -0.89±7.01 -0.14±4.92 0.224
Δ CCQ Total 12 monthsa -0.16±1.08 0.02±0.69 0.077
Δ SGRQ Total 12 monthsa -3.94±15.38 0.87±11.55 < 0.001*
a Data expressed as mean ± SD or median (IQR). 
b Data expressed as frequencies (% of total). 
* Significance at level P < 0.05. All listed P-values were corrected using the Benjamini-Hochberg method.
Abbreviations: CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive pulmonary disease; FEV
1
%pred, 
forced expiratory volume in one second % predicted; GOLD, global initiative for chronic obstructive lung disease; IQR, interquartile range; 
mMRC, modified Medical Research Council Dyspnoea scale; N, number of patients; SD, standard deviation; SGRQ, St. George’s Respiratory 
Questionnaire.
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Figure 2: Distribution of the GRC scores during PR and RCP
The blue bars (left half) represented the observed frequencies per GRC category during PR. The green bars (right half) represented the 
observed frequencies per GRC category during RCP. The GRC scores differed significantly between both study settings (P < 0.001). 
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Table 4: Distribution-based MCID estimates for CAT, CCQ and SGRQ using the half standard deviation
Patients CAT CCQ SGRQ CAT CCQ SGRQ 
Improved Improved Improved Deteriorated Deteriorated Deteriorated
All Patients -2.99 -0.46 -6.43 2.79 0.42 5.65
PR Patients -3.04 -0.47 -6.54 3.10 0.47 6.28
RCP Patients -2.24 -0.30 -4.08 2.11 0.30 4.54
Better Baseline Health Status -2.81 -0.41 -6.17 2.88 0.39 5.46
Worse Baseline Health Status -2.81 -0.44 -6.12 2.28 0.39 4.80
Males -3.02 -0.44 -6.30 2.52 0.43 6.12
Females -2.94 -0.48 -6.63 3.23 0.37 4.62
Age Low -2.97 -0.47 -6.07 2.71 0.48 6.26
Age High -3.01 -0.45 -6.89 2.84 0.36 5.07
GOLD I-II -3.15 -0.44 -6.16 2.61 0.45 5.41
GOLD III-IV -2.82 -0.49 -6.64 2.95 0.38 5.85
Comorbidities Low -2.40 -0.31 -4.40 2.13 0.28 4.51
Comorbidities High -1.79 -0.28 -3.18 2.09 0.33 4.47
Data presented as 0.5SD MCID estimates of the health status change score. 
Scores marked in lighter green represented smaller MCID estimates; whereas darker green represented larger MCID estimates.
Abbreviations: 0.5SD, half standard deviation; CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive 
pulmonary disease; GOLD, global initiative for chronic obstructive lung disease; PR, pulmonary rehabilitation; RCP, routine clinical 
practice; SGRQ, St. George’s Respiratory Questionnaire. 
7.4.4 Baseline health status
Better and worse baseline levels were grouped according to the median (CAT 20, CCQ 
2.60, SGRQ 49.09). MCID estimates for improvement were significantly smaller and 
for deterioration significantly larger in patients with a lower (meaning better) baseline 
health status during both PR and RCP (P < 0.001) (Table 2, Figure 3, Supplementary material 
7.7.1). Improvement thresholds for lower (meaning better) baseline compared with higher 
(meaning worse) baseline were for CAT -0.67 vs. -4.78; for CCQ -0.13 vs. -0.82; for SGRQ 
-4.66 vs. -12.18. Thresholds for deterioration were for CAT 6.30 vs. 0.92; for CCQ 0.84 vs. 
0.21; and for SGRQ 12.86 vs. 2.15. ROC curves confirmed the pattern, although differences 
were less extreme between baseline severity groups (Table 3). The 0.5SD method did 
not show large differences between both groups (Table 4, Supplementary material 7.7.2). 
Relative MCID estimates compared with baseline were for improvement and deterioration 
-7.42% and +19.25% (CAT); -11.29% and +22.65% (CCQ), and -14.31% and +18.84% for SGRQ. 
Their confidence intervals included for improvement -10% and for deterioration +20%. 
Percentages regression to the mean ranged for low baseline (meaning better) patients 
31.66-37.55% (PR: 29.36-37.55%; RCP: 38.36-48.52%) and 36.91-39.67% (PR: 38.52-40.84%; 
RCP: 28.80-34.20%) for high baseline (meaning worse) patients.
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Box-plots of the MCID estimates for the COPD Assessment Test (CAT), Clinical COPD Questionnaire (CCQ) and St. George’s Respiratory 
Questionnaire (SGRQ) were grouped per health status baseline severity category. The left graphs represented MCID estimates for 
improvement and the right half represented MCID estimates for deterioration. The red horizontal line represented the currently accepted 
fixed MCIDs from the literature (CAT 2 points; CCQ 0.40 points; SGRQ 4 points). P-values represented the significant difference between high 
and low baseline groups. 
Abbreviations: CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive pulmonary disease; MCID, minimal 
clinically important difference; SGRQ, St. George’s Respiratory Questionnaire.
Figure 3: Box plots of the MCID estimates for both improvement and deterioration defined by low 
(meaning better) and high (meaning worse) baseline health status
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7.4.5 Other variables
Compared with males, females noted larger MCID estimates for improvement (CAT -3.23 vs. 
-2.56, P = 0.544; CCQ -0.63 vs. -0.38, P = 0.028; SGRQ -8.74 vs. -8.01, P = 0.655); and smaller ones 
for deterioration (CAT 2.51 vs. 2.74, P = 0.872; CCQ 0.23 vs. 0.54, P = 0.011; SGRQ 4.43 vs. 6.79, 
P = 0.193) during both PR and RCP (Table 2, Supplementary material 7.7.1). ROC curves partly 
confirmed this, yet MCID estimates for deterioration were smaller than for improvement 
(Table 3). The 0.5SD estimates were similar for gender, except for deterioration on the CAT 
and SGRQ (Table 4, Supplementary material 7.7.2). 
Younger patients had compared with older patients (median 60 years) smaller MCID 
estimates for improvement (CAT -2.49 vs. -3.25, P = 0.413; CCQ -0.41 vs. -0.57, P = 0.099; SGRQ 
-7.98 vs. 8.71, P = 0.635); but larger estimates for deterioration (CAT 3.18 vs. 2.19, P = 0.985; CCQ 
0.50 vs. 0.37, P = 0.370; SGRQ 5.88 vs. 6.02, P = 0.916) (Table 2). This pattern was different in RCP 
(Supplementary material 7.7.1). ROC curves confirmed this pattern, except for deterioration on 
the CAT (Table 3). The 0.5SD estimates were consistent between both age groups (Table 4). 
Patients with COPD GOLD grades III-IV scored smaller MCID estimates for improvement (CAT 
-2.63 vs. -3.01, P = 0.661; CCQ -0.44 vs. -0.53, P = 0.425; and SGRQ -6.64 vs. -9.90, P = 0.062) 
and larger ones for deterioration (CAT 2.97 vs. 2.35, P =  0.670; SGRQ 7.10 vs. 4.86, P = 0.224) 
(Table 2). The pattern was different for improvement in RCP (Supplementary material 7.7.1). 
ROC curves confirmed the pattern for improvement (Table 3). The 0.5SD estimates were 
consistent between both GOLD groups (Table 4). 
7.4.6 Linear multiple regression analysis and interaction
Supplementary material 7.7.3 demonstrates the best regression models for the MCID 
estimates of the CAT, CCQ and SGRQ. Baseline health status and study setting were 
frequent significant and independent factors in most models. Various interactions were 
noted. In general, females had worse baseline health status; baseline health status was 
worse in PR; patients in PR were younger; younger patients had worse baseline health 
status and GOLD classification; patients with a worse GOLD classification had worse 
baseline health status. Proportion of the variance of the MCIDs (R2) explained in these 




7.5.1 Summary of main findings 
The present study demonstrated first of all that MCID estimates for improvement on the 
CAT, CCQ and SGRQ were significantly three to seven times larger for patients with COPD 
and a worse baseline health status than for those with better baseline health status; 
however, they were much smaller for deterioration. Second, MCID estimates proved to be 
larger during intervention, in this case PR, compared with RCP possibly due to baseline 
differences. Females, elderly, patients with COPD GOLD grades I and II, and patients with 
fewer comorbidities had overall larger MCID estimates for improvement and smaller 
ones for deterioration compared with their counter groups - although not necessarily all 
significant. Complex interactions between the variables were observed.  
7.5.2 Interpretation of outcomes
MCID estimates for CAT, CCQ and SGRQ
Most MCID estimates for the CAT for improvement and deterioration were between ±1.50 
and ±3.50, which is in accordance with existing literature [40, 43-49]. MCID estimates 
for the CCQ were overall in the range of ±0.30 and ±0.60, which also matched previous 
studies [40, 43-44, 48-52]. SGRQ MCID estimates ranged mostly between 4 and 9 points, 
which to some extent matched existing evidence [40, 43-44, 53-57]. An estimate of 4 
points is generally accepted in interpreting the relevance of clinical trial outcomes. This 
estimate derived among others from patients treated with Salmeterol in a clinical trial, 
but also from PR and hospital admitted patients [53-56]. The present study confirms 
that this 4-point estimate could potentially be valid in RCP, but should be larger for 
interventions, like PR.
Baseline health status
MCIDs may be dependent on the initial baseline health state of the patient [16-17, 20-21, 
23-39, 69]. It did significantly impact our MCID estimates of health status tools for COPD. 
Higher (meaning worse) baseline scores resulted in three to seven times larger MCID 
estimates for improvement and four to six times smaller estimates for deterioration 
compared with patients with a better baseline status. This means that these patients 
required a larger reduction in symptoms and burden of disease before they felt better, 
and only little deterioration before they felt worse. Interaction between baseline health 
status and other variables (gender, study setting, age and spirometry classification) was 
observed, potentially influencing this observed MCID pattern. 
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Most authors recognise that patients with worse baseline scores require more change 
before it is to be considered clinically relevant, simply because there is more room for 
change [16, 20, 24, 30-31, 34-39]. Small improvements are not considered important after 
intervention or during routine medical care. On the other hand, only small progression 
of their severe health status would be considered a relevant deterioration. Although 
perhaps this may be considered a predictable outcome, no former studies in health 
status for COPD have explored this phenomenon in MCID research. Regression to the 
mean in our study may explain part of the outcome. Other studies considered the use 
of relative MCIDs - defined as change in percentage from baseline - to solve the baseline 
dilemma [20-21, 29, 36, 70]. Relative MCID estimates in the present study were around 
-10% for improvement and +20% for deterioration. This could possibly be a solution and 
may perhaps be applied in clinical practice to interpret individual change scores. 
COPD disease severity  
It has been hypothesised that disease severity - measured in the present study by 
spirometry classification - could impact the MCID [16-17, 20, 23-39]. Previous - but also 
present - research demonstrated that worse health status was correlated with worse lung 
function [9-13], although this correlation was only weak to moderate [4-7]. Patients with 
worse COPD GOLD grades had also worse baseline health status in our study, and were in 
general younger. Our study suggested that MCID estimates were larger for improvement 
and smaller for deterioration in patients with COPD GOLD grades I/II compared with GOLD 
grades III/IV. This pattern is vice versa the pattern found for the impact of the baseline 
health status severity on the MCID. Severity of health status is thus not equivalent to COPD 
disease severity, as expressed in the small to moderate correlation between spirometry 
and health status. It could be argued that patients with more severe lung function would 
experience more exacerbations and hospital admissions, which could mean that small 
changes in the disease state could already be considered important [33]. Age might have 
interacted in the pattern observed.    
Study setting 
Setting may impact an instrument’s MCID [17, 20, 25, 38], potentially leading to larger 
MCIDs during intervention [71]. In the current study, MCID estimates for improvement 
and deterioration in health status for COPD were indeed larger during intervention in PR 
compared with RCP, although not all results were significant. Patients experienced more 
change during intervention as a result of treatment, leading to a larger MCID estimate. 
This perhaps predictable result has not been demonstrated in previous health status 
research for COPD. A systematic review by Alma et al. (2018) [40] on these MCIDs could 
not observe a similar pattern. In RCP, smaller changes may be noted and regarded 
relevant. In the present study, patients during PR were significantly younger, and had 
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worse spirometry and health status at baseline. These factors could have interacted 
with the different MCID estimates between both settings. The sole impact of setting on 
the MCID can therefore not be quantified. Furthermore, the sample size during RCP was 
much smaller, possibly impacting estimates too. Finally, it remains unclear, whether 
this finding is specific for a rehabilitation intervention or is generally true for any kind of 
intervention. For this question, further studies would be needed.
Gender, age and comorbidities 
Gender, age and comorbidities could impact health status [8-10, 13-15]. First, gender 
was hypothesised to impact health status and its MCIDs [23]. Men and women evaluate 
health status differently. Females pay more attention to dyspnoea, emotions and 
anxiety; and they have more comorbidities [5, 72]. The present study demonstrated that 
females had (nonsignificant) larger MCID estimates for improvement, and smaller ones 
for deterioration. Here, the worse baseline health status of females could interact and 
explain our findings. 
Next, age may possibly impact the MCID too [17, 23]. Younger patients experienced 
significantly worse health status and dyspnoea compared with elderly [5, 73]. However, 
older age has also been associated with worse health status [5, 14]. In the present study, 
MCID estimates were larger for improvement and smaller for deterioration in elderly, 
although not all significant. Older patients had significantly better baseline health 
status and spirometry. The study in RCP included significantly more elderly than during 
PR. However, the other interacting patterns found above cannot explain the impact 
of age on the MCID. Our findings contradict the results by Arima et al. [22] that older 
patients had lower/smaller MCIDs. These authors hypothesised that elderly had lower 
expectations, being satisfied and thus requiring smaller MCIDs.    
Finally, comorbidities could impact health status and its MCIDs [17]. Patients with COPD 
experience a variety of comorbidities [74]. MCIDs for improvement were larger for patients 
in RCP with fewer comorbidities, and smaller for deterioration in this group. Comorbidities 
contribute to the overall disease severity, which would match the pattern found for the 
COPD disease severity defined by spirometry. Patients with fewer comorbidities were 
significantly younger, which could imply that age interacted in the pattern too.
7.5.3 Strengths and limitations
The present study is the first study to explore the impact of various factors on MCID 
estimates for health status tools for COPD. It used a large number of observations 
obtained from two settings during different follow-up periods applying both anchor- 
and distribution based approaches. Although the impact of study setting, intervention 
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and baseline health status score were perhaps predictable, no previous studies have 
confirmed this in COPD research. No standard approach exists to evaluate the impact of 
factors on the MCID. The present study dichotomised the impact factors into subgroups. 
This has been applied by other authors in MCID research outside the field of COPD [24, 28, 
34-35, 38-39, 69]. The current authors summed up and subsequently analysed all health 
status change scores simultaneously to allow for subgroup analysis. The dependency of 
the change scores was only moderate. Alma et al. [44] showed that the recall period was 
of limited influence on the MCID, supporting the validity of combining all measurements. 
Finally, the difference between MCID estimates was tested and P-values were corrected 
for multiple testing. 
There are, however, limitations too. Overall, the patterns observed were not all significant 
after correcting for multiplicity. Owing to the exploratory nature of this study, the current 
authors chose to report general trends. Next, impact factors on the MCID were analysed 
individually; however, interactions have been observed between the various factors. This 
makes simple conclusions difficult to establish; especially as the explained variance R2 
was low. Furthermore, in the anchor-based approach, the GRC was used to differentiate 
between important and unimportant change. Although correlations fulfilled the pre-set 
requirements [68], observed correlations were considered weak to moderate. Moreover, 
it has been argued that GRC estimates could be more related with the follow-up health 
status score, because of a response shift, therefore not certainly representing change 
from baseline [75]. Next, the division between PR and RCP patients was unequal, therefore 
providing more weight to PR measurements. GRC scoring patterns between PR and RCP 
were also significantly different. Setting impacted the MCID, possibly influencing other 
subgroup analyses too. Finally, the study on comorbidities, was only valid during RCP, as 
scores were not readily available for PR.
7.5.4 Implications for clinical practice and future research 
At the group level, regression to the mean may play a major role in clinical trials. This 
means that less weight will be distributed to outlying measurements, balancing out 
extreme scores. It could be hypothesised that this will minimise the impact of individual 
patient-related factors and the health status baseline score on the MCID. However, if 
samples have extreme baseline characteristics or unbalanced divisions, subgroup 
analyses with clustered MCIDs would be preferred to interpret outcomes in scientific 
research more precise. The specific trends found for the impact factors on the MCIDs 
of health status tools for COPD in the present study, might be a start to develop an 
algorithm in evaluating individual health status changes during clinical practice using 
tailored MCIDs. More research would be required here to confirm our findings and 




The MCID is currently used as a nonadaptable parameter in the interpretation of health status 
for patients with COPD in clinical trials. However, our study demonstrated that a complex 
interaction of study setting, baseline health status, gender, age, spirometry classification 
and comorbidities potentially impacted the MCID estimates for both improvement and 
deterioration on three major health status questionnaires. More accurate individual 
interpretation of outcomes in scientific research and clinical practice would benefit from 
developing and using possibly clustered or even tailored MCIDs.
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7.7.2 Full details distribution-based MCIDs 













All patients -2.99 -0.46 -6.43 2.79 0.42    5.65
PR -3.04 -0.47 -6.54 3.10 0.47    6.28
RCP -2.24 -0.30 -4.08 2.11 0.30    4.54
Better Baseline 
Health Status All
-2.81 -0.41 -6.17 2.88 0.39    5.46 
Worse Baseline 
Health Status All
-2.81 -0.44 -6.12 2.28 0.39    4.80
Better Baseline 
Health Status PR
-2.84 -0.43 -6.25 3.28 0.46    6.42
Worse Baseline 
Health Status PR
-2.92 -0.42 -6.24 2.37 0.38    5.16
Better Baseline 
Health Status RCP
-2.27 -0.44 -4.03 1.61 0.27    4.32
Worse Baseline 
Health Status RCP
-1.98 -0.33 -3.37 2.05 0.23    4.24
Males All -3.02 -0.44 -6.30 2.52 0.43    6.12
Females All -2.94 -0.48 -6.63 3.23 0.37    4.62
Males PR -3.06 -0.45 -6.37 2.69 0.49    6.80
Females PR -3.01 -0.49 -6.80 3.83 0.41    5.16
Males RCP -2.35 -0.31 -4.39 2.17 0.29    4.83
Females RCP -2.15 -0.30 -3.78 2.00 0.32    3.75
Age Low All -2.97 -0.47 -6.07 2.71 0.48    6.26
Age High All -3.01 -0.45 -6.89 2.84 0.36    5.07
Age Low PR -3.07 -0.48 -6.34 2.75 0.49    6.65
Age High PR -3.02 -0.46 -6.74 3.59 0.44    5.71
Age Low RCP -1.94 -0.32 -6.07 2.71 0.33    6.25
Age High RCP -2.52 -0.24 -6.89 2.84 0.28    5.07
GOLD I-II All -3.15 -0.44 -6.16 2.61 0.45    5.41
GOLD III-IV All -2.82 -0.49 -6.64 2.95 0.38    5.85
GOLD I-II PR -3.23 -0.45 -6.26 2.84 0.51    6.00
GOLD III-IV PR -2.84 -0.49 -6.72 3.38 0.43    6.62
GOLD I-II RCP -1.92 -0.29 -3.32 2.17 0.31    4.17
GOLD III-IV RCP -2.68 -0.33 -4.90 2.16 0.30    4.75
Comorbidities 
Low RCP
-2.40 -0.31 -4.40 2.13 0.28    4.51
Comorbidities 
High RCP
-1.79 -0.28 -3.18 2.09 0.33    4.47
Data presented as 0.5SD MCID estimates of the health status change score. 
Scores marked in lighter green represented smaller MCID estimates; whereas darker green represented larger MCID estimates.
Abbreviations: 0.5SD, half standard deviation; CAT, COPD Assessment Test; CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive 
pulmonary disease; GOLD, global initiative for chronic obstructive lung disease; PR, pulmonary rehabilitation; RCP, routine clinical practice; 
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The primary research objective of this thesis was to gain insight into the dynamics of 
the minimal clinically important difference (MCID) as an outcome parameter of health 
status instruments used in patients with chronic obstructive pulmonary disease (COPD). 
The concept of health status measurement was introduced in Chapter 1, where it was 
defined as a standardised way of quantifying and scoring the impact of health and 
disease on a patient’s quality of life (QoL) and well-being [1-7]. In many chronic diseases, 
including COPD, standard physiological outcome parameters often fail to cover the 
full impact of the disease on the patient [1-3, 5-19]. Indeed, such tests lack a strong 
correlation with the patient’s experienced QoL, symptoms, functional capabilities 
and mental status. Therefore, many generic and disease-specific patient-reported 
outcome (PRO) questionnaires have been introduced during recent decades to quantify 
the full health and disease states of patients more comprehensively [1-2, 4, 7-13, 20]. 
These questionnaires have frequently and obligatorily been incorporated as outcome 
measures in clinical trials (Box 1).
Box 1: Interpreting individual results of a clinical trial during pulmonary rehabilitation 
In Chapter 1, an interview was presented 
with a 63-year old female patient with 
grade IV COPD according to the global 
initiative for obstructive lung disease (GOLD) 
criteria. At the time, she was participating 
in a randomised controlled clinical trial 
(RCT) on the effects of adding inspiratory 
muscle training (IMT) to an extended 3-week 
pulmonary rehabilitation (PR) intervention 
in Germany (the RIMTCORE trial). Her main 
goals were to minimise dyspnoea, prevent 
the recurrence of exacerbations and slow 
disease progression. Driving her car again 
was another major goal. 
Immediately after PR, her health status 
questionnaire scores improved by 4 points 
on the COPD Assessment Test (CAT), 1.20 
point on the Clinical COPD Questionnaire 
(CCQ) and 10 points on the St. George’s 
Respiratory Questionnaire (SGRQ). However, 
she experienced an exacerbation during 
follow-up, which reduced her questionnaire 
improvements to just 2 points on the CAT, 
0.60 point on the CCQ and 7 points on 
the SGRQ in comparison with her scores 
prior to PR. Correct interpretation of these 
improvements is critical to assessing the real 
effects of PR. Both immediately after PR and 
during follow-up, it could be argued that 
this patient experienced clinically relevant 
improvement, because her change scores 
exceeded the minimal clinically important 
differences (MCIDs) calculated in this thesis. 
Although the MCID is a parameter defined 
at the group level, as most clinical and 
physiological parameters are, it can certainly 
also imply something about individual 
changes when taking into account a certain 
level of clinical variation.
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In Chapter 2, COPD was defined as a chronic disease with multiple, persistent, but not 
fully reversible, respiratory symptoms caused by obstructive airflow limitation and 
emphysema [14, 21-22]. Of note, it was highlighted as a leading cause of mortality and 
morbidity worldwide that had increased over the past decade, which is often present 
with multiple comorbidities [14, 23-28]. Although there is currently no cure, progression 
can be halted by combinations of education, self-management, smoking cessation, 
pharmacotherapy, pulmonary rehabilitation (PR), oxygen therapy and/or surgery 
[14, 21, 29]. Many tools exist to quantify changes in health status [14, 30-34], but three 
questionnaires were identified as the most important for patients with COPD: the COPD 
Assessment Test (CAT, range 0-40), Clinical COPD Questionnaire (CCQ, range 0-6) and 
the St. George’s Respiratory Questionnaire (SGRQ, range 0-100). 
In addition to requiring an appropriate questionnaire design for use with COPD, it 
is important that these tools measure true change (i.e., a signal) [6-8, 12, 20, 35]. The 
observed changes during a trial intervention, such as those reported in Box 1, should 
provide physicians and scientists with valid and clinically important data. This is 
especially relevant given that many health status PROs have been integrated in scientific 
research and clinical practice as obligatory measures of the interpretation of change 
related to an intervention [1-2, 8-12, 36]. The MCID was introduced in Chapter 1 as the 
threshold at which this observed change can be considered the minimal that is clinically 
important and relevant to the patient, thereby justifying the therapy [37-39]. As shown in 
the case reported in Box 1, the parameter allows for the interpretation of change, making 
it ideal for use as an outcome parameter in clinical trials, and including those related 
to COPD. However, as identified in Chapter 1, there has been a lack of clarity about the 
dynamics of the MCID in general. In Chapters 3-7, the results of measuring the dynamics 
of the MCID in a COPD population were presented and discussed. A summary of the 
main findings is provided in the next section, following which there is a discussion that 
seeks to answer the primary research question, elaborate on the clinical implications 
and outline opportunities for future research.
8.2 Summary of main findings
The currently accepted MCIDs for the most important health status tools for COPD are 
2 points for the CAT, 0.40 point for the CCQ and 4 points for the SGRQ [31-32, 40-42]. 
To gain insight into the evidence underpinning these MCIDs for the three health status 
PROs in COPD, a systematic review and triangulation was performed in Chapter 3 [43]. 
This identified 21 publications related to the MCIDs of 12 different COPD health status 
instruments. The results for improvement only (Table 1, Figures 1-3) were as follows: -2.54 
196
Chapter 8
for the CAT (6 papers, range -3.80 to -1.00), -0.43 for the CCQ (5 papers, range -0.62 to 
-0.21) and -7.43 for the SGRQ (4 papers, range -10.19 to -2.40). Studies were too few in 
number and/or too heterogeneous to triangulate the MCIDs for the other nine identified 
instruments. No patterns were observed for the MCID estimates by setting and/or 
follow-up period. Of note, evidence for the MCID of the CAT and CCQ was strong and 
the triangulation seemed valid in comparison with currently accepted MCIDs. However, 
the MCID currently used for the SGRQ in clinical practice and scientific research did not 
match that in the reviewed content, which was much higher. Using MCIDs that are too 
low may have led to an overestimation of treatment effects in clinical trials. Also, MCIDs 
for deterioration were rarely considered, highlighting the need for more research in this 
specific domain.
8.2.1 Using multiple approaches in defining a valid MCID 
A first important issue regarding the MCID of (COPD) health status tools is that an 
extensive variety of anchor-, distribution- and opinion-based methods exists to establish 
an instrument’s MCID [44-68]. Some of these are considered better than others, but at 
present, there is neither a gold standard method nor agreement on the use of each 
method. In Chapter 4, the scales of anchor- and distribution-based methods were 
investigated with a selection of anchors when determining the MCIDs of the CAT, CCQ 
and SGRQ for use in COPD [69]. MCIDs for the domain scores of the CCQ and SGRQ were 
newly determined. The anchor-based methods required change in health status to be 
compared with another measure of clinical change (e.g., a patient’s global rating of 
change (GRC), a COPD exacerbation as clinical event criterion, or a correlated health 
status PRO questionnaire) [44, 47, 51-52, 62, 68]. Distribution-based methods required 
comparison of change with a statistical measure of variability of this change [44, 47, 
51-52, 56-57, 62, 64, 66-68]. The resulting MCID estimates differed with the method used 
in an analysis of 451 patients, who had moderate to very severe COPD (mean age 58 
years, 65% male) and participated in a 3-week tailored PR programme with inspiratory 
muscle training (IMT) as an add-on randomised-controlled intervention [70], giving 
pooled MCIDs of -3.28 (CAT), -0.52 (CCQ) and -7.91 (SGRQ) (Table 1, Figures 1-3). Most MCID 
estimates for the CAT and CCQ agreed with or were slightly higher than the accepted 
2- and 0.40-point thresholds [41-42]. By contrast, all MCID estimates for the SGRQ were 
higher than the accepted 4-point threshold that has been applied extensively as cutoff 
value in clinical trials [31-32, 40]. However, its former methodology was analysed and 
considered unconventional.
Looking at the MCID methods applied in Chapter 4, the results from the various anchor-
based methods (patient-, criterion- and questionnaire-referencing) were rather 
comparable. A careful selection of anchors (e.g., using correlated health status PRO 
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questionnaires) was advocated, especially when their MCIDs had not been thoroughly 
established. The distribution-based method half standard deviation (0.5SD) was best 
comparable with anchor-based results. The standard error of measurement (SEM) was 
noted to be inconsistent, while the 1.96SEM was much more conservative for the CAT and 
SGRQ. Hence, different methods resulted in a range of MCIDs and did not converge on a 
single estimate. Based upon the pooled MCIDs, however, clinically relevant improvements 
for patients with moderate to very severe COPD during PR would generally be shown at 
3 points on the CAT, 0.50 point on the CCQ and 7 points on the SGRQ. These suggested 
thresholds roughly equate to 7% of the instrument’s maximum total score. Domain MCID 
values were somewhat similar on the CCQ and SGRQ, except for the mental status on the 
CCQ and symptoms on the SGRQ.
8.2.2 The impact of follow-up length and GRC anchor question on the MCID 
A second uncertainty was whether the length of the follow-up period for change 
measurement affected the MCID estimates due to recall bias or response shift [4, 47, 
50, 52, 54, 71-73]. Chapter 5 summarised a longitudinal exploration of this impact and 
the design of the GRC anchor question on the MCID of the CAT, CCQ and SGRQ [74]. 
No significant differences were observed during follow-up at 3 weeks or at 3, 6, 9 and 
12 months between the MCID estimates for improvement. Data were evaluated for 451 
patients with COPD engaging in a PR intervention of whom 309 completed all follow-up. 
Using a 15-point GRC anchor question, MCID estimates for improvement ranged from -3.1 
to -2.3 for the CAT, -0.6 to -0.4 for the CCQ and -10.3 to -7.6 for the SGRQ (Table 1, Figures 
1-3). Larger MCIDs were noted for the CAT and CCQ at the 3-week recall period directly 
after PR, though these were not significantly different. Measuring change over such a 
short follow-up directly after an event may be associated with a temporary raise in the 
MCID estimate. 
However, MCID results using a 5-point GRC were significantly smaller for the CAT and 
CCQ in comparison with the 15-point GRC after one year of follow-up. Estimates were -1.4 
for the CAT (significant difference -1.4), -0.3 for the CCQ (significant difference -0.2), and 
-7.7 for the SGRQ (nonsignificant difference -1.1) (Table 1, Figures 1-3). Patient classification 
by both GRCs was only 55% consistent. Hence, introducing fewer choice options on the 
GRC anchor question resulted in smaller absolute MCIDs. Too few reply options on a GRC 
could potentially lead to a loss of relevant information, resulting in less discriminative 
power and lower sensitivity. Overall, the MCIDs for the CAT and CCQ were somewhat 
comparable or slightly higher than those currently used [41-42], whereas the MCID 
estimates of the SGRQ were significantly higher compared with those currently used 
extensively in clinical trials [31-32, 40].
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8.2.3 Can we assume similar MCIDs for improvement and deterioration?
A third matter of concern regarding the MCID was whether estimates for clinically relevant 
improvement compare to those for deterioration [4, 37, 53-54]. As demonstrated in the 
systematic review in Chapter 3, this issue has not previously been explored in the context 
of COPD [43]. It was therefore addressed in the work presented in Chapter 6 of this thesis 
[75]. The primary purpose of an intervention is generally to improve health status, but 
because COPD is a chronic and progressive disease [14, 21-22], preventing deterioration 
should also be considered key outcome of therapy. To do so, one needs to differentiate 
real worsening of a patient’s status (e.g., signal) from random variations (e.g., noise). 
Currently, the accepted MCIDs for improvement on the CAT, CCQ and SGRQ are simply 
also used for deterioration. However, there was no evidence that this approach was 
appropriate. 
When assessing the data at multiple follow-up points for 451 patients during PR and 
207 patients during routine clinical practice (RCP), the anchor- and distribution-based 
MCIDs for improvement and deterioration were similar overall, but the absolute MCIDs 
differed between the PR and RCP groups (Table 1, Figures 1-3). The results indicated that 
appropriate cutoff values for both minimal improvement and deterioration could be as 
follows: CAT ≥3 (intervention), CAT ≥2 (RCP), CCQ ≥0.40 (intervention), CCQ ≥0.30 (RCP), 
SGRQ ≥6-7 (intervention) and SGRQ ≥4-5 (RCP). Again, the MCID ranges for CAT and CCQ 
matched well with the currently accepted MCIDs [41-42], but the estimates for the SGRQ 
during PR were larger than previously reported (although the MCID estimates for the RCP 
group could be close to the 4-point estimate) [31-32, 40]. Thresholds for moderate and 
large clinically important improvement and deterioration differed both between each 
other and between settings; however, the number of patients with moderate or large 
changes was too small to draw valid conclusions. Thresholds for moderate and large 
changes need to be explored further, but they may fall in respective ranges of 4-5 and 
5-6 points on the CAT, 0.80 and 1.00 point on the CCQ, and 10-15 and 15-20 points on the 
SGRQ.
8.2.4 The impact of context- and patient-related factors on the MCID
Various factors are known to affect a patient’s health status [4, 12, 37, 44, 47, 50, 52, 54-
55, 59, 76-79]; however, it is unclear if these also affect the MCID. The impact of patient-
related factors, study setting and baseline health status severity on the MCID of the 
CAT, CCQ and SGRQ were analysed during various follow-up measurements [80]. In 
total, 658 patients with COPD and no respiratory comorbidities were retrospectively 
analysed during PR and RCP, providing data for 2299 change scores from baseline. 
Anchor- and distribution-based methods were applied and the MCID estimates were 
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Figure 1: Plot of all MCID estimates obtained for the CAT in this thesis
Overview of all MCID estimates for improvement and deterioration (horizontal axis) from intervention/PR versus RCP (vertical axis). Estimates 
are presented as circles (anchor-based estimates), squares (distribution-based estimates), diamonds (weighted or triangulated MCIDs), or 
asterisks (lower and upper limit of the observed range or 95%CI). The vertical orange reference line represented the currently accepted MCID 
in the literature. The dashed vertical orange reference line mirrors the accepted MCID for improvement into deterioration. 
MCID estimates are colour coded per chapter: systematic review and triangulation in Chapter 3 (black); MCID methods in Chapter 4 (red); 
follow-up period and GRC anchor question in Chapter 5 (green); improvement versus deterioration in Chapter 6 (blue); MCID and dynamic 
factors in Chapter 7 (orange). 
Abbreviations: 95%CI, 95% confidence interval; AECOPD, acute exacerbation chronic obstructive pulmonary disease; CAT, COPD 
Assessment Test; COPD, chronic obstructive pulmonary disease; MCID, minimal clinically important difference; PR, pulmonary rehabilitation; 
RCP, routine clinical practice. 
evaluated and statistically tested between several subgroups, including study setting 
(PR vs. RCP), gender (males vs. females), age (median as cutoff), COPD disease severity 
(GOLD grades I-II vs. GOLD grades III-IV), Charlson Comorbidity Index (median as cutoff) 
and baseline health status (median as cutoff). Most estimates for improvement and 
deterioration resulted in a CAT MCID score between ±1.50 and ±3.50, a CCQ MCID score 
between ±0.30 and ±0.60, and a SGRQ MCID score between ±4 and ±9 points. Trends were 
also observed during subgroup analyses. Clinically relevant thresholds for change on the 
respective health status questionnaires differed significantly between the intervention (PR) 
and RCP groups, with larger absolute MCIDs overall during the intervention. In patients 
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with worse baseline health statuses, MCID estimates for improvement on the CAT, CCQ 
and SGRQ were 3-7 times larger; however, MCIDs for deterioration were 4-6 times smaller. 
Females, older patients (>60 years), patients with GOLD grade I-II COPD by spirometry, 
and patients with COPD and fewer comorbidities had larger but nonsignificant MCID 
estimates for improvement, and smaller but nonsignificant estimates for deterioration 
when compared with their paired subgroup.
Figure 2: Plot of all MCID estimates obtained for the CCQ in this thesis
Overview of all MCID estimates for improvement and deterioration (horizontal axis) from intervention/PR versus RCP (vertical axis). Estimates 
are presented as circles (anchor-based estimates), squares (distribution-based estimates), diamonds (weighted or triangulated MCIDs), or 
asterisks (lower and upper limit of the observed range or 95%CI). The vertical orange reference line represented the currently accepted MCID 
in the literature. The dashed vertical orange reference line mirrors the accepted MCID for improvement into deterioration. 
MCID estimates are colour coded per chapter: systematic review and triangulation in Chapter 3 (black); MCID methods in Chapter 4 (red); 
follow-up period and GRC anchor question in Chapter 5 (green); improvement versus deterioration in Chapter 6 (blue); MCID and dynamic 
factors in Chapter 7 (orange). 
Abbreviations: 95%CI, 95% confidence interval; AECOPD, acute exacerbation chronic obstructive pulmonary disease; CCQ, Clinical COPD 
Questionnaire; COPD, chronic obstructive pulmonary disease; MCID, minimal clinically important difference; PR, pulmonary rehabilitation; 
RCP, routine clinical practice. 
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Figure 3: Plot of all MCID estimates obtained for the SGRQ in this thesis
Overview of all MCID estimates for improvement and deterioration (horizontal axis) from intervention/PR versus RCP (vertical axis). Esti-
mates  are presented as circles (anchor-based estimates), squares (distribution-based estimates), diamonds (weighted or triangulated 
MCIDs), or asterisks (lower and upper limit of the observed range or 95%CI). The vertical orange reference line represented the currently 
accepted MCID in the literature. The dashed vertical orange reference line mirrors the accepted MCID for improvement into deterioration. 
MCID estimates are colour coded per chapter: systematic review and triangulation in Chapter 3 (black); MCID methods in Chapter 4 (red); 
follow-up period and GRC anchor question in Chapter 5 (green); improvement versus deterioration in Chapter 6 (blue); MCID and dynamic 
factors in Chapter 7 (orange). 
Abbreviations: 95%CI, 95% confidence interval; BLVR, bronchoscopic lung volume reduction; MCID, minimal clinically important difference; 
PR, pulmonary rehabilitation; RCP, routine clinical practice; SGRQ, St. George’s Respiratory Questionnaire. 
Multiple linear regression models demonstrated that baseline health status severity and 
setting were frequent significant independent factors in most models of the MCIDs of health 
status tools used in COPD. Importantly, complex interactions between the variables were 
observed with possible regression to the mean also noted. The explained variance of the 
models was low. Although the MCID is currently used as a non-adaptable parameter, there 
was a complex interaction by study setting, baseline health status, gender, age, spirometry 
classification and comorbidities, which potentially affected the MCID estimates for both 
improvement and deterioration on the CAT, CCQ and SGRQ. More accurate individual 
interpretation of outcomes in scientific research and clinical practice may benefit from 
developing and using clustered or even tailored MCIDs.
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8.3 MCIDs of health status questionnaires in COPD
8.3.1 Important issues in health status interpretation in COPD
To date, the MCID parameter has been used to interpret results in both scientific studies 
and clinical practice. The SGRQ, in particular, has frequently been used to evaluate 
health status in patients with COPD. A random example of this can be seen in the study 
by Gottfried et al. [81], who reported the effects of pharmacotherapy with indacaterol 75 
μg once daily on dyspnoea and health status. They used the MCID of the SGRQ based on 
the threshold of 4 points, as has been widely accepted based on prior research [31-32, 40]. 
In this study, patients using indacaterol improved by 4.9 (group 1) and 5.8 points (group 
2) on the SGRQ after 12 weeks. It was concluded that the within-patient change exceeded 
the MCID of 4 points and that the respective odds ratios for achieving the MCIDs of the 
SGRQ were 1.80 and 1.71. This finding indicated that the between-patient change (placebo 
vs. intervention) based on achieving the MCID favoured the intervention, indicating that 
indacaterol was an effective therapy for patients with moderate-to-severe COPD.
Many more examples exist in which the MCIDs of health status instruments have been used 
as important primary outcome parameters to evaluate therapy and interpret its effects 
in COPD. Given that the approval of new drugs and interventions depends on achieving 
the MCID, it is pivotal that the parameter is set correctly to prevent inaccurate estimates 
of treatment effects [77]. As such, it is remarkable that so many different methods are 
not only used as the basis for the MCID, but that they are also used interchangeably 
and considered of equal value without clarity on how the outcomes differ [44-68]. These 
issues result in uncertainties, a lack of clear direction and limited evidence regarding 
the MCID parameter and its dynamics (Chapter 1). Why then, should we as clinicians or 
researchers be satisfied with the frequent use of the MCID as a key absolute and static 
evaluation threshold? Indeed, is it now appropriate that we consider the dynamics and 
complex nature of this parameter? Although any interpretation based on a single MCID 
threshold appears too simplistic, as currently applied in scientific research and clinical 
practice, one needs to consider what alternative options realistically exist. Therefore, 
much of this thesis has focused on investigating the dynamics of the MCID for three 
recommended PROs used to assess health status in COPD (I.e., the CAT, CCQ and SGRQ) 
[14, 30].
Health status PROs in COPD cover items such as breathlessness, dyspnoea, fatigue, cough, 
sputum production, physical functioning and exercise tolerance, social functioning, 
depression and/or anxiety, and exacerbations [13, 18, 82]. Many tools exist to evaluate 
QoL in COPD (Chapter 2). The CAT questionnaire has been recommended by the GOLD 
committee as the primary health status tool for the evaluation of the symptomatic 
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burden of COPD in patients [14]. The CCQ, which was developed prior to the CAT, is mostly 
equivalent, and is perhaps even slightly preferred, because it includes specific domain 
scores [30, 41, 83-85]. By contrast, the SGRQ is a much more extensive health status PRO 
that is considered most suitable for use in scientific research [30-32].
The currently accepted MCIDs are 2 points for the CAT, 0.40 point for the CCQ and 4 
points for the SGRQ [31-32, 40-42]. The systematic review in Chapter 3 demonstrated 
gaps in the evidence for each of these MCIDs [43]. The resulting triangulated values for 
improvement were -2.54 for the CAT, -0.43 for the CCQ and -7.43 for the SGRQ. Study 
size, quality and methodology were incorporated in the triangulation to validate its 
procedures. It was especially worrying that the currently applied MCID of the SGRQ (4 
points) [31-32, 40] and of the Chronic Respiratory Questionnaire (CRQ) (MCID 0.5 point 
on a maximum score of 7 points [38, 86]) were set much lower than the triangulated 
and reviewed values. Moreover, these lower MCID values were based on evidence that 
was of poor quality or on studies of questionable value, which in fact were not aimed at 
determining MCIDs. This may have resulted in overestimation of the treatment effects of 
many currently approved therapies. The example study on indacaterol by Gottfried et 
al. [81] provides a good example of a pharmacological study with results that exceeded 
the 4-point MCID threshold for the SGRQ, but that would not reach the triangulated 
threshold of 7 points. The conclusions of this study should therefore be altered to 
state that indacaterol might not be an effective therapy for patients with COPD. This 
conclusion may not be welcomed by all stakeholders.
Given the issues with the SGRQ and CRQ questionnaires, it is alarming that they have 
been used as anchors to determine the MCIDs of other health status tools and diagnostic 
tests in COPD too. The CRQ dyspnoea domain, for instance, was used as an anchor 
in the SGRQ MCID determination process. This resulted in an outlying low estimate of 
approximately 3 points with insufficient anchor correlations reported [87]. The 4-point 
MCID of the SGRQ has also been used as an anchor for calculating the MCID of the CAT 
and CCQ, resulting in these tools having the lowest MCID estimates (Chapter 4 [69]). 
In addition to these concerns, the literature review revealed no evidence of MCIDs for 
deterioration and no research into the impact of study setting or follow-up duration on 
the MCID estimates (Chapter 3 [43]). Lastly, it was notable that evidence for the MCID 
of other COPD health status tools was limited in terms of quantity, quality or both 
in the systematic review of Chapter 3 [43]. These MCIDs should not, at this stage, be 
recommended for use in clinical practice or scientific research for COPD.
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8.3.2 MCID outcomes and proposed framework for the dynamic 
evaluation of changes
The results from the systematic review in Chapter 3 [43] and the analyses in Chapters 
4–7 [69, 74-75, 80] highlighted that there is a range of MCID values for the CAT, CCQ 
and SGRQ. In clinical practice, it would be more convenient to use a single cutoff value, 
although a range does provide more room to consider the methodological-, time-, 
patient-, direction-, and context-related dynamics of the MCID parameter. 
The total ranges for the MCID estimates in this thesis were as follows (Table 1, Figures 1-3): 
- CAT: -6.43 to -0.67 for improvement and 0.50 to 6.30 for deterioration;
- CCQ: -0.82 to -0.10 for improvement and 0.19 to 0.84 for deterioration;
- SGRQ: -12.28 to -2.40 for improvement and 0.33 to 12.86 for deterioration. 
Various outliers were observed in the proposed ranges. Of note, this included the 
following: the MCID estimates for baseline health status severity subgroups (Chapter 7 
[80]), the 1.96 standard error of measurement (1.96SEM) (Chapter 4 [69]), the distribution-
based estimates of the 95% minimum detectable change (95MDC) and the 0.2 standard 
deviation (0.2SD) (Chapter 3 [43]), using the CRQ dyspnoea domain as an anchor for 
the MCID of the SGRQ (Chapter 3 [43]), and the estimates obtained from RCP (Chapters 
6 and 7 [75, 80]). Most of the MCID estimates in this thesis [43, 69, 74-75, 80], calculated 
for both improvement and deterioration, ranged between ±2.00 and ±3.50 for the CAT 
and between ±0.30 to ±0.50 for the CCQ (Table 1, Figures 1-3). These ranges for the SGRQ 
were -9.00 and -6.00 for improvement and +5.00 to +8.00 for deterioration. Possible 
cutoff values for clinically relevant moderate and large changes could lie in the range 
of respectively ±4 to ±5 and ±5 to ±6 points for the CAT, ±0.80 and ±1.00 point for the 
CCQ, and ±10 to ±15 and ±15 to ±20 points for the SGRQ (Chapter 6 [75]). These thresholds, 
however, require more research before they can be recommended with confidence, 
not least because the number of patients with moderate or large change was small in 
the study samples. Thresholds for change on the domain scores of the CCQ and SGRQ 
may also be comparable to those for the total score (Chapter 4 [69]), but again, more 
research is required.
Applying the MCID as a range instead of a single cutoff point may have important 
benefits, potentially offering greater flexibility to the interpretation of change and better 
incorporating the complexity and dynamics of this parameter [44-47]. One could argue 
that, based on the findings reported in this thesis thus far, an adaptive extension of the 
framework as published prior by Man-Son Hing [48] (Paragraph 1.3.2 Figure 1) could be 
suggested. Clinical trial outcomes presented as a point estimate with its 95% confidence 
interval (95%CI), but also changes observed by physicians in clinical practice, could 
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be interpreted in relation to the proposed ranges for the CAT, CCQ and SGRQ in this 
thesis (Table 2, Figure 4). Of course, clinical trial outcomes should at least be statistically 
significant for any detected change to be considered relevant or important. Then, the 
outcomes of the scientific trial or in clinical practice should be evaluated in relation to the 
proposed MCID ranges. If the outcome exceeds the lower threshold of the MCID range, 
this should be classified as definite. However, if the trial outcome does not meet this 
threshold, but its upper 95%CI does, then a cautious conclusion of probable or possible 
classification may be appropriate.
As example, the study by Gottfried et al. on indacaterol once daily [81] could be considered. 
The trial outcomes (improvements of 4.9 (group 1) and 5.8 points (group 2) on the SGRQ 
after 12 weeks) would classify according to Table 2 as a definite classification of “minimal 
clinicaly important change somewhat likely”. Based on the value of the upper 95%CI, which 
unfortunately was not reported, a cautious possible/probable classification of “minimal 
clinicaly important change likely” could be considered for clinical trial outcome on health 
status.  
Important notes must be highlighted when using this proposed classification, with 
emphasis placed on the importance of researchers and clinicians considering the 
various dynamic factors of the MCID. The variables of the sample or patient at stake 
should be incorporated, including the context and baseline variables. Setting can affect 
the MCID of COPD health status tools, with larger estimates for interventions (in this case 
PR) compared with stable RCP without additional interventions (Chapters 6 and 7 [75, 
80]). The MCID may also be higher when measuring change directly after intervention/
management compared with measuring change during long-term stable follow-
up (Chapter 5 [74]). Such issues can be incorporated by adjusting the categorisation 
level. For example, when measuring change during RCP without additional changes 
in its management, as well as measuring change during long-term follow-up after 
intervention, it is recommended to step down one level of interpretation in the proposed 
classification framework (Table 2, Figure 4).
One could also take into account if the investigated cohort includes highly symptomatic 
patients with worse baseline health status (i.e., CAT ≥20, CCQ ≥2.50 and SGRQ ≥50) and 
thus require a larger MCID for improvement and a smaller MCID for deterioration. Taking 
this example further, one may consider shifting categorisation left or right along the 
horizontal axis of Figure 4 to alter the strictness of classification according to the baseline 
health status score. Similar processes could be considered for cohorts with significantly 
more females and elderly patients (Chapter 7 [80]), because these subgroups appear to 
require larger MCIDs for improvement and smaller MCIDs for deterioration too. However, 
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these patient characteristics had less of an impact than either the baseline health status 
severity or the study setting, and the patterns were less obvious. Interaction may also 
have influenced these outcomes. The MCID patterns were less clear when samples 
included patients with worse COPD GOLD grades and/or worse comorbidity levels, which 
may affect the MCID estimate. More research with larger samples from multiple settings 
is needed to elucidate these trends, and such research may uncover other influencing 
factors that should be integrated into the framework for dynamic MCID evaluation 
(Table 2, Figure 4).
8.4 Theoretical considerations in defining an instrument’s MCID
Many generic- and disease-specific health status instruments exist [20]. In the future, 
more tools may emerge or the currently applied tools may be adapted. A central 
aim of this thesis was to provide clear guidance to help scientists determine an 
instrument’s MCID. Based on the research presented throughout the thesis [43, 69, 74-
75, 80], a set of theoretical and practical recommendations has been developed. These 
recommendations are divided into three quality levels (Box 2): bronze, silver and gold. The 
necessary minimum methodological requirements for determining an MCID are included 
first, and any additional recommendations to improve the methodological quality and 
draw final conclusions are included later. Overall, determining an instrument’s MCID 
should combine multiple anchor- and distribution-based methods, preferably obtained 
from multiple settings with various follow-up periods and predefined usage criteria [44, 
47, 49]. The impact of context- and patient-related factors should be incorporated at the 
next level to investigate the need for clustered MCIDs. 
8.4.1 Bronze level – using a variety of MCID methods with sound criteria
The first level of quality (bronze level) for determining the MCID is to ensure that 
appropriate methodology is used (Box 2 Recommendations 1–5). Although there is 
currently no standard methodology [12, 44, 47, 50], the many different methods that exist 
can produce a useful range of MCID estimates [4, 12, 39, 44-47, 51-62]. Anchor-based 
methods use an external reference criterion to provide the threshold for clinically relevant 
change [4, 12, 39, 44-47, 51-54, 56-61, 79], giving a clear link to medical practice, and often, 
patients’ judgements [63]. Such methods are limited by dependence on correlations 
between the anchor and the instrument under review and by subjective patient variation 
[4, 54]. By contrast, distribution-based methods use statistical parameters to assess the 
significance of a change against its clinical relevance [4, 12, 39, 44-47, 52-53, 56-62, 64]. 
They can be calculated quickly and can be stable in the face of random variation [4], 
but they may not convey the clinical importance of an observed change or incorporate 
patient judgement, and they may result in larger MCIDs in heterogeneous populations. 
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Differences between MCID estimates obtained by anchor- and distribution-based methods 
were observed in this thesis too, resulting in the observed range of estimates (Table 2, Figure 
4). Some good agreement was observed among the various anchor-based methods, 
though unsurprisingly, with some variation (Chapter 4 [69]). Using a variety of anchor-based 
methods with multiple statistical approaches may resolve this issue (Box 2 Recommendations 
1–2). In the current thesis, criterion-referencing with COPD exacerbations as the clinical 
criterion event (so-called between-group change/difference) was rather equivalent to patient-
referencing with a GRC as the anchor (so-called within-group change). Given that MCIDs are 
used for both between and within-patient interpretation of change, this could mean that a 
similar MCID could be applied in each situation, as follows [36]:
- evaluation of pre- and post-intervention scores within the same group;
- evaluation of differences between intervention and control groups;
-  evaluation of odds ratios between groups in achieving the instrument’s MCID 
after intervention.
It was also shown that the questionnaire-referencing results were comparable to the 
patient- and criterion-referencing results (Chapter 4 [69]), despite the major concern that 
anchor selection was doubtful. Selecting another health status PRO questionnaire as an 
anchor, especially one for which the MCID has not been thoroughly investigated, could 
severely impact the MCID of the instrument under review. In Chapter 4 [69], MCID estimates 
based on using the original MCID of the SGRQ as the anchor were the lowest of all methods. 
The MCID for the SGRQ was considered to be set too low. Revised MCIDs based on other 
anchor-based results for the MCID of the SGRQ better correlated with other methods like 
patient- and criterion-referencing. The review in Chapter 3 confirmed the finding that careful 
anchor selection is needed if one is to guard against faulty MCIDs in new instruments [43]. 
Clinicians and researchers should therefore avoid using anchors without strong MCIDs set 
according to the guidelines recommended in this thesis (Box 2 Recommendation 3).
In addition to using sound, preferably multiple, anchors and anchor-based approaches 
(Box 2 Recommendations 1–3), another recommendation is that correlations between the 
anchors and instruments should be both reported and of an appropriate degree (Box 2 
Recommendation 4). In the systematic review (Chapter 3), it was observed that correlations 
between selected anchors and studied health status tools not only were infrequently 
reported, but also were infrequently sufficient [43]. As a criterion for eligibility, correlation 
coefficients (r) should preferably be ≥0.50, with a minimum standard of ≥0.30 [47]. 
However, not all correlations between selected anchors and health status instruments 
in this thesis met the 0.50 threshold, with correlations being lowest directly after an 
intervention, especially for GRC anchors. Correlations between anchors and change 
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scores approached or even exceeded the 0.50 threshold during follow-up (Chapters 5–7 
[74-75, 80]). Also, the correlations between anchors and health status questionnaires 
were stronger for the follow-up health status score than for its change value or baseline 
score (Chapter 6 [40]). This may represent a possible response shift [88] that should be 
taken into consideration (Box 2 Recommendation 4).
In Chapters 3–7, multiple statistical methods were used within the anchor-based 
approaches when calculating the MCID [43, 69, 74-75, 80]. These included the mean 
change method, the use of receiver operating characteristics (ROC) curves and 
regression analysis to define thresholds for clinically relevant change. In general, the 
results were comparable and stable between methods, though it must be noted that 
using ROC curves resulted in somewhat larger estimates for improvement and smaller 
estimates for deterioration (Chapters 4 and 7 [69, 80]). Furthermore, despite requiring 
the area under the ROC curve (AUC) to be ≥0.70, this was infrequently reported in the 
reviewed literature (Chapter 3) [43]. Multiple statistical approaches are recommended 
when using anchor-based methods (Box 2 Recommendation 2).
In comparison with the anchor-based approaches, the distribution-based methods 
appeared more stable over time, and between subgroups and study settings in this 
thesis. However, these estimates were generally smaller than for the anchor-based 
outcomes during follow-up (Chapters 5–7 [74-75, 80]). Distribution-based outcomes 
could therefore better define the lowest MCID without conveying clinical importance 
(Box 2 Recommendation 5). Anchor-based methods provide real patient and/or clinical 
perspectives and can provide supportive information [12, 47, 49, 59]. The distribution-
based 0.5SD method was most comparable to the anchor-based methods. However, it 
was less sensitive for evaluating and measuring the dynamics of the MCID over various 
follow-up periods and between subgroups (Chapters 5 and 7 [74, 80]). Most 0.5SD 
results were also lower than those given by anchor-based approaches (Chapter 6 [75]), 
especially during RCP (but also during PR). The other distribution-based applications, 
like the SEM and 1.96 SEM, were less consistent in the explored literature (Chapter 3) 
and throughout the thesis (Chapter 4) [43, 69]. Although the 1.96 SEM was much more 
conservative than the other methods, this has not been reported in previous studies [43]. 




Box 2: Theoretical and methodological recommendations for determining an instrument’s MCID
Bronze level
Recommendation 1: Combine multiple anchor- and distribution-based methods, 
including various types of patient-referencing, criterion-referencing and questionnaire-
referencing with more than one anchor. 
Recommendation 2: Apply various statistical techniques in the anchor-based methods, 
including the mean change method, ROC curves (including AUCs) and regression analysis.  
Recommendation 3: Select anchors for questionnaire-referencing that have well-
established MCIDs according to the current recommendation levels here. 
Recommendation 4: Assess and report correlations between the selected anchors, 
including GRCs and health status questionnaires, and requiring a minimum level 
of r ≥ 0.30, but preferably r ≥ 0.50. Assess correlations between the anchor and the 
instrument’s change/baseline/follow-up scores to assess for a potential response shift.  
Recommendation 5: Assess the minimum level for clinically relevant change and 
confirm the anchor-based MCID estimates by calculating the distribution-based 0.5SD 
in different study settings, populations, measurement periods and subgroups.
Silver level
Recommendation 6: Determine an instrument’s MCID over multiple recall periods 
directly after an intervention and during long-term follow-up. Compare significant 
differences in estimates for dependency-adjusted confidence intervals based upon the 
intraclass correlation coefficient (ICC). 
Recommendation 7: For patient-referencing in the anchor-based method, select at 
least two GRC scales during follow-up, with each having a different number of reply 
categories in both numerical and verbal versions. 
Recommendation 8: Determine MCIDs for improvement and deterioration separately 
with a variety of methods and in different time periods. Do not assume that each MCID 
type is similar. 
Recommendation 9: Expand on Recommendation 8 to include multiple settings, 
interventions and routine medical care. If context- or population-specific differences 
exist, consider using different MCIDs in clinical practice and scientific research. 
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Gold level
Recommendation 10: Assess the impact of baseline health status on an instrument’s 
MCID by (dichotomised) subgroup analysis and multiple linear regression modelling. If 
significantly large differences exist, different MCIDs should be used in clinical practice 
and scientific research when samples/patients have extreme baseline characteristics 
or when individual assessment of change is required. 
Recommendation 11: Assess the impact of appropriate patient- and disease-related 
factors on an instrument’s MCID. If significantly large differences exist, different MCIDs 
should be used in clinical practice and scientific research when samples/patients have 
extreme baseline characteristics or when individual assessment of change is required.
Recommendation 12: Assess the interaction between patient-, disease- and context-related 
factors that affect the MCID by independent t-tests and multiple linear regression modeling. 
Recommendation 13: Collect all MCID evidence in a systematic review and use 
triangulation procedures based on the study size, methodological quality, and MCID 
estimates. Consider whether a single estimate, multiple estimates or a range for 
dynamic MCID evaluation is required to interpret therapy effects.
The three levels of quality for MCID determination are shown. 
Abbreviations: 0.5SD, half standard deviation; AUC, area under the curve; GRC, global rating of change; ICC, intraclass correlation 
coefficient; MCID, minimal clinically important difference; R, correlation coefficient; ROC, receiver operating characteristics; SEM, standard 
error of measurement.
8.4.2 Silver level – integrating follow-up duration, direction of change 
and context
Whereas the bronze level requires that MCIDs are determined using sound anchor- and 
distribution-based approaches with valid criteria, the second level (silver level) requires 
that researchers look deeper into specific dynamic factors that could affect the MCID 
of an instrument. Change during various follow-up periods should be investigated (Box 
2 Recommendation 6), because MCIDs may be influenced by the length of the follow-
up (i.e., the recall period) [4, 47, 50, 52, 54, 71-73]. The longer the recall period, the more 
difficult it may be for a patient to assess the change in health status (recall bias) [71-
73, 88-92], and this indicates that MCIDs can change over time. The systematic review 
in Chapter 3 found no specific time-related pattern [43], and testing the hypothesis in 
Chapter 5 confirmed that the overall impact of the recall period and of recall bias on the 
MCID was limited during follow-up [74]. It is possible that the fixed recall moment before 




It was interesting that the MCIDs determined directly after the PR intervention were 
larger than those measured during follow-up (Chapter 5) [74]. This means that MCIDs 
determined directly after an intervention could be larger than those determined during 
longer follow-up. At the same time, correlations between the anchor and the reviewed 
instrument were lowest directly after the intervention, which might help explain the 
findings. The fact that the calculated MCID was larger after therapy is not surprising: 
most change would be expected directly after the intervention due to a combination of 
the therapy itself, placebo effect and/or (high) patient expectations. MCIDs are typically 
used when evaluating change directly after an intervention, though interpreting change 
during follow-up may need to be an additional goal when evaluating long-term trial 
effects. Even though there was only a limited impact of recall bias on the MCID in this 
thesis, other authors have shown that the recall period affects patients’ assessments of 
change [54, 71-72, 91-97]. It is therefore recommended to check if the recall period affects 
the MCID estimate (Box 2 Recommendation 6).
GRCs are often used as anchors when measuring change during follow-up (so-
called patient-referencing). Their use is recommended at the bronze level in Box 2 
(Recommendation 1). However, at the silver level, it is important to investigate the impact 
of the design of the GRC anchor question on the MCID (Box 2 Recommendation 7). Fewer 
choice options with the GRC resulted in less discriminative power and lower MCID 
estimates in this thesis (Chapter 5 [74]). There was only limited agreement (55%) between 
anchor GRCs with 5 and 15 choice options, so patients scored the GRCs differently. This 
may have been due to the number of choice categories, but may also have been due 
to the design (i.e., verbal vs. numerical scales). In the systematic review (Chapter 3 [43]), 
it was noted that GRCs with fewer response categories were frequently used, possibly 
explaining the smaller MCID estimates seen for the SGRQ and (possibly) for the CAT.
A third recommendation at the silver level is that the direction of change should be 
taken into consideration (i.e., improvement and deterioration; Box 2 Recommendation 8). 
When doing so, one should certainly consider all prior recommendations. MCIDs have 
usually been developed for use with interventions designed to improve health status, 
which is an important goal of therapy. However, in a chronic progressive disease like 
COPD, preventing true deterioration is an important outcome too [11, 98-100]. Measuring 
and preventing deterioration would perhaps be of most interest in routine medical care 
and for patients with worse baseline disease severity. The systematic review of Chapter 
3 clearly demonstrated that MCIDs for deterioration were non-existent in the existing 
literature for COPD [43], a situation that may be reflected in other medical sciences.
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MCIDs for improvement and deterioration are not necessarily similar [4, 37, 47, 53-54]. 
While some studies found differences between these MCIDs, others did not [101-107]. 
Also, it was hypothesised elsewhere that MCIDs for improvement would be smaller than 
those for deterioration [4, 107], but this was not confirmed in the current thesis. Overall, 
no major structural discrepancies between MCIDs for improvement and deterioration 
were observed during PR and RCP [75, 80], although some differences were noted with 
the CAT during RCP and the SGRQ during PR (Chapter 7 [80]); in those cases, MCIDs for 
deterioration were smaller than those for improvement. By contrast, the MCID of the 
SGRQ during RCP was larger for deterioration than for improvement, possibly due to 
a difference in the number of patients in the respective change groups. Relative MCIDs 
were also smaller for improvement (approximately 10% change from baseline) than for 
deterioration (approximately 20% change from baseline) (Chapter 7 [80]). Generally 
smaller absolute estimates were also observed in Chapter 7 for deterioration than for 
improvement when comparing subgroups by baseline health status severity, gender, 
age, GOLD grade and comorbidity [80]. Thus, one should not assume that MCIDs for 
improvement and deterioration are alike (Box 2 Recommendation 8). Thresholds for 
moderate and large deterioration were also notably different from those for improvement 
[75]; however, interpretation of these data was complicated by the rather small number 
of patients in these categories.
A final silver recommendation is that study setting should be considered for the MCIDs 
for both improvement and deterioration (Box 2 Recommendation 9). As has already 
been stated, differences were shown to exist between improvement and deterioration 
measures during PR and RCP, while measures directly after PR were associated with higher 
MCID thresholds (Chapter 5 [74]). Importantly, the study setting could also influence these 
results, especially considering that MCIDs appear to be context- or setting specific [12, 
37, 47, 52, 59, 79, 78, 108]. In Chapters 6 and 7, it was shown that larger MCIDs for both 
improvement and deterioration (except for the CAT during RCP) tended to be observed 
during PR compared with RCP [75, 80]. This was clear with both anchor- and distribution-
based methods. Possible baseline differences in health status disease severity, age and 
spirometry could have influenced the observed trend. No structural pattern for study 
setting was observed in the systematic review (Chapter 3 [43]), but it is still considered 
important that multiple settings and populations be explored to check for significant 
differences in the MCID threshold, and that this should include both intervention and 
routine medical care groups.
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8.4.3 Gold level – integrating patient-, disease- and context-related 
factors 
At the highest level of MCID determination (gold level), efforts should be made to 
incorporate patient-, disease- and context-related factors into the MCID framework (Box 2 
Recommendations 10 and 11). Many factors demonstrated to affect health status, potentially 
also influencing the MCID for health status tools. Baseline- and patient-related factors have 
previously been hypothesised to influence MCID estimates [12, 36-37, 44, 50, 52, 54, 68, 76-
77, 105, 107, 109-119], but there was a lack of evidence prior to this thesis. In general, large 
differences were found to exist in MCID estimates for patients with a worse baseline health 
status score than in those with a better baseline score (Chapter 7 [80]). MCIDs for improvement 
were 3- to 7-times larger for patients with worse baseline health statuses, while MCIDs for 
deterioration were 4- to 6-times smaller for patients with worse baseline health statuses. This 
reflected the fact that patients with worse baseline health status simply had greater room for 
improvement and less room for deterioration. One could also conclude that patients with an 
already severe health status only require a small deterioration to feel worse and much larger 
improvement to feel better. The study setting could have affected this pattern too, because 
the PR intervention trial included more patients with severe baseline health status scores. 
Overall, females also had larger MCIDs for improvement and smaller MCIDs for deterioration. 
Although females generally interpret health status differently to males [120], it should be noted 
that females had a worse baseline health status in the study in this thesis. Nonsignificant 
trends were furthermore noted for age, disease severity and comorbidity levels. MCIDs for 
improvement were larger in groups comprising older patients, those with better spirometry 
results and those with fewer comorbidities. By contrast, their MCIDs were generally smaller for 
deterioration. Younger patients had worse overall baseline health statuses and were more 
represented in the PR intervention, which contradicts the observed results for age.
Chapter 7 highlighted the difficulty of simple interpretation when defining the impact of single 
factors on an instrument’s MCID [80]. Given that a complex pattern of interaction interrupted 
the process, it is recommended that factors be considered in an integrated manner for MCID 
determination (Box 2 Recommendation 12). However, the best regression models in this thesis 
could not explain more than 20%–40% of the observed variation in the MCID. Furthermore, 
phenomena such as regression to the mean could have occurred at the group level, especially 
in the analysis of baseline health status severity: in large samples, any baseline and patient-
related differences tend to disappear at the group level. However, in samples with extreme 
characteristics or when more individual or clustered analyses are needed, integrating factors 
could be worthwhile for considering the effects of therapy. Therefore, a dynamic framework 
for (individual) MCID interpretation was proposed in Paragraph 8.3.
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At the pinnacle of the gold level for determining an instrument’s MCID, it is recommended that 
all evidence should be collected and evaluated in a systematic review (Box 2 Recommendation 
13). Triangulation procedures could then be applied based on the study size, methodological 
quality and MCID estimates. In the end, one should consider whether a single estimate, 
multiple estimates or a dynamic range for the MCID evaluation best serves the requirements 
of the instrument under investigation.
8.5 Methodological considerations 
8.5.1 Background
Data analysed in this thesis were derived from a single systematic review and meta-
analysis and two clinical trials. The review (Chapter 3) was conducted independently by 
two researchers, using a predefined protocol in a structured way to explore and evaluate 
existing literature on the MCIDs of health status tools commonly used for COPD. It provided 
an overview of the methodological quality and MCID estimates and used triangulation 
procedures to provide a comprehensive analysis. Study 1, the routine inspiratory muscle training 
within COPD rehabilitation (RIMTCORE) trial, was then conducted in which data were included 
from a randomised controlled clinical trial (RCT) on the effects of IMT as add-on therapy to 
a 3-week PR programme for patients with COPD at the Klinik Bad Reichenhall, Germany [70]. 
Finally, study 2, the MCID Study, included patients with COPD receiving routine medical care 
in both primary and secondary care in the Netherlands. These patients only received care 
according to the Dutch COPD treatment guidelines for RCP without additional management.
8.5.2 Strengths of the study methods
The systematic review performed in Chapter 3 offered the first structured analysis and 
triangulation of the literature on the MCIDs of 12 health status tools commonly used for 
patients with COPD [43]. A predefined and published protocol in PROSPERO was used for 
manuscript inclusion, analysis and assessments, which were done independently by two 
researchers. An extensive tool was applied to evaluate the methodological quality and 
risk of bias of the included studies and their MCID estimates, which comprised existing and 
previously used checklists for the assessment of scientific publications. Triangulation was 
applied for three health status instruments by incorporating elements of study size, quality 
assessment, MCID methods and MCID estimates. A concise overview of all results was then 
presented and published.
Both clinical trials also had predefined protocols that were evaluated for appropriateness 
by medical ethics committees. The trials included a variety of patients with COPD from 
two different study settings: an intervention setting (PR) and a routine medical care setting 
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(RCP). Data from various follow-up periods were integrated for a total duration of 12 months, 
and both trials had large samples at baseline (study 1 n = 451; study 2 n = 207), with loss to 
follow-up percentages of 68.5% for study 1 and 85.6% for study 2 due to active follow-up 
by the researchers (Chapter 6 [75]). The total number of change measurements was also 
large, resulting in nearly 2300 scores for both samples (Chapter 7 [80]). Study procedures 
were punctually followed and audited internally. Study 1 included patients with COPD GOLD 
grades II–IV in a strong dataset over a 3-week PR intervention. There was reasonable balance 
among the GOLD grades and among the baseline groups. However, slightly more males 
were included, and most patients were GOLD grade II or III based on spirometry. Patients 
were randomised to either IMT or sham-IMT by predefined randomisation lists and included 
via their treating physician at the clinic. Study 2 included patients with COPD GOLD grades 
I–IV, but the cohort had slightly more males and more patients with GOLD grades II and III 
disease. In this study, patients received RCP from their physician or general practitioner, and 
no randomisation was required.
Concerning the applied MCID methodology in the various chapters of this thesis [43, 69, 
74-75, 80], it should be noted that multiple anchor- and distribution-based techniques 
were applied simultaneously for the three main COPD health status tools. Most previous 
MCID publications have focused only on a single instrument and have used only a limited 
number of techniques. This thesis combined and standardised the context for these 
frequently used health status tools for COPD to provide equal test situations. Hence, 
much of the resulting content was novel, providing unique data that has not previously 
been evaluated critically. No prior research has investigated the impact of recall bias on 
the MCIDs of health status instruments for COPD over multiple follow-up periods using 
a unique test of significance by means of dependency-adjusted confidence intervals 
(Chapter 5 [74]). Equally, none have investigated the MCIDs for both deterioration and 
improvement at the same time (Chapter 6 [75]). Last, but not least, no prior research 
has considered the various dynamic factors that affect the MCIDs of health status tools 
for COPD, incorporating patient-, method- and context-related aspects (Chapter 7 [80]).
8.5.3 Limitations of the study methods
Certain limitations of the included studies should be noted. For example, many of the 
procedures for evaluating and determining the MCIDs of health status instruments were 
executed for the first time, and as such, no standard processes existed. Similarly, there 
were no procedures to investigate the impact of dynamic factors on the MCID estimates. 
This included the following elements of the thesis [43, 69, 74-75, 80]:
-  the evaluation tool used for the risk of bias and quality assessment, as well as the 
triangulation procedures in the systematic review (Chapter 3);
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-  the application of the various anchor- and distribution-based techniques throughout 
the thesis;
-  the evaluation method to assess the impact of the recall period upon the MCID 
estimates (Chapter 5);
-  the subgroup analysis for baseline-, context- and patient-related factors (Chapter 7); 
and
-  the development and application of dynamic linear multiple regression models 
(Chapter 7).
The lack of standardised procedures for evaluating the MCID became evident in the 
systematic review (Chapter 3 [43]). Here, one was forced to use a new purpose-built tool 
for the quality and risk of bias assessments, and although this was based on existing 
checklists, the final instrument itself was not validated. The absence of an established 
checklist for evaluating studies of an instrument’s MCID necessitated this decision. By 
integrating elements from validated checklists, one can have some confidence in its 
validity. Coupled with this, the triangulation procedures applied in the systematic 
review were specifically developed for this research, because no current procedures 
existed. By including a variety of aspects, such as study size, quality, and MCID methods 
and estimates, triangulation was considered valid. Indeed, it was unfortunate that 
triangulation could not be performed for all included health status instruments due 
to limited number of studies or their heterogeneity. In addition, some studies that had 
claimed to investigate the MCID of instruments, were excluded from the review for failing 
to meet the inclusion criteria. This is a pity too, because it would have been worthwhile 
to evaluate these critically. Another important point here is that the systematic review 
included the article presented in Chapter 4 of this thesis [69] because of the timing of 
publication and the required search update. It was one of the largest studies included, 
and this may have affected the triangulation results.
Regarding the RIMTCORE trial (study 1), which compared IMT with placebo (sham IMT) 
[70], no differences were observed between the intervention arms in the MCID analyses 
of this thesis. All data were analysed collectively with those patients meeting the inclusion 
requirements for MCID analysis, but the analyses were performed retrospectively and 
without corrections between the intervention arms. This RCT design may have affected the 
findings in this thesis. By comparison, the MCID study (study 2) had a simpler design, requiring 
patients to assess their health statuses by questionnaire at various times at home. Patients 
were included by telephone, mail, general practitioner or pulmonary physician. No formal 
face-to-face evaluation of the patient was made by the researcher. The administration of 
questionnaires at home could also have biased the follow-up results.
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It is important to note that not all chapters in this thesis included data from both studies, 
mainly due to the timing of the various publications. Incorporating data from both settings 
in each chapter would have made the analyses stronger, especially in Chapters 4 and 5 [69, 
74]. While comparing the included RIMTCORE trial and MCID study, significant baseline 
differences were observed in terms of age, spirometry and health status results, with no 
corrections made for the exploratory nature of this thesis. Furthermore, only the MCID study 
included patients with COPD GOLD grade I, making comparisons between the datasets 
more difficult. In addition, the RIMTCORE trial included significantly more patients than the 
MCID study, giving a greater weighting to the patients receiving PR in the combined MCID 
analyses (Chapter 7 [80]). Moreover, more follow-up periods and measurement moments 
were used in the RIMTCORE trial, again providing its data with greater weight. Some benefit 
would also have been gained from incorporating data from other interventions, thereby 
allowing discussion of whether the results obtained in this thesis were valid for PR only or for 
interventions in general. 
In the various MCID analyses of Chapters 4–7 [69, 74-75, 80], many different anchor- 
and distribution-based methods were used. However, not all chapters included all 
methods simultaneously in an effort to preserve the overview and prevent the reader 
from being overburdened by the sheer number of MCID estimates. Given that Chapter 
4 demonstrated that there was good agreement between several techniques, one may 
argue that not all methods would be required. However, it was unfortunate that a limited 
number of patients with deterioration, or with moderate or large changes, were included 
for the anchor-based methods. This resulted in small subgroups with larger confidence 
intervals. The anchor-based mean change method used this kind of subgroup analysis 
based on the GRC categorisation. Although the overall sample sizes were large in both 
studies, the numbers of patients in each subgroup were limited, reducing the power.
Another major limitation of the anchor-based methods applied here was that some 
correlations between the selected anchors and questionnaires under review were 
insufficiently strong. This was especially true directly after PR intervention. Furthermore, 
Chapter 6 [75] indicated that there was a response shift, with stronger correlations 
between the GRC and follow-up scores than with the change scores. No corrections were 
made for this finding, which could limit the conclusions. It is unknown how to correct for 
this in MCID research. Next, it was noted that the design of the GRCs could affect the 
MCID estimates (Chapter 5 [74]). Preferably, a greater number of different GRCs would 
have been applied during the various follow-up periods in each setting, but just two 
anchor questions were applied and only at the 12-month follow-up assessment for the 
PR intervention. Moreover, it is important to state that the assessment of change with the 
GRC was performed by the patient, and that there was no formal clinical assessment 
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by the physician to confirm the self-reported data. The costs of treatment were also 
ignored when reaching the MCID. Finally, concerning the anchor-based methods, it is 
worth noting that exacerbations were used as clinical events for criterion-referencing. 
Although good agreement was observed between the patient- and criterion-referencing 
(Chapter 4 [69]), exacerbations may not necessarily represent a minimal event. It would 
also have been interesting to execute the criterion-referencing approach during RCP 
in study 2.
A limitation of the conclusions presented in Chapter 7 of this thesis [80] was that a 
complex interaction existed between the various factors affecting the MCID. Indeed, the 
models and interaction terms only explained 20% to 40% of the MCID estimates in the 
final analyses, and not all the observed trends were significant. Therefore, due to the 
inherent complexity, this thesis could not provide a comprehensive answer on the scope 
of the MCID dynamics. A regression to the mean phenomenon could explain this finding, 
but despite being quantified, it was not further integrated in the results. It is unknown 
how to incorporate this in MCID research.
8.6 Clinical implications and suggestions for future 
research
8.6.1 Suggestions for researchers and physicians concerning MCID 
research in general 
The current thesis demonstrated that the MCID is a complex and dynamic parameter 
for which not all details could be fully explained or clarified. For general MCID 
measurement, a set of evidence-based recommendations was developed to guide 
researchers on how to determine an instrument’s MCID with greater scientific rigor 
(Box 2). Future instruments will benefit from incorporating these guidelines in MCID 
determination processes. The recommendations can be applied to many different 
(physiological) tests and tools, not specifically those limited to health status, having 
potential utility with any measurement outcome used to interpret treatment effects. It 
is highly recommended that these guidelines are integrated into future MCID research. 
Moreover, it is important to evaluate the level to which they are applicable and whether 
they hold firm for instruments used with chronic diseases other than COPD. It is especially 
interesting to understand the dynamics of the MCID model better. This will help with the 
interpretation of more tailored, clustered or even individual change scores that are of 
more use to physicians in clinical practice. If the recommendations from this thesis do 
not hold firm, they should be adapted to each setting, which may be facilitated by a 
consensus meeting of experts.
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An important consideration that arose from our findings and recommendations for 
MCIDs was that many existing questionnaires, PROs and physiological parameters may 
benefit from researchers re-evaluating their currently applied MCIDs and techniques 
used to obtain them. Gaps in the body of evidence should be noted, and where possible, 
filled with evidence from new studies based on the recommendations set out in Box 2. 
Clinical trials should incorporate relevant anchors to be able to determine anchor- and 
distribution-based MCIDs on a large scale with evidence from multiple settings and 
populations. There can be no excuse for the continued use of insufficiently founded 
MCIDs when interpreting treatment outcomes in the future.
8.6.2 Suggestions for researchers and physicians concerning COPD 
research
The current thesis should by no means be considered the end of the evaluation process 
for the MCIDs of health status tools for patients with COPD. Many of the outcomes of this 
thesis were based on first time thorough research into the dynamics of this parameter. 
The results need to be either confirmed or refuted in clinical replication studies, 
potentially building on the limited number and methodological quality of existing 
research. Incorporating relevant anchors in clinical trials from multiple settings and 
samples would enable to investigate MCIDs in COPD health status at a large scale with 
anchor- and distribution-based methods. This is especially true when defining the MCIDs 
for deterioration, moderate clinically important changes and large clinically important 
changes. It is also relevant to discover the full dynamics of the MCIDs for health status 
tools for COPD. Despite having now taken the first steps towards validating these 
thresholds, more evidence should be collected to determine whether the MCIDs for the 
domain scores of the CCQ and SGRQ are indeed similar to the overall patterns observed 
for the MCID. 
There is also a need to confirm whether the differences observed between the MCIDs 
for the PR and RCP settings are applicable to other interventions too, not least because 
these differences were not confirmed by the systematic review in Chapter 3 [43]. Based 
on the outcomes, of this systematic review, it could be argued that MCIDs for different 
interventions may expected to be similar and not just context-specific to PR only. One 
may also wonder why MCIDs for various interventions would need to differ. Should 
thresholds for minimal clinically important change be lower if the effect of outcomes 
of a specific intervention are expected to be less than in PR? It would make more sense 
to argue that patient characteristics and baseline severity would have more impact 
on the value of the required MCID threshold than a specific setting or intervention. This 
would be expected because patient characteristics and baseline severity seem highly 
correlated with the type of a specific context or setting. 
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An important implication of this thesis is that current COPD treatment guidelines may 
be grounded on MCIDs of questionable robustness. The MCIDs of the SGRQ (4 points) 
and the CRQ (0.5 points) have played especially large roles in studies of pharmaceutical 
and other medical interventions. However, these MCID estimates appear to have been 
inadequately researched, with evidence that for the SGRQ one should use higher 
thresholds than are appropriate, especially when used to assess interventions or change 
directly after therapy. As such, any research based on its MCID over recent decades 
may have overestimated the clinical trial effects. The currently used MCIDs should be 
higher for both improvement and deterioration, raising two important questions: (1) 
Would this mean that most of the scientific evidence, currently integrated in treatment 
guidelines, is invalid and should not have been approved for patients? (2) Does the basis 
for certain therapies and treatment regimens remain solid? Patients in clinical practice 
seem to respond to treatments based on the traditional health status MCIDs; if not, 
they may have stopped using a given medication or have stopped participation in an 
intervention. Future research should systematically review the validity of current evidence 
and thresholds for MCIDs. Consensus should be reached between COPD experts on how 
to handle this and on the extent to which treatment guidelines are affected.
A more dynamic framework for evaluating treatment effects by the MCID was proposed 
for the CAT, CCQ and SGRQ (Table 2, Figure 4). This could serve not only as a guideline 
for use in COPD research, but also as an example of appropriate MCID development in 
other chronic disease research. The dynamic framework requires more flexibility from 
scientists in research and physicians in clinical practice, but benefits from integrating 
both the point estimate and its 95%CI as an outcome of a clinical trial. This modified 
approach also benefits from (more individual) assessment by shifting up or down 
categories based on differences in setting, follow-up period, baseline severity (including 
extreme groupings) and patient characteristics. One should, however, be cautious for 
an overly flexible interpretation of treatment effects. It is important to discuss the criteria 
that need to be considered in this dynamic framework, and further research should seek 
to confirm or refute the purported benefits of the framework. Validating the proposed 
dynamic MCID framework in scientific trials and clinical practice is highly recommended 
to confirm or falsify this thesis’ findings. 
Given that the MCIDs for the traditional SGRQ and CRQ health status tools were less firm 
than those for the CAT and CCQ, it would be argued that these latter instruments should 
be used in future research and clinical practice; and it is promising to see that trials are 
increasingly doing so when evaluating outcomes. Based on the findings of this thesis, their 
MCIDs for deterioration could now be applied, and due to the differing MCID dynamics, 
it may even be appropriate to suggest that clinical trials should integrate more than one 
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health status tool when evaluating outcomes. Irrespective of the route chosen, it appears 
that the currently accepted thresholds for clinically relevant change measured by the SGRQ 
and CRQ need to be applied more carefully. Moreover, there is definitely no justification for 
using the MCIDs of other health status instruments for COPD, because existing evidence is of 
poor quality and/or quantity (Chapter 3 [43]).
A final important implication is that frequently applied MCIDs for physiological para- 
meters may now need to be re-evaluated according to this thesis’ recommendations 
(Box 2). These include the forced expiratory volume in one second (FEV
1
), six minute walking 
distance (6MWD) and exacerbations. Currently, these physiological MCIDs are also used 
as obligatory primary outcome parameters when interpreting observed changes in 
scientific trials and clinical practice, but questions may now exist over how their MCIDs were 
determined. This was beyond the scope of this thesis and must be investigated further.
8.6.3 Suggestions for physicians in clinical practice
In clinical practice, physicians require tests and tools that can help to interpret the effects 
of therapy in individual patients. Today, PROs are integrated into many consultations 
along with history taking and physical examination, but physicians require guidance on 
how to interpret the observed changes on PROs (e.g., whether an observed difference in 
an item score represents a real change or just random variation). Unfortunately, there 
is no straight forward answer for the physician due to the large individual variation of 
the patients. MCIDs are defined at the group level. The proposed dynamic framework for 
MCID interpretation (Table 2, Figure 4) offers a reasonable starting point to aid individual 
interpretation of changes observed, also for clinical practice. The interpretation using 
this framework could be tailored to specific patient characteristics, contexts and/or 
baseline (health status) severities by requiring a more or less firm categorisation of the 
changes observed. Personality, comorbidities and spirometry severity could perhaps 
be incorporated too. Validating this framework at the individual patient level would be 
highly recommended. Based on a recent study evaluating expert opinions on the MCID 
of the SGRQ, thresholds for minimal clinically important change would even need to 
exceed 10 points for individual patients [121]. This would suggest that for an individual 
interpretation of change scores, the classification of patients on the dynamic MCID 
framework would need to be more strict.  
It would perhaps even be worthwhile to develop the dynamic aspects of the MCID 
into a formula (score) that facilitates the change assessments in both primary and 
secondary care. To develop a more tailored MCID formula, one would need to confirm 
or refute the trends observed in Chapter 7 of this thesis [80]. These concerned the impact 
of the various patient-, disease- and context-related factors on the MCID. Ideally a 
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large database of clinical trial data should be combined with clinical event data and 
patient- or clinician-assessed GRC anchors. In this way, MCIDs can be determined and 
developed into formulas for tailored evaluation of individual change scores. This would 
need to originate from international collaboration and should include data on patient 
characteristics, setting, intervention, clinical events and measurement period, as well as 
a rating of the clinical importance of the observed change.
Finally, it is important for physicians in clinical practice to remain aware of how MCIDs 
play a role in interpreting treatment outcomes and approving new therapies. They need 
to be alerted to this, especially when reading and evaluating national and international 
treatment guidelines. Understanding the dynamics of the MCID concept is therefore crucial 
if physicians are to remain critical when interpreting literature and guidelines.
8.7 Final conclusions
The MCID is a complex parameter that is key to the interpretation of treatment 
outcomes. Although its dynamics have not been fully explored, there are few alternatives 
for evaluating and interpreting therapy effects. As such, the MCID remains of vital 
importance, but it should also be treated with caution. Current practices use MCIDs as 
static and fixed thresholds that lack the flexibility to deal with the existing limitations. 
Therefore, a framework was suggested in this thesis to facilitate the dynamic and 
flexible interpretation of observed changes in patients with COPD. Coupled with this, 
general recommendations were presented to guide a more evidence-based approach 
to determining an instrument’s MCID. Developing an instrument’s MCID requires that a 
structural and uniform approach be adopted, and one must certainly endeavour to 
protect against this process continuing to be taken for granted. Failure to do so could 
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0.5SD Half standard deviation
6MWD Six minute walking distance
95%CI 95% confidence interval
A Activity score on the SGRQ
ACOS Asthma COPD overlap syndrome
AECOPD Acute exacerbation chronic obstructive pulmonary disease
AQ Airway Questionnaire
ATS American Thoracic Society
AUC Area under the curve
BDI Baseline Dyspnoea Index
BCSS Breathlessness Cough and Sputum Scale
BLVR Bronchoscopic lung volume reduction
BMI Body mass index
BPQ Breathing Problems Questionnaire
BTS British Thoracic Society
CAL Chronic airflow limitation
CAT COPD Assessment Test
CCQ Clinical COPD Questionnaire
CDLM Capacity of Daily Living during the Morning Questionnaire
CI Confidence interval 
CID Clinically important difference
COPD Chronic obstructive pulmonary disease
COPD-SIB COPD Specific Item Bank
CRQ Chronic Respiratory Questionnaire
CSD Cough Severity Diary
D Dyspnoea score on the CRQ
DALY Disability adjusted life year
DartmCoop Dartmouth Northern New England Primary Care Cooperative Information Project chart system
DMQ-CAT Dyspnoea Questionnaire Computer Adaptive Test
E Emotion score on the CRQ
ED Emergency department
EQ-5D EuroQol-5D
EQ-5D-3L-UI EuroQol 5 Dimensions 3 Levels Utility Index
EQ-5D-3L-VAS EuroQol 5 Dimensions 3 Levels Visual Analogue Scale
EQ-5D-5L-UI EuroQol 5 Dimensions 5 Levels Utility Index
EQ-5D-5L-VAS EuroQol 5 Dimensions 5 Levels Visual Analogue Scale
ERS European Respiratory Society
ES Effect size
EU European Union
F Functional score on the CCQ or fatigue score on the CRQ
FDR False discovery rate
FEV
1
Forced expiratory volume in one second
FEV
1
%pred Forced expiratory volume in one second percentage predicted
FT Feeling Thermometer
FVC Forced vital capacity
GIC Global impression of change




GOLD Global initiative for obstructive lung disease
GRC Global rating of change
GRIAC Groningen research institute for asthma and COPD
GRIAC-PC Groningen research Institute for asthma and COPD primary care group
GCSQ Global Chest Symptoms Questionnaire
HRQoL Health-related quality of life
HS-COPD Health States COPD
I Impact score on the SGRQ
ICC Intraclass correlation coefficient
IMT Inspiratory muscle training
IQR Inter quartile range
JSM Junior Scientific Masterclass
LAS/VAS Linear Analogue Scale/Visual Analogue Scale
LCOPD Living with COPD Questionnaire
LCADL London Chest Activity of Daily Living Questionnaire
LCQ Leicester Cough Questionnaire
LTOT Long-term oxygen therapy
M Mental score on the CCQ or mastery score on the CRQ
MCD Minimal clinical difference
MCID Minimal clinically important difference
MCSD Minimal clinically significant difference
MDC Minimum detectable change
MDC95 Minimal detectable change 95%
MDD Minimally detectable difference
MIC Minimally important change
MID Minimum important difference
mMRC Modified Medical Research Council Dyspnoea Scale
MPD Minimally perceptible difference
MRF-28 Maugeri Respiratory Failure 28 items
MYMOP Measure Yourself Medical Outcome Profile
N Number of patients
NA Not applicable
NHG Nederlands Huisartsen Genootschap
NHP Nottingham Health Profile
NR Not reported
NS Not significant
OSAS Obstructive sleep apnoea syndrome
PFSDQ Pulmonary Functional Status and Dyspnoea Questionnaire
PFSS Pulmonary Functional Status Scale
PR Pulmonary rehabilitation
PRISMA Preferred reporting items for systematic reviews and meta-analyses
PRO Patient-reported outcomes
QoL Quality of life
QOLRIQ Quality of Life for Respiratory Illness Questionnaire 
QWBSA Quality of Well Being Self-Administered
R Range
R2 Proportion of the variance of the dependent factor explained by independent factors
RCI Reliability of change index
RCP Routine clinical practice
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RCT Randomised controlled clinical trial
ROC Receiver operating characteristics 
RIMTCORE Routine inspiratory muscle training within COPD rehabilitation 
RQLQ Respiratory Quality of Life Questionnaire
RV Residual volume
S Symptoms score on the CCQ or SGRQ
SBOH Employer of general practitioner trainees
SD Standard deviation
SDD Smallest detectable difference
SEM Standard error of measurement
Sens Sensitivity
SF-6D Short-Form 6 Dimensions
SF-12 Short-Form-12
SF-36 Short-Form-36
SF-CRQ Short-Form Chronic Respiratory Questionnaire
SGRQ St. George’s Respiratory Questionnaire
SIP Sickness Impact Profile
SMD Standardised mean difference
SOBDA Shortness of Breath with Daily Activities Questionnaire
Spec Specificity
SRI Severe Respiratory Insufficiency Questionnaire
SRM Standardised response mean
SSD Subjectively significant difference
SWT Shuttle walking test
T Total score on the CCQ, CRQ or SGRQ
T0 Time-point 0: Baseline measurement
T1 Time-point 1: Post-rehabilitation at 3 weeks
T2 Time-point 2: 3-months follow-up
T3 Time-point 3: 6-months follow-up
T4 Time-point 4: 9-months follow-up
T5 Time-point 5: 12-months follow-up
TDI Transition Dyspnoea Index
TR Transition rating
UCSD-SOBQ University of California San Diego Shortness of Breath Questionnaire
UI Utility Index
UK United Kingdom
UMCG University Medical Center Groningen
USA United States of America
VAS Visual Analogue Scale
VSRQ Visual Simplified Respiratory Questionnaire
WHOQOLBREF World Health Organisation Quality of Life short version list
WPAI-COPD Work Productivity and Activity Impairment Questionnaire











10.1.1 Achtergrond en doelstellingen
De arts en wetenschapper kunnen diverse medische onderzoeken uitvoeren, zoals het 
meten van de bloeddruk, bloedprikken en een blaastest voor de longen. Deze lichamelijke 
testen zeggen echter weinig over de door de patiënt ervaren kwaliteit van leven. Deze 
kwaliteit van leven wordt vaak niet bepaald door lichamelijke afwijkingen, maar door 
de combinatie van ervaren symptomen, invloed op het leven en beperkingen door een 
ziekte. Dit wordt ook wel iemands gezondheidsstatus genoemd. Er bestaan heel veel 
vragenlijsten om gezondheidsstatus te meten. Voor elke test of vragenlijst geldt in ieder 
geval dat er bepaald moet kunnen worden: a) wanneer een patiënt zich daadwerkelijk 
beter of slechter voelt na een behandeling, en b) welke verandering in de score daarbij 
hoort. Soms is de gemeten verandering namelijk onvoldoende belangrijk voor de 
patiënt. Dit zijn dan de normale schommelingen in de testuitslag. Net zoals dat iemand 
de ene dag meer kan wegen dan de andere, zonder dat iemand echt is afgevallen 
of aangekomen. De veranderscore, die wel past bij een echte ervaren verbetering of 
verslechtering, noemen we de drempelwaarde voor klinisch relevante verandering. In 
het Engels wordt dit de minimal clinically important difference genoemd. De afkorting 
hiervoor is MCID. 
In dit proefschrift hebben de onderzoekers de MCID’s van meerdere vragenlijsten opnieuw 
berekend, met elkaar vergeleken en gekeken welke factoren daarop van invloed waren. 
Het onderzoek is specifiek uitgevoerd bij mensen met de longziekte chronic obstructive 
pulmonary disease (COPD) met de drie belangrijkste vragenlijsten om gezondheidsstatus 
bij die ziekte te meten. De namen van deze drie vragenlijsten zijn de COPD Assessment Test 
(CAT), Clinical COPD Questionnaire (CCQ) en St. George’s Respiratory Questionnaire (SGRQ). 
Bij mensen met de longziekte COPD zien we dat deze vragenlijsten veel worden gebruikt 
door de arts, en ook verplicht zijn binnen het wetenschappelijke onderzoek.
10.1.2 Belangrijkste bevindingen
In dit proefschrift werden gegevens verzameld vanuit drie verschillende onderzoeken: (1) 
een analyse van de studies, die door anderen al gedaan zijn (een literatuuronderzoek); 
(2) een studie bij mensen met COPD in een Duitse longrevalidatiekliniek; en (3) een 
vragenlijstonderzoek bij mensen met COPD onder behandeling bij de huisarts en/of 
longarts in Nederland. 
Allereerst, uit het literatuuronderzoek kwam naar voren dat er voor 12 verschillende 
vragenlijsten voor mensen met COPD al MCID’s zijn bepaald. De kwaliteit van deze 




St. George’s Respiratory Questionnaire was niet goed bepaald. Grofweg is de drempel-
waarde voor klinisch relevante verandering (een MCID) 7 tot 10% op de totaalscore 
van een vragenlijst. Dit proefschrift laat dan ook zien dat de in de literatuur algemeen 
erkende MCID van de meest gebruikte vragenlijst - de SGRQ - 7 punten is op een schaal 
van maximaal 100 punten. Dit in plaats van de algemeen aangenomen waarde van 4 
punten. De gemeten MCID’s van de CCQ (0.40-0.50) en CAT (2-3) komen min of meer 
overeen met de in de literatuur gevonden waarden. Aangezien de effecten van veel 
medicijnen en behandelingen voor mensen met de longziekte COPD voornamelijk zijn 
gemeten met de SGRQ en de hierbij aangenomen drempelwaarde (MCID) van 4 punten 
in plaats van 7 punten, wordt de invloed van deze behandelingen op de kwaliteit van 
leven van de patiënt systematisch overschat. Met andere woorden, geneesmiddelen en 
behandelingen lijken effectief op basis van die vragenlijst, maar zijn dit wellicht toch niet. 
Ten tweede, in de Duitse longrevalidatiestudie en in het Nederlandse vragenlijst-
onderzoek, zagen de onderzoekers dat er een heleboel verschillende methodieken 
gebruikt kunnen worden om een MCID te berekenen. Er werden dan ook kleine 
verschillen gevonden tussen de resultaten van de gebruikte methodieken (Hoofdstuk 4). 
De onderzoekers zagen ook enkele kleine verschillen in de vragenlijst MCID’s, wanneer 
ze deze berekenden gedurende verschillende periodes van verandering (Hoofdstuk 5). 
De meetperiodes varieerden daarbij van drie weken tot een jaar. Ondanks de kleine 
verschillen, bleken de vragenlijst MCID’s voor mensen met een verbetering in de 
gezondheidsstatus, redelijk goed vergelijkbaar met de MCID’s voor mensen met een 
ervaren verslechtering in de gezondheidsstatus (Hoofdstuk 6). 
Ten derde, de onderzoekers beoordeelden verschillende factoren, die van invloed 
waren op de waarde van een MCID. Er werd ontdekt dat MCID’s voor mensen met 
de longziekte COPD in de Duitse longrevalidatiestudie veel hoger waren dan voor de 
Nederlandse patiënten bij de huisarts en de longarts (Hoofdstuk 7). Daarnaast werd een 
grotere verbetering in gezondheidsstatus (een hogere MCID) gezien bij deelnemers, die 
al veel klachten en beperkingen hadden aan het begin van het onderzoek, en die zich 
daadwerkelijk beter voelden na beide studies. Dat was ook zo voor vrouwen, deelnemers 
ouder dan 60 jaar, patiënten met een goede longfunctie, en mensen met minder 
andere bijkomende ziektes. Echter, deze deelnemers hadden juist weinig aanvullende 
verslechtering in gezondheidsstatus nodig (een lagere MCID) om zich daadwerkelijk 
slechter te voelen. De MCID’s van de drie COPD vragenlijsten in dit proefschrift konden niet 




Het is goed om te beseffen dat MCID’s voor gezondheidsstatusvragenlijsten een 
verplichte ondergrens zijn voor de goedkeuring en evaluatie van nieuwe medicijnen 
en andere behandelingen. Het is daarom dan ook erg belangrijk dat er goede MCID’s 
voor testen en vragenlijsten worden berekend. Het zou ook waardevol kunnen zijn om 
verschillende MCID’s in de praktijk te gebruiken voor mensen met de longziekte COPD 
op basis van hun eigenschappen en de onderzoekssituatie. Op die manier kan er een 
meer individueel oordeel worden gegeven aan de gemeten verandering. In de discussie 
van dit proefschrift presenteren de onderzoekers een dynamisch model voor het gebruik 
van de MCID’s van de drie belangrijkste COPD vragenlijsten. Ook worden aanbevelingen 
gedaan hoe andere onderzoekers en artsen goede MCID’s kunnen bepalen voor hun 
(nieuwe) vragenlijsten en medische testen. 
10.2 Academische samenvatting
10.2.1 Achtergrond en doelstellingen proefschrift
De primaire doelstelling van dit proefschrift was om meer inzicht te verkrijgen in de 
dynamiek van de belangrijke internationale parameter minimal clinically important 
difference (MCID) voor vragenlijsten op het gebied van gezondheid-gerelateerde kwaliteit 
van leven (ook wel gezondheidsstatus) van patiënten met de chronische longziekte chronic 
obstructive pulmonary disease (COPD). Het bepalen van gezondheidsstatus behelst een 
gestandaardiseerde manier om de impact van ziekte en gezondheid te meten op het welzijn 
van de patiënt in het dagelijks leven. Uit eerder wetenschappelijk onderzoek is gebleken 
dat bekende fysiologische uitkomstmaten, zoals bloedonderzoek en diagnostische 
testen, slechts beperkt correleren met de door de patiënt ervaren symptomen, functionele 
mogelijkheden en kwaliteit van leven. Dit is met name actueel voor patiënten met een 
(progressieve) chronische ziekte, zoals COPD. Gedurende de afgelopen decennia zijn er dan 
ook diverse instrumenten ontwikkeld om gezondheidsstatus te meten (Hoofdstuk 1 en 2). 
COPD is wereldwijd één van de meest frequent voorkomende aandoeningen, gekenmerkt 
door een diversiteit aan luchtwegklachten zoals dyspneu, hoesten en overmatige 
slijmvorming. Deze symptomen worden veroorzaakt door een chronische ontsteking 
van de luchtwegen, resulterend in onomkeerbare schade. Voor patiënten met de 
longziekte COPD zijn de belangrijkste gevalideerde gezondheidsstatusvragenlijsten 
de COPD Assessment Test (CAT, 8 vragen, 1 domein, score 0-40 punten), de Clinical 
COPD Questionnaire (CCQ, 10 vragen, 3 domeinen, score 0-6 punten) en de St. George’s 
Respiratory Questionnaire (SGRQ, 50 vragen, 3 domeinen, score 0-100 punten). Voor deze 




patiënt (Hoofdstuk 2). Een negatieve veranderscore representeert daarmee dan ook een 
verbetering. 
Gezondheidsstatusvragenlijsten zijn tegenwoordig een verplichte uitkomstmaat in 
wetenschappelijke studies en worden frequent toegepast in de klinische praktijk. 
Belangrijk voor welke uitkomstmaat dan ook is dat deze geïnterpreteerd moet kunnen 
worden door de arts en onderzoeker. Hierbij geldt dat er ten aanzien van de gemeten 
verandering na een behandeling onderscheid gemaakt moet worden tussen toevallige 
verandering (ruis) en daadwerkelijk relevante verandering (signaal). Een MCID kan hier 
tussen differentiëren. De parameter is in de jaren `90 geïntroduceerd als de minimale 
drempelwaarde waarbij de gemeten verandering na therapie als klinische relevant 
kan worden beschouwd voor de patiënt. Dit rechtvaardigt het succes van de gekozen 
behandeling. Sinds de ontwikkeling van het concept, wordt de MCID van een instrument 
frequent toegepast in wetenschappelijke studies om de gemeten veranderingen te 
evalueren en te interpreteren (Hoofdstuk 1). 
Tot op heden is er nog weinig duidelijkheid omtrent de diverse dynamische factoren, die 
mogelijk van invloed zijn op de hoogte van een MCID. Zo zijn er onduidelijkheden omtrent 
welke methodologie (anker-gebaseerde, statistische of opinie-gebaseerde technieken) 
gebruikt dient te worden voor het bepalen van de MCID van een instrument. Daarnaast 
is het onduidelijk in hoeverre de duur van de periode voor het meten van de verandering 
(de zogeheten follow-up periode) van invloed is op de MCID. Factoren zoals recall bias 
(moeite met het herinneren van de vorige gezondheidsstatus ter vergelijking) en response 
shift (een verandering in de interpretatie van de gezondheidsstatus) zouden hierbij van 
invloed kunnen zijn. Ten derde is het onduidelijk of MCID’s voor verbetering vergelijkbaar 
zijn met die voor de interpretatie van verslechtering in gezondheidsstatus. Tot slot, is er 
maar weinig bekend in hoeverre context- en patiënt-gerelateerde factoren van invloed 
zouden kunnen zijn op de MCID van een instrument (Hoofdstuk 1). Dit proefschrift geeft 
meer inzicht in deze aspecten.
In dit proefschrift worden in de analyses data gebruikt uit drie studies. Het betreft 
(1) een systematisch literatuuronderzoek en meta-analyse omtrent de MCID van 
gezondheidsstatusvragenlijsten voor patiënten met COPD; (2) een gerandomiseerde 
klinische studie naar de effectiviteit van additionele ademhalingstherapie (zogeheten 
inspiratory muscle training (IMT)) tijdens drie weken longrevalidatie van 451 COPD 
patiënten in Duitsland; en (3) een observationele studie met 207 Nederlandse COPD 
patiënten in de reguliere eerste- en tweedelijns zorg gedurende 12 maanden zonder 




De huidige gebruikte MCID’s zijn voor de CAT 2 punten, voor de CCQ 0.40 punten en voor 
de SGRQ 4 punten. In het systematische literatuuronderzoek in de databases PubMed, 
EMBASE en de Cochrane Library werden vanuit 785 artikelen uiteindelijk 21 publicaties 
geïdentificeerd over de MCID van 12 verschillende gezondheidsstatusvragenlijsten voor 
patiënten met COPD (Hoofstuk 3). Op basis van de meta-analyse waren de gewogen 
MCID’s voor verbetering als volgt: -2.54 voor de CAT (6 publicaties, bereik -3.80 tot 
-1.00), -0.43 voor de CCQ (5 publicaties, bereik -0.62 tot -0.21), en -7.43 voor de SGRQ 
(4 publicaties, bereik -10.19 tot -2.40) (Hoofdstuk 8, Tabel 1, Figuren 1-3). Voor de andere 
9 instrumenten waren de geïncludeerde publicaties te heterogeen of te weinig in 
aantal. Er werden geen duidelijke patronen waargenomen voor een eventuele invloed 
van studie, context en duur van de follow-up periode van de geïncludeerde studies op 
de hoogte van de MCID. Het bewijs voor de MCID’s van de CAT en CCQ bleek sterk en 
de gewogen schattingen werden beoordeeld als valide. De momenteel in de praktijk 
toegepaste MCID voor de SGRQ (4 punten), maar ook die van een andere vragenlijst, 
de Chronic Respiratory Questionnaire (CRQ, 0.50 punten), kwamen slecht overeen 
met de onderzochte inhoud. Deze MCID’s bleken in werkelijkheid veel hoger te zijn. De 
toepassing van een te lage MCID als drempelwaarde, kan leiden tot een overschatting 
van de interpretatie van de effecten van behandelingen voor patiënten met COPD in 
wetenschappelijke studies en de dagelijkse praktijk. Tot slot, MCID’s voor verslechtering 
waren schaars en toonden aan dat daar meer onderzoek voor nodig is. 
Op basis van de geanalyseerde data van de 451 COPD patiënten tijdens het 
longrevalidatietraject in Duitsland (gemiddelde leeftijd 58 jaar, 65% man) konden 
diverse methoden vergeleken worden voor de bepaling van de MCID van de CAT, CCQ en 
SGRQ (Hoofstuk 4). Ook werden de MCID’s voor de domeinscores van de CCQ en SGRQ 
voor het eerst beoordeeld. De bepaalde MCID’s verschilden afhankelijk van de gebruikte 
technieken en dit resulteerde in een diversiteit van schattingen (Hoofdstuk 8, Tabel 1, 
Figuren 1-3). De gewogen MCID’s waren -3.28 voor de CAT (bereik -6.43 tot -1.46), -0.52 
voor de CCQ (bereik -0.62 tot -0.28), en -7.91 voor de SGRQ (bereik -10.19 tot -5.20). Over 
het algemeen waren de resultaten vanuit de verschillende anker-gebaseerde technieken 
redelijk vergelijkbaar. De ankers ter referentie betroffen hier (1) een globale schatting van 
de ervaren verandering voor de patiënt; (2) een COPD exacerbatie als criterium voor 
een klinische gebeurtenis; (3) de andere COPD gezondheidsstatusvragenlijsten met de 
huidige gebruikte MCID’s. Een zorgvuldige selectie van ankers ter referentie moet echter 
wel worden overwogen, zeker wanneer diens MCID’s betwist zouden kunnen worden. 
De MCID op basis van de statistische techniek halve standaard deviatie (0.50SD) was 




van de standard error of measurement (SEM) was inconsistent, en de 1.96SEM was zeer 
conservatief voor de CAT en de SGRQ. De MCID’s voor de domeinscores op de CCQ en 
SGRQ waren redelijk vergelijkbaar met de waarden voor de totale vragenlijstscore, met 
uitzondering van de mentale score op de CCQ en de symptoomscore op de SGRQ. De 
meeste MCID schattingen voor de CAT en CCQ waren vergelijkbaar of net iets hoger dan 
de geaccepteerde waarden vanuit de literatuur (respectievelijk 2 en 0.40 punten). Echter, 
de MCID’s voor de SGRQ waren allemaal fors hoger dan de geaccepteerde drempel van 
4 punten. Deze drempel wordt uitgebreid toegepast in de huidige wetenschappelijke 
literatuur. Dit zou kunnen hebben geresulteerd in een overschatting van de interpretatie 
van de gevonden behandeleffecten. Samenvattend, klinisch relevante verbetering 
dient over het algemeen te worden overwogen bij een verandering van 3 punten op de 
CAT, 0.50 punten op de CCQ en 7 punten op de SGRQ. Deze voorgestelde drempels zijn 
grofweg 7% van de maximale totaalscore.
Gegevens van de longrevalidatiepatiënten in Duitsland werden ook gebruikt om te 
bepalen of de MCID’s van de CAT, CCQ en SGRQ verschilden wanneer deze bepaald 
werden direct na de interventie en tijdens verschillende follow-up periodes ten gevolge 
van eventuele recall bias (Hoofdstuk 5). Van de 451 patiënten, voltooiden 309 patiënten 
de gehele follow-up na 1 jaar. Als anker-gebaseerde techniek werden een ankervraag 
(global rating of change) gebruikt met 15 antwoordopties en één met 5 antwoordopties, 
waarbij de patiënt werd gevraagd om retrospectief te beoordelen hoe de huidige 
gezondheidsstatus was in vergelijking tot het begin van de interventie. Globaal gezien 
werden er geen significante verschillen gevonden tussen de MCID schattingen voor 
verbetering na een follow-up periode van 3 weken, en 3, 6, 9 en 12 maanden bij gebruik 
van de ankervraag met 15 antwoordopties. De MCID’s voor verbetering varieerden 
van -3.1 tot -2.3 voor de CAT; -0.6 tot -0.4 voor de CCQ; en -10.3 tot -7.6 voor de SGRQ 
(Hoofdstuk 8, Tabel 1, Figuren 1-3). Hogere (niet-significante) MCID’s werden waargenomen 
voor de CAT en CCQ met een follow-up periode van 3 weken direct na afronding van het 
longrevalidatietraject. De waarde van de MCID van een instrument kan mogelijk dus 
hoger uitvallen, wanneer deze bepaald wordt direct na een interventie met een kortere 
follow-up periode. 
Echter, het gebruik van een ankervraag met slechts 5 antwoordopties resulteerde wel in 
significant lagere MCID’s voor de CAT en CCQ na 12 maanden follow-up in vergelijking 
tot de ankervraag met 15 antwoordopties (Hoofdstuk 5). De MCID schattingen op basis 
van deze alternatieve ankervraag waren -1.4 voor de CAT (significant verschil -1.4), -0.3 
voor de CCQ (significant verschil -0.2), en -7.7 voor de SGRQ (niet-significant verschil -1.1) 
(Hoofdstuk 8, Tabel 1, Figuren 1-3). De classificatie van de geïncludeerde patiënten volgens 
beide ankervragen kwam voor 55% overeen. Kennelijk resulteerde het hebben van minder 
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antwoordopties op een ankervraag in een lagere MCID. Minder antwoordopties zou 
kunnen leiden tot verlies van belangrijke informatie en een verminderd discriminerend 
vermogen van de schaal. 
In Hoofdstuk 6 werden data van de beide klinische studies in Duitsland en Nederland gebruikt 
om te beoordelen in hoeverre MCID’s voor verbetering in gezondheidsstatusvragenlijsten 
vergelijkbaar waren met die voor verslechtering. Het voorkomen van verslechtering bij 
een progressieve en chronische aandoening zoals COPD, kan een belangrijk resultaat 
van behandeling zijn. Hiertoe is het noodzakelijk klinisch relevante verslechtering van 
willekeurige variaties (ruis) te onderscheiden. Het systematische literatuuronderzoek 
(Hoofdstuk 3) toonde aan dat MCID’s voor verslechtering niet bekend zijn voor de CAT, 
CCQ en SGRQ. Op dit moment worden diens MCID’s voor verbetering simpelweg ook 
toegepast voor de interpretatie van verslechtering. Bij de beoordeling van de data van 
451 COPD patiënten tijdens hun longrevalidatie en 207 COPD patiënten in de reguliere 
medische zorg, bleek dat de anker-gebaseerde en statistisch-gebaseerde MCID’s voor 
verbetering en verslechtering redelijk overeen kwamen. De MCID schattingen verschilden 
wel tussen de Duitse longrevalidatiegroep en de patiënten zonder aanvullende 
interventie in de reguliere Nederlandse medische zorg. 
Op basis van de huidige data gedurende diverse follow-up momenten, werden de 
volgende drempelwaarden gevonden voor minimale relevante verbetering dan wel 
verslechtering: CAT≥3 (interventie) en CAT≥2 (reguliere medische zorg); CCQ ≥0,40 
(interventie) en CCQ≥0,30 (reguliere medische zorg), SGRQ≥6 (interventie) en SGRQ ≥5 
(reguliere medische zorg) (Hoofdstuk 6, Hoofdstuk 8, Tabel 1, Figuren 1-3). De gevonden 
MCID schattingen voor de CAT en CCQ kwamen goed overeen met eerdere resultaten 
vanuit de literatuur. De MCID schattingen voor de SGRQ vanuit de longrevalidatiegroep 
waren wederom fors hoger dan de voorgestelde en toegepaste drempel van 4 punten 
in de literatuur. De MCID schattingen voor COPD patiënten gedurende de reguliere 
medische zorg waren deels vergelijkbaar met deze drempelwaarde van 4 punten op de 
SGRQ. Daarnaast zouden mogelijk de afkappunten voor middelmatige en grote klinisch 
relevante verandering kunnen liggen in het bereik van respectievelijk 4-5 en 5-6 punten 
op de CAT; 0.80 en 1.00 punten op de CCQ; en 10-15 en 15-20 punten op de SGRQ. Meer 
onderzoek hiernaar is echter noodzakelijk, gezien de kleine hoeveelheid patiënten met 
een dergelijke grote verandering. 
Tot slot werd in dit proefschrift onderzocht in hoeverre patiënt-gerelateerde factoren, 
onderzoekssituatie en de ernst van het beginniveau van de gezondheidsstatus van 
invloed waren op de hoogte van de MCID van de drie gezondheidsstatusvragenlijsten 




longrevalidatie of reguliere medische zorg werden retrospectief geanalyseerd (2299 
veranderscores) met behulp van anker-gebaseerde en statistische methodieken. De 
meeste MCID schattingen voor verbetering en verslechtering lagen voor de CAT tussen 
de ±1.50 en ±3.50; voor de CCQ tussen de ±0.30 en ±0.60; en voor de SGRQ tussen de 4 en 
9 punten (Hoofdstuk 8, Tabel 1, Figuren 1-3). Vanuit de subgroepanalyses werden diverse 
trends gezien. De drempelwaardes voor klinisch relevante verandering waren significant 
hoger voor de interventiegroep in vergelijking tot de reguliere medische zorg patiënten. 
Daarnaast waren de MCID’s voor verbetering op de CAT, CCQ en SGRQ significant drie- tot 
zevenmaal hoger voor patiënten met vanaf het begin een slechtere gezondheidsstatus; 
echter de MCID’s voor verslechtering waren vier- tot zesmaal kleiner in vergelijking tot 
de groep patiënten met een betere gezondheidsstatus. Vrouwen, patiënten ouder 
dan 60 jaar, patiënten met een betere longfunctie (GOLD categorie I-II), en patiënten 
met minder comorbiditeiten hadden (niet-significante) hogere MCID schattingen voor 
verbetering. Zij hadden daarentegen kleinere MCID’s voor verslechtering in vergelijking 
tot hun counter-groep. 
Multipele lineaire regressiemodellen toonden dat de ernst van het beginniveau van de 
gezondheidsstatus en de onderzoekssituatie belangrijke significante onafhankelijke 
factoren waren voor de hoogte van de MCID. Er werden echter complexe interacties 
waargenomen tussen de diverse variabelen en mogelijk ook invloed van het regressie naar 
het gemiddelde fenomeen. De verklaarde variantie van de modellen was laag. Hoewel 
de MCID op dit moment gezien wordt als een statische parameter voor de interpretatie 
van behandeleffecten, speelt een complexe interactie van setting, niveau van de 
gezondheidsstatus en patiëntfactoren een rol in de uitkomstwaarde. Indien een individuele 
interpretatie van verandering wenselijk is in het wetenschappelijke onderzoek of in de 
klinische praktijk, zou men baat kunnen hebben bij geclusterde of zelfs gepersonaliseerde 
MCID’s gebaseerd op de diversiteit aan dynamische factoren. Hiertoe is nader onderzoek 
wenselijk met grote aantallen patiënten uit verschillende populaties. 
10.2.3 Discussie en conclusie
Op basis van bovenstaande resultaten werden alle MCID’s geschat voor de CAT tussen de 
-6.43 en -0.67 voor verbetering, en tussen de 0.50 en 6.30 voor verslechtering. Voor de CCQ 
waren deze schattingen -0.82 tot -0.10 voor verbetering, en 0.19 tot 0.84 voor verslechtering. 
En voor de SGRQ waren deze waardes -12.28 tot -2.40 voor verbetering, en 0.33 tot 12.86 voor 
verslechtering (Hoofdstuk 8, Tabel 1, Figuur 1-3). Echter, de meeste van deze schattingen voor 
verbetering en verslechtering waren tussen de ±2.00 en ±3.50 voor de CAT, en tussen de 
±0.30 en ±0.50 voor de CCQ. Voor de SGRQ waren de meeste MCID’s voor verbetering tussen 
de -9.00 en -6.00, en voor verslechtering tussen de +5.00 en +8.00. 
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De MCID is en blijft een complexe parameter, die cruciaal is voor de interpretatie van 
behandeleffecten. Hoewel in dit proefschrift de dynamiek niet volledig is opgehelderd, zijn 
er weinig alternatieven voor het evalueren en interpreteren van verandering. Als zodanig 
blijft de MCID van vitaal belang, maar moet ook met voorzichtigheid worden behandeld. 
Op dit moment wordt de MCID als statische vaste drempelwaarde gebruikt zonder enige 
flexibiliteit. Daarom wordt in dit proefschrift een model gepresenteerd op basis van de 
diverse schattingen voor de dynamische MCID evaluatie van gezondheidsstatus in patiënten 
met COPD. Hierbij wordt niet alleen gekeken naar de resultaten van een onderzoek en het 
betrouwbaarheidsinterval, maar kan de interpretatie ook verschuiven op basis van de 
onderzoekssituatie en steekproefkenmerken (Hoofdstuk 8, Tabel 2, Figuur 4). 
De bepaling van de MCID van een instrument vereist dat een structurele en uniforme 
aanpak wordt gevolgd en dient niet als vanzelfsprekend te worden beschouwd. Daarom 
worden in dit proefschrift meerdere aanbevelingen gedaan voor de onderzoeker en arts 
om op een gestructureerde manier een MCID te bepalen voor een instrument (Hoofdstuk 
8, Box 2). Hierbij worden drie kwaliteitsniveaus gepresenteerd: brons, zilver en goud. De 
aanbevelingen gelden niet alleen voor de MCID’s van vragenlijsten, maar eigenlijk voor 
elke diagnostische test waarmee een verandering kan worden gemeten. Dit kan zowel 
betrekking hebben op nieuwe als bestaande instrumenten. Wanneer een kwalitatieve 
aanpak niet gevolgd wordt, kan dit leiden tot foutieve MCID’s waarbij er een over- of 
onderschatting volgt van de interpretatie van de uitkomsten van wetenschappelijke 
studies en behandeling in de kliniek.
Tot slot moet er kritisch gekeken worden naar de interpretatie van bestaande 
studieresultaten voor de behandeling van COPD. Dit is noodzakelijk, aangezien de MCID 
van met name de SGRQ hoger zou moeten zijn dan de huidige gebruikte waarde van 
4 punten. Artsen, onderzoekers en instituten voor de beoordeling van geneesmiddelen 
moeten kritisch blijven en zich bewust zijn van de achtergrond van de gebruikte MCID’s 









In 2011 maakte ik voor het eerst kennis met het uitvoeren van wetenschappelijk onderzoek 
binnen de afdeling huisartsgeneeskunde van het UMCG als onderdeel van de Junior 
Scientific Masterclass (JSM) van de Rijksuniversiteit Groningen. Als beginnend student 
geneeskunde mocht ik helpen data te verzamelen binnen het IMI ProActive project. 
Het contact met jullie, Corina en Thys, resulteerde in een stage wetenschap waarin ik 
de basis kon leggen voor mijn promotietraject. Een klein jaar later bood de JSM mij de 
mogelijkheid om mijn onderzoek en het promotietraject daadwerkelijk te starten. Ik wil 
dan ook de JSM hartelijk danken voor de financiering van mijn MD-PhD traject naar de 
minimal clinically important difference (MCID) van gezondheidsstatusvragenlijsten voor 
patiënten met COPD. 
Uiteraard wil ik allereerst mijn promotieteam enorm bedanken voor de samenwerking, 
overleggen, feedback, plezier en kennisoverdracht. Thys, ik weet nog goed dat je destijds 
opperde om iets te gaan doen met de MCID van vragenlijsten bij COPD. Jij stelde voor 
om dat vooral eens tot op de bodem uit te zoeken, want dat was nog niet goed gedaan. 
Op dat moment had ik nog geen flauw idee wat een MCID was, wat voor belang het 
zou dienen en waarom dokters eigenlijk vragenlijsten gebruiken bij patiënten met COPD. 
Inmiddels ben ik overtuigd van de toegevoegde waarde ervan. Heel veel dank Thys, als 
eerste promotor, voor je initiële aanzet tot dit onderzoek. En ook voor jouw kennis en 
netwerk, waardoor het proces uiteindelijk heeft geresulteerd in dit proefschrift. Samen 
hebben we een brede invulling kunnen geven aan het onderwerp met mooie resultaten. 
Jij met name kijkend als huisarts, hoogleraar en pragmaticus; ik misschien iets meer 
theoretisch. Ik heb de samenwerking met jou als zeer prettig, informeel en open ervaren. 
Ik ben trots dat ik als promovendus bij jou heb mogen groeien. Ik wens je veel gezondheid 
en plezier tijdens je welverdiende pensioen samen met Phil, je kinderen en kleinkinderen. 
Robbert, als tweede promotor ben je iets later bij het onderzoek betrokken geraakt. 
Binnen het team behield jij het overzicht van waaruit jij suggesties gaf hoe we iets beter 
konden organiseren, of meer gestructureerd konden opschrijven. Je hield me daarin 
scherp waardoor ik helder kreeg wat de boodschap voor de lezer moest zijn. Ik ben 
ervan overtuigd dat jouw rol de inhoud van dit proefschrift zeer heeft versterkt. De 
samenwerking met jou was prettig en open, met een dosis humor her en der. Dank voor 
jouw leerzame en wijze visie. Ook voor jou veel gezondheid en plezier toegewenst tijdens 
je pensioen samen met je familie. 
Corina, als copromotor was je mijn dagelijkse aanspreekpunt en rots in de branding. 
Bedankt voor jouw frequente en heldere feedback, alsmede jouw begeleiding in alle 
facetten van het onderzoek. Je hebt een praktische instelling, tekstueel welgemeende 




hebben we ook veel gezellige momenten gehad tijdens de diverse reizen en congressen. 
Onze samenwerking was vertrouwd, gezellig en zeker ook serieus. Ik ben ontzettend 
trots dat jij als copromotor het team compleet maakt. We gaan elkaar in de toekomst 
uiteraard nog vaker zien, en ik wens je alle geluk en gezondheid. 
Tot slot, Janwillem, ook al ben je door omstandigheden geen officiële copromotor 
geworden, toch beschouw ik jou wel degelijk zo. Jouw bijdrage aan de inhoud van de 
stukken en onze overleggen waren absoluut van dien aard. Als huisarts en onderzoeker 
was jouw vraag vaak wat de huisarts hier nu mee moest. Zeker op het vlak van de MCID 
is het soms lastig om de praktijk dichtbij te houden. Ook heb je me gestimuleerd om 
de enorme hoeveelheid aan data meer visueel te presenteren. Ik heb bewondering 
voor je enorme diversiteit aan taken en het drukke gezinsleven. Bedankt voor onze 
samenwerking en we komen elkaar in het werkveld zeker nog tegen.
Naast het promotieteam in Nederland, zou het onderzoek beschreven in dit proefschrift, 
nooit mogelijk zijn geweest zonder de samenwerking met de medewerkers van de 
Klinik Bad Reichenhall, Center for Rehabilitation, Pulmonology and Orthopedics 
in Duitsland. In een gerandomiseerd onderzoek naar de werking van additionele 
ademhalingsoefeningen tijdens de longrevalidatie werden in grote getalen vragenlijsten 
afgenomen. Thys, jij legde de basis voor de samenwerking om zodoende ook verder 
onderzoek te kunnen doen naar de MCID van deze vragenlijsten. 
First, Konrad Schultz, as medical director and physician, you involved me and the team 
in your enthusiasm for executing research (“your little hobby”). Thank you so much for 
allowing me to investigate the dynamics of the MCID within your data from pulmonary 
rehabilitation. It has been an honor working with you. I have great respect for your 
extensive energy to execute clinical research in the rehabilitation center. Thank you for 
your hospitality in Bad Reichenhall. I am convinced that we have collectively composed 
wonderful results. I hope that we can have some more time in performing additional 
analyses. 
A warm thank you, to all (former) colleagues within the RIMTCORE team, especially 
Michael Wittmann and Danijel Jelusic. Thank you for educating me more on 
rehabilitation principles and pulmonology during my visits in Bad Reichenhall. I would 
also like acknowledge all (former) study nurses and physiotherapists within the RIMTCORE 
team. Furthermore, Michael Schuler, thank you for your great methodological input in 
the manuscripts. It has been wonderful meeting you in Würzburg. Thank you all for your 
input and co-authoring of most of the published manuscripts concerning the MCID. 
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Most certainly the data collection would not have been possible without all the 
RIMTCORE patients participating in the trial. Thank you very much for your efforts in 
filling out the questionnaires. I hereby would like to acknowledge specifically one of the 
female RIMTCORE participants, who allowed me to interview her about her personal 
experiences with COPD, pulmonary rehabilitation and questionnaires. 
Naast de studie binnen de longrevalidatie in Bad Reichenhall, wilden we als team 
ook graag data vanuit de eerste en tweede lijn in Nederland toevoegen. Mijn enorme 
dank gaat wat dat betreft allereerst uit naar de verschillende deelnemende 
huisartsenpraktijken, waar ik samen met de huisartsen en praktijkondersteuners 
potentiële deelnemers heb mogen werven. Bedankt voor jullie gastvrijheid, interesse en 
prettige contacten. Daarbij in het bijzonder wil ik jou, Siebrig Schokker, bedanken voor 
het helpen werven van COPD patiënten. Ook wil ik het Longfonds hartelijk danken voor 
jullie hulp bij de werving van deelnemers. Daar is een zeer grote respons op gekomen 
vanuit heel Nederland. Tot slot, ben ik veel dank verschuldigd aan alle deelnemers van 
deze Nederlandse studie. Zonder u was het onderzoek niet mogelijk geweest. Bedankt 
ook voor de soms persoonlijke notities over uw ervaringen met COPD. En dank voor uw 
loyaliteit in het beantwoorden van alle vragen. Ik wens u alle goeds. 
Graag wil ik benadrukken dat het geweldig is geweest om als MD-PhDer te worden 
opgenomen binnen het team van de afdeling huisartsgeneeskunde van het 
UMCG. Het is fijn om jullie als collega’s te hebben ontmoet en meer te leren over de 
methodologische aspecten van onderzoek en het vak van huisarts. Mijn grootste 
dank gaat uit naar de (voormalige) “longenclub” (GRIAC-PC) van de afdeling. 
Thys, Janwillem, Corina, Bertine, Esther, Fredrik, Job, Ellen, Roland, Hendrik-
Jan, Suzanne, Anna-Jetske, Tina, Boudewijn, Ioanna, Bruce, Miguel, Onni en 
alle anderen. Uiteraard ook dank voor de overdracht van kennis, maar zeker ook de 
gezelligheid tijdens congressen en andere bijeenkomsten. We gaan elkaar zeker zien in 
de toekomst! Bertine en Ioanna, dank ook voor jullie rol als medeauteur en feedback 
bij twee hoofdstukken van dit proefschrift. 
Naast de GRIAC-PC groep, wil ik in het bijzonder Boudewijn Kollen van de afdeling 
huisartsgeneeskunde bedanken. Dank voor je overweldigende input op het gebied 
van statistiek en methodologie. Samen hebben we heel wat moeten uitzoeken en 
ontdekken op het gebied van de MCID-methodologie. Dank voor je enthousiasme en 
betrokkenheid. Dank voor al jouw wijze woorden en de mooie bijdrage aan twee van de 
hoofdstukken van dit proefschrift. Ik hoop dat je geniet van je welverdiende pensioen 
met je familie. Ook wil ik graag Marjolein Berger, Sytse Zuidema, Gea Holtman en 




hebben geboden, om verder onderzoek te kunnen blijven doen binnen de afdeling. Tot 
slot wil ik ook Truus van Ittersum (SHARE) bedanken voor jouw geweldige bijdrage aan 
de ontwikkeling van de zoekstrategie voor het literatuuronderzoek in dit proefschrift. 
Graag wil ik ook de leden van de beoordelingscommissie - professor Huib Kerstjens, 
professor Adelita Ranchor en professor Dave Singh - bedanken. Thank you! Ik 
waardeer het enorm dat jullie tijd hebben gemaakt om mijn proefschrift te lezen en 
te voorzien van feedback. I appreciate it very much that you have taken the time and 
effort to provide my PhD thesis with interesting feedback. Ik zie uit naar het moment 
dat ik jullie vragen mag beantwoorden tijdens de openbare verdediging. I am looking 
forward to answering your questions during the public defence.  
Lieve paranimfen, ik ben jullie heel erg dankbaar dat jullie mij willen bijstaan tijdens 
een heel belangrijk moment in mijn leven. Lieve Stephanie, als mede MD-PhDer 
hebben we veel ervaringen uitgewisseld. We hebben elkaar in het eerste blok van de 
studie leren kennen, en ook nu is het als we elkaar zien weer als vanouds. We kunnen 
alles aan elkaar vragen als arts, onderzoeker en ook op persoonlijk vlak. Ik bewonder 
je doorzettingsvermogen en je enthousiasme. Ik wens je alle goeds voor de toekomst 
samen met Arne en je familie. Lieve Manna, lieve zus, zowel op onderzoeksgebied bij 
POG als op persoonlijk vlak heb ik veel van je mogen leren. Ik kan me dan ook geen 
betere paranimf bedenken voor dit bijzondere moment. Bedankt voor jouw steun, 
liefde, gezelligheid en plezier. Ik bewonder hoe je je in alle verschillende rollen staande 
houdt. Je bent een hele sterke zus waar ik trots op ben. Geniet samen met je lieve gezin 
Thijs, Stijn en Noortje. Uiteraard jullie ook bedankt voor jullie liefde, vrolijkheid en 
interesse. Dat we in de toekomst nog veel mooie momenten samen mogen beleven.
Lieve vrienden, bedankt voor jullie gezelligheid en interesse in mijn onderzoek. Het 
was niet altijd even makkelijk om uit te leggen waar mijn onderzoek over ging. Ik hoop 
dat er na de promotie weer wat meer tijd voor sociale activiteiten vrijkomt. Ik wil in het 
bijzonder ook Vera bedanken. Dank voor jouw loyale vriendschap, je lieve woorden en 
je oprechte steun. Ook al zien we elkaar niet vaak vanwege de afstand, het doet me 
goed dat ik weet dat je er bent. Alle goeds voor jou en je lieve gezin. 
Lieve pap en mam, jullie hebben me de kans gegeven om te kunnen studeren. En 
ook toen ik toch nog geneeskunde wilde studeren, hebben jullie me altijd gesteund. 
Jullie hebben er alles aan gedaan om mijn jeugd en de tijd erna tot een geweldige 
tijd te maken. Het is in woorden niet uit te drukken hoe dankbaar ik ben voor jullie 
onvoorwaardelijke liefde en steun. Ik hoop dat jullie weten dat dit ook wederzijds is. Ik 
ben trots op jullie. 
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Lieve Jaco, bedankt dat je mijn mooie en oprechte broer bent. Al besef je niet waar het 
over gaat en ben je er niet bij tijdens de promotie, weet dat je er altijd onvoorwaardelijk 
bij hoort. 
Lieve schoonfamilie, lieve Gerry, James, Rianne, Thijs, Sophie en Josephine. Bedankt 
voor jullie interesse, geduld, ondersteuning en gezelligheid de afgelopen jaren.  
Tot slot, het allerbelangrijkste en dierbaarste in mijn leven is mijn gezin. Lieve Daan, 
toen we elkaar leerden kennen ruim tien jaar geleden, vertelde ik je dat ik nog 
geneeskunde wilde studeren. Je hebt mij elke seconde sindsdien ondersteund. Je 
hebt met mij meegedacht, geholpen pakketjes met vragenlijsten samen te stellen en 
vooral veel geluisterd. Zonder jou, zou dit alles niet mogelijk zijn geweest. Ik ben ervan 
overtuigd dat we samen elke berg kunnen beklimmen, al zitten er soms wat hobbels op 
de weg. Dank je wel voor jouw onvoorwaardelijke liefde, steun en geduld. Ik beloof dat 
er meer tijd voor onthaasten gaat komen! Mijn allerliefste Lieke. Je bent nu iets meer 
dan een jaar in ons leven. Met jou in de buik heb ik mijn proefschrift afgerond. En nu 
je de eerste stappen begint te zetten, heb ik nieuwe energie om het dan ook eindelijk 
te gaan verdedigen. Je bent zo vrolijk, guitig, vol verwondering, open, oprecht en een 
tikkeltje eigenwijs. Eigenschappen, die je zeker moet bewaren voor later. Dank je wel 
voor je prachtige lach, je vertrouwen in Daan en mij, en het feit dat je er bent. Ik weet 
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